U.S. patent application number 12/843682 was filed with the patent office on 2010-11-18 for sulfonamide compounds.
Invention is credited to Brett Allison, Victor K. Phuong, Mama C.W. Pippel, Michael H. Rabinowitz, Hariharan Venkatesan.
Application Number | 20100292240 12/843682 |
Document ID | / |
Family ID | 35781432 |
Filed Date | 2010-11-18 |
United States Patent
Application |
20100292240 |
Kind Code |
A1 |
Allison; Brett ; et
al. |
November 18, 2010 |
SULFONAMIDE COMPOUNDS
Abstract
Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors
useful in the treatment of CCK1/CCK2 mediated diseases.
Inventors: |
Allison; Brett; (Del Mar,
CA) ; Phuong; Victor K.; (San Diego, CA) ;
Pippel; Mama C.W.; (Del Mar, CA) ; Rabinowitz;
Michael H.; (San Diego, CA) ; Venkatesan;
Hariharan; (San Diego, CA) |
Correspondence
Address: |
PHILIP S. JOHNSON;JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
35781432 |
Appl. No.: |
12/843682 |
Filed: |
July 26, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11230249 |
Sep 19, 2005 |
7297816 |
|
|
12843682 |
|
|
|
|
60612720 |
Sep 24, 2004 |
|
|
|
Current U.S.
Class: |
514/249 ;
514/362; 514/375; 514/469; 514/604; 544/353; 548/126; 548/217;
549/438; 564/91 |
Current CPC
Class: |
C07D 241/42 20130101;
C07D 417/12 20130101; A61P 1/16 20180101; A61P 1/18 20180101; A61P
3/04 20180101; C07D 409/12 20130101; C07D 317/62 20130101; A61P
7/06 20180101; A61P 1/00 20180101; A61P 43/00 20180101; A61P 25/04
20180101; A61P 25/30 20180101; A61P 1/10 20180101; A61P 25/00
20180101; A61P 1/14 20180101; C07D 285/14 20130101; A61P 25/22
20180101; C07D 277/62 20130101; C07D 263/56 20130101; C07C 311/21
20130101; A61P 1/04 20180101; A61P 35/00 20180101; A61P 25/18
20180101 |
Class at
Publication: |
514/249 ;
548/126; 544/353; 564/91; 548/217; 549/438; 514/362; 514/604;
514/375; 514/469 |
International
Class: |
A61K 31/498 20060101
A61K031/498; C07D 285/14 20060101 C07D285/14; C07D 417/12 20060101
C07D417/12; C07D 241/42 20060101 C07D241/42; C07C 311/21 20060101
C07C311/21; C07D 263/56 20060101 C07D263/56; C07D 317/62 20060101
C07D317/62; A61K 31/433 20060101 A61K031/433; A61K 31/18 20060101
A61K031/18; A61K 31/423 20060101 A61K031/423; A61K 31/36 20060101
A61K031/36; A61P 25/30 20060101 A61P025/30; A61P 1/04 20060101
A61P001/04; A61P 35/00 20060101 A61P035/00; A61P 3/04 20060101
A61P003/04; A61P 1/18 20060101 A61P001/18; A61P 25/22 20060101
A61P025/22 |
Claims
1. A compound of formula (I): ##STR00178## wherein X is
C.sub.1-2alkyl or a bond; R.sup.1 is selected from the group
consisting of a) naphthyl, phenyl, said phenyl optionally fused at
two adjacent carbon atoms to R.sup.f, R.sup.f is a linear 3- to
5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds and
having 0, 1 or 2 carbon members which is a carbonyl, b) Ar.sup.6--,
where Ar.sup.6 is a 6-membered heteroaryl having carbon as a point
of attachment, having 1 or 2 heteroatom members which are --N.dbd.
and optionally benzo or pyrido fused, c) Ar.sup.5--, where Ar.sup.5
is a 5-membered heteroaryl having carbon as a point of attachment,
having 1 heteroatom member selected from the group consisting of O,
S, >NH, and >NC.sub.1-4alkyl, having 0 or 1 additional
heteroatom member which is --N.dbd. and optionally benzo or pyrido
fused, d) Ar.sup.6-6--, where Ar.sup.6-6 is phenyl having the point
of attachment and fused to a 6-membered heteroaryl having 1 or 2
heteroatom members which are --N.dbd., e) Ar.sup.6-5--, where
Ar.sup.6-5 is phenyl or pyridyl having the point of attachment and
fused to a 5-membered heteroaryl having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd., where each of a) to e) is substituted with 0, 1,
2, or 3 of R.sup.q, R.sup.q is independently selected from the
group consisting of --C.sub.1-4alkyl, hydroxy, fluoro, chloro,
bromo, iodo, trifluoromethyl, nitro, cyano, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
C.sub.1-4alkylO--C.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS-C.sub.1-4alkyl, C.sub.1-4alkoxy, and
C.sub.1-4alkylS--; R.sup.2 is selected from the group consisting of
--H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.2-6alkynyl,
--C.sub.3-7cycloalkyl, and --C.sub.3-7cycloalkenyl; R.sup.a is,
independently, selected from the group consisting of
--C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.3-6cycloalkyl,
phenyl, furanyl, thiophenyl, benzyl, pyrrol-1-yl, --OH,
--OC.sub.1-6alkyl, --OC.sub.3-6cycloalkyl, --Ophenyl, --Obenzyl,
--SH, --SC.sub.1-6alkyl, --SC.sub.3-6cycloalkyl, --Sphenyl,
--Sbenzyl, cyano, nitro, --N(R.sup.y)R.sup.z (wherein R.sup.y and
R.sup.z are independently --H, --C.sub.1-4alkyl, or
C.sub.1-6cycloalkylC.sub.1-4alkyl), --(C.dbd.O)C.sub.1-4alkyl,
--SCF.sub.3, halo, trifluoromethyl, --OCF.sub.3, and
--COOC.sub.1-4alkyl, --COOH, or, alternatively, two adjacent
R.sup.a, may be taken together with the carbons of attachment to
form a fused ring selected from the group consisting of phenyl,
pyridyl, and pyrimidinyl; alternatively, R.sup.2 and one of R.sup.a
may be taken together as --CH.sub.2-- or >C.dbd.O to form a
fused ring to the phenyl; R.sup.b is selected from the group
consisting of 2,4-difluoro, 2,6-difluoro, or alternatively, two
adjacent R.sup.b substituents at 2- and 3-positions may be taken
together to form a five- or six-membered heterocyclic ring selected
from the group consisting of oxazole, thiazole, thiadiazole,
[1,3]dioxole, and pyrazine; R.sup.c is independently selected from
the group consisting of hydrogen, --C.sub.1-4alkyl,
perhaloC.sub.1-4alkyl, mono- or di-haloC.sub.1-4alkyl,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS-C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.0-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.s)R.sup.t; R.sup.s and R.sup.t
are independently selected from the group consisting of --H,
--C.sub.1-4alkyl, C.sub.1-6cycloalkylC.sub.1-4alkyl, phenyl, phenyl
substituted with halo, benzyl, benzyl substituted with halo, or
alternatively, R.sup.s and R.sup.t taken together with their
nitrogen of attachment form pyrrolidine, piperidine, or morpholine;
ringA is selected from the group consisting of i) a 6-membered
heteroaryl having carbon as a point of attachment and having 1 or 2
heteroatom members which are --N.dbd.; ii) a 5-membered heteroaryl
having carbon as a point of attachment, having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd.; and iii) a 5- or 6-membered non-aromatic
heterocycle having a carbon or nitrogen as a point of attachment,
having 1 or 2 heteroatoms selected from the group consisting of O,
S, and N, having 0 or 1 double bonds, having 0 or 1 carbon member
replaced by a carbonyl, and optionally substituted with
--C.sub.1-4alkyl, --OH, or halo; R.sup.d is independently selected
from the group consisting of hydrogen, --C.sub.1-4alkyl, --OH,
--OC.sub.1-6alkyl, perhaloC.sub.1-4alkyl, mono- or
di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.c is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; alternatively, one R.sup.c
and one R.sup.d may be taken together to form a double bond; and
enantiomers, diastereomers, hydrates, solvates and pharmaceutically
acceptable salts, esters and amides thereof.
2. The compound of claim 1 wherein X is a bond.
3. The compound of claim 1 wherein R.sup.1 is selected from the
group consisting of a) phenyl, naphthyl,
6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally
5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3
or 4-yl, optionally 5,6, 7 or 8 oxo substituted, b) pyridyl,
pyrazinyl, pyrimidinyl, pyridazinyl, quinolin-2,3 or 4-yl,
isoquinolin-1,3 or 4-yl, quinazolin-2 or 4-yl, quinoxalin-2 or
3-yl, naphthyridinyl, c) furanyl, thiophenyl, 1-(H or
C.sub.1-4alkyl)pyrrolyl, oxazolyl, thiazolyl, pyrazolyl,
imidazolyl, isoxazolyl, isothiazolyl, benzofuran-2 or 3-yl,
benzothiophen-2 or 3-yl, 1-(H or C.sub.1-4alky)-1H-indol-2 or 3-yl,
1-(H or C.sub.1-4alkyl)-1H-benzimidazol-2-yl, benzooxazol-2-yl,
benzothiazol-2-yl, 1H-pyrrolopyridin-2 or 3-yl, d) quinolin-5,6,7
or 8-yl, isoquinolin-5,6,7 or 8-yl, quinazolin-5,6,7 or 8-yl,
quinoxalin-5,6,7 or 8-yl, and e) benzofuran-4,5,6 or 7-yl,
benzothiophen-4,5,6 or 7-yl, 1-(H or C.sub.1-4alkyl)-1H-indo1-4,5,6
or 7-yl, 1-(H or C.sub.1-4alkyl)-1H-benzimidazol-4,5,6 or 7-yl,
benzooxazol-4,5,6 or 7-yl, benzothiazol-4,5,6 or 7-yl,
1H-pyrrolopyridin-4,5,6 or 7-yl, where each of a) to e) is
substituted with 0, 1, 2, or 3 of R.sup.q.
4. The compound of claim 1 wherein R.sup.1 is selected from the
group consisting of phenyl,
6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl optionally 5,6,7,8 or 9
oxo substituted, naphthyl, pyridyl, furanyl, thiophenyl, and
benzothiophenyl, where each member is substituted with 0, 1, 2, or
3 of R.sup.q.
5. The compound of claim 1 wherein R.sup.1 is selected from the
group consisting of phenyl, 2-bromophenyl, 3-bromophenyl,
4-bromophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,6-dichlorophenyl,
2,4,6-trichlorophenyl, 2-fluorophenyl, 4-fluorophenyl,
2,4-difluorophenyl, 3,4-difluorophenyl, 2,6-difluorophenyl,
2,4,6-trifluorophenyl, 2-chloro-4-fluorophenyl,
2-fluoro-4-bromophenyl, 2-fluoro-4-chlorophenyl,
3-bromo-4-chlorophenyl, 3-bromo-4-fluorophenyl,
4-chloro-3-iodophenyl, 2-methylphenyl, 4-methylphenyl,
4-methoxyphenyl, 4-dimethylaminophenyl, 2-methylsulfanylphenyl,
2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl,
3-cyanophenyl, 4-cyanophenyl, naphthyl, thiophen-3-yl,
5-bromothiophen-3-yl, and benzothiophen-3-yl.
6. The compound of claim 1 wherein R.sup.f is selected from the
group consisting of --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--(C.dbd.O)CH.sub.2CH.sub.2CH.sub.2--.
7. The compound of claim 1 wherein R.sup.q is selected from the
group consisting of methyl, ethyl, propyl, t-butyl, hydroxy,
fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, cyano,
aminomethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
methoxymethyl, methylsulfanyl, methylsulfanylmethyl, methoxy,
ethoxy, mercaptomethyl, and mercaptoethyl.
8. The compound of claim 1 wherein R.sup.q is selected from the
group consisting of methyl, fluoro, chloro, bromo, iodo,
trifluoromethyl, nitro, and cyano.
9. The compound of claim 1 wherein R.sup.2 is selected from the
group consisting of --H, methyl, ethyl, i-propyl, t-butyl, allyl,
propargyl, cyclopropyl, cyclohexyl, and cyclopentenyl.
10. The compound of claim 1 wherein R.sup.2 and one of R.sup.a are
taken together as --CH.sub.2-- or >C.dbd.O to form a fused ring
to the phenyl.
11. The compound of claim 1 wherein R.sup.2 is --H or methyl.
12. The compound of claim 1 wherein R.sup.2 is selected from the
group consisting of methyl, ethyl, propyl, i-propyl, ethenyl,
propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thiophenyl,
pyrrol-1-yl, benzyl, methoxy, ethoxy, propoxy, cyclopropoxy,
cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, mercapto,
methylsulfanyl, ethylsulfanyl, t-butylsulfanyl,
cyclopropylsulfanyl, phenylsulfanyl, nitro, cyano, amino,
dimethylamino, (cyclohexylmethyl)amino, acetyl, --SCF.sub.3, iodo,
fluoro, chloro, bromo, trifluoromethyl, --OCF.sub.3, and
methoxycarbonyl.
13. The compound of claim 1 wherein there is one R.sup.a.
14. The compound of claim 1 wherein there is one R.sup.a positioned
on the ring para to the amide substituent.
15. The compound of claim 1 wherein two adjacent R.sup.2 are taken
together with the carbons of attachment to form a fused phenyl
ring.
16. The compound of claim 1 wherein there are two R.sup.a
substituents.
17. The compound of claim 1 wherein each R.sup.a is independently
selected from the group consisting of methyl, i-propyl, ethenyl,
2-propenyl, cyclopropyl, phenyl, thiophenyl, methoxy, ethoxy,
propoxy, i-propoxy, nitro, cyano, dimethylamino,
(cyclohexylmethyl)amino, acetyl, fluoro, chloro, bromo, iodo,
--CF.sub.3, and fused phenyl.
18. The compound of claim 1 wherein two R.sup.b are 2,6-difluoro or
2,4-difluoro.
19. The compound of claim 1 wherein two adjacent R.sup.b
substituents at 2- and 3-positions are taken with the benzene ring
of attachment to form benzothiazole, benzothiadiazole, or
quinoxaline.
20. The compound of claim 1 wherein R.sup.c is selected from the
group consisting of hydrogen, methyl, ethyl, i-propyl,
hydroxymethyl, methoxymethyl, dimethylaminomethyl,
methylsulfanylmethyl, methoxycarbonyl, ethoxycarbonyl,
tert-butoxycarbonyl, methoxycarbonylmethyl, carboxy, carboxymethyl,
carbamoyl, carbamoylmethyl, dimethylcarbamoyl,
piperidine-1-carbonyl,
5-methyl-2-oxo-[1,3]dioxol-4-yl-methoxycarbonyl,
3-pyridylmethoxycarbonyl, 3-chlorobenzylcarbamoyl,
4-fluorobenzylcarbamoyl, benzylcarbamoyl, phenylcarbamoyl,
dimethylcarbamoylmethoxycarbonyl, and
2-morpholin-4-ylethoxycarbonyl.
21. The compound of claim 1 wherein the carbon to which the two
R.sup.c groups are attached is in the (S) configuration.
22. The compound of claim 1 wherein R.sup.d is selected from the
group consisting of hydrogen, methyl, ethyl, i-propyl, hydroxy,
hydroxymethyl, methoxymethyl, dimethylaminomethyl, phenyl,
4-chlorophenyl, and methylsulfanylmethyl.
23. The compound of claim 1 wherein two R.sup.d together form
.dbd.O.
24. The compound of claim 1 wherein R.sup.d is selected from the
group consisting of hydrogen, methyl, phenyl, and hydroxy.
25. The compound of claim 1 wherein said pharmaceutically
acceptable salt is an amino addition salt.
26. The compound of claim 1 wherein said pharmaceutically
acceptable salt is an acid addition salt.
27. The compound of claim 1 wherein said pharmaceutically
acceptable salt is selected from the group consisting of
hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate,
oxalate, valerate, oleate, palmitate, stearate, laurate, borate,
benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate,
succinate, tartrate, naphthylate, mesylate, glucoheptonate,
lactiobionate, and laurylsulfonate.
28. The compound of claim 1 wherein said pharmaceutically
acceptable salt is selected from the group consisting of sodium,
potassium, calcium, magnesium, ammonium, quaternary ammonium,
tetramethyl ammonium, methylammonium, trimethylammonium, and
ethylammonium.
29. The compound of claim 1 selected from the group consisting of:
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chlor-
o-phenyl)-propyl]-benzamide;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3,4-dichloro-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-
-3-phenyl-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-phenyl)-propionic acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(3,4-dichloro-ph-
enyl)-propyl]-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2,2-bis-(4-chloro-phenyl)--
ethyl]-4-chloro-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-pheny-
l)-2-methyl-propyl]-benzamide;
(S)-3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-propionic acid methyl ester;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-naphthale-
n-2-yl-propionic acid;
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,4-difluorobenzene-
sulfonylamino)-benzamide;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-carbamoyl-2-(4-chlor-
o-phenyl)-ethyl]-4,5-dichloro-benzamide;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-
-1-hydroxymethyl-ethyl]-4-methyl-benzamide;
(S)-Benzo[1,2,5]thiadiazole-4-sulfonic acid
[6-bromo-1,3-dioxo-2-(2-phenyl-propyl)-2,3-dihydro-1H-isoindol-4-yl]-amid-
e;
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoyl-
amino]-3-(4-chloro-phenyl)-propionic acid;
(R)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-benzoyl-
amino]-propionic acid;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[2-(3,4-dic-
hloro-phenyl)-propyl]-benzamide;
(R)-2-[2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoylamino]-3-pheny-
l-propionic acid;
(.+-.)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3,4-d-
ichloro-phenyl)-3-oxo-propionic acid methyl ester;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(-
3,4-dichloro-phenyl)-3-hydroxy-propionic acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-phenethyl--
benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chl-
oro-phenyl)-propyl]-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-1-meth-
yl-ethyl]-4-trifluoromethyl-benzamide;
2-(Benzothiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro-phenyl)-1-methyl-
-ethyl]-benzamide;
4-Bromo-N-[2-(4-chloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonylami-
no)-benzamide;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]-3-ph-
enyl-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethyl-benzoyla-
mino]-3-phenyl-propionic acid;
2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phenyl-propioni-
c acid;
2-[2-(Benzothiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-phenyl-
-propionic acid;
2-[4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phenyl-pr-
opionic acid;
4-Bromo-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfony-
lamino)-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-propyl)-b-
enzamide;
3-(3,4-Dichloro-phenyl)-242-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzoylamino]-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4--
chloro-phenyl)-propionic acid;
3-(4-Chloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-benzo-
ylamino]-propionic acid;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-propy-
l)-benzamide;
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-propy-
l)-benzamide;
(S)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-propyl)-ben-
zamide;
(R)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-prop-
yl)-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phenyl)-pr-
opyl]-4-iodo-benzamide;
N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-sulfonylamino)-
-benzamide;
2-[4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(2,4-dic-
hloro-phenyl)-propionic acid;
N-[2-(3,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzamide;
4-Chloro-N-[2-(2,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfon-
ylamino)-benzamide;
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-nitro-phenyl)-prop-
yl]-benzamide;
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-trifluoromethyl-ph-
enyl)-propyl]-benzamide;
2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(2,4-di-
chloro-phenyl)-propionic acid;
N-[2-(2,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzamide;
2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-N-[2-(4-nitro-phenyl)-propyl-
]-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-((2S,1R)-2-hydroxy-
-1-methyl-2-phenyl-ethyl)-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-indan-2-yl-benzami-
de;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(2-pyr-
idin-2-yl-ethyl)-benzamide hydrochloride;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chlor-
o-phenyl)-1-hydroxymethyl-ethyl]-benzamide;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro-
-phenyl)-1-methyl-ethyl]-benzamide;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-
-propyl]-4-methyl-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[(1R,2S)-2-(4-chlo-
ro-phenyl)-2-hydroxy-1-methyl-ethyl]-benzamide;
(2S,3R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylam-
ino]-3-(3,4-dichloro-phenyl)-butyric acid;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-dic-
hloro-phenyl)-propyl]-benzamide ;
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-N-[2-(3,4-
-dichloro-phenyl)-propyl]-benzamide;
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(quinoxaline-5-sulfo-
nylamino)-benzamide;
(R)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-ben-
zoylamino]-propionic acid;
(.+-.)-N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-sulfony-
lamino)-benzamide;
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoylamino]-
-3-(4-chloro-phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3-cyano--
phenyl)-propionic acid;
(S)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,4-dich-
loro-phenyl)-butyric acid;
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-b-
enzoylamino]-propionic acid methyl ester;
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-b-
enzoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(4-chloro-phenyl)-propionic acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(4-chloro-phenyl)-propionic acid;
(R)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-3-(4--
chloro-phenyl)-propionic acid methyl ester;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(2,4-dichloro-p-
henyl)-ethyl]-benzamide;
(S)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-3-(4--
chloro-phenyl)-propionic acid methyl ester;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-propyl-
]-4-iodo-benzamide;
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-m-
ethyl-2,2-diphenyl-ethyl)-benzamide;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-m-
ethyl-2,2-diphenyl-ethyl)-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(2,4-dichloro-phenyl)-et-
hyl]-benzamide;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(4-fluoro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-thiophen-3-yl-propionic acid;
(S)-3-(3-Chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzo-
ylamino]-propionic acid;
(S)-2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-p-tolyl-pro-
pionic acid;
N-[2-(4-Bromo-phenyl)-ethyl]-4-chloro-2-(2,6-difluoro-benzenesulfonylamin-
o)-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-6-chloro-N-[2-(3,4-dichloro-p-
henyl)-propyl]-benzamide;
(R)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,4-dich-
loro-phenyl)-butyric acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoylamino]-
-3-(4-chloro-phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3-nitro--
phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3,4-difl-
uoro-phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(4-cyano--
phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-thiophen--
3-yl-propionic acid;
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzo-
ylamin]-butyric acid methyl ester;
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzo-
ylamin]-butyric acid;
(S)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-benzoyl-
amino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-4-chloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(4-chloro-3-iodo-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-4-fluoro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
,3-bis-(4-chloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(4-chloro-phenyl)-3-methyl-butyric acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4--
chloro-phenyl)-2-methyl-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3--
bromo-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4--
chloro-phenyl)-3-hydroxy-propionic acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(4-chloro-phenyl-
)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phenyl)-2--
hydroxy-1-methyl-ethyl]-4-iodo-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-phenyl)-
-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,-
4-dichloro-phenyl)-3-hydroxy-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3--
bromo-phenyl)-butyric acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-propyl]-
-4-iodo-benzamide;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,-
4-dichloro-phenyl)-acrylic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3,3-bis-(4-chloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(4-chloro-phenyl)-3-methyl-butyric acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-phenyl)-
-2-hydroxy-1-methyl-ethyl]-4-chloro-benzamide;
2-[2-(Benzooxazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-3-(4-chlor-
o-phenyl)-propionic acid;
2-[2-(Benzooxazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,4-dichloro--
phenyl)-propionic acid;
2-[2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,4-dich-
loro-phenyl)-propionic acid;
2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-phenyl)-2-h-
ydroxy-1-methyl-ethyl]-benzamide;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-
-3-(3-bromo-4-fluoro-phenyl)-propionic acid
5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-
-3-(3-bromo-4-fluoro-phenyl)-propionic acid pyridin-3-ylmethyl
ester;
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-phenyl)-propionic acid;
(2S,3R)-3-(3,4-Dichloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzoylamino]-butyric acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid;
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid;
(S)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(3,-
4-dichloro-phenyl)-propionic acid;
(R)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(3,-
4-dichloro-phenyl)-propionic acid;
anti-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino-
]-3-(3,4-dichloro-phenyl)-3-hydroxy-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-4-chloro-phenyl)-propionic acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzoylamino]-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-propionic acid;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)--
4-iodo-benzoylamino]-propionic acid;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3-chloro-b-
enzylcarbamoyl)-2-(3,4-dichloro-phenyl)-ethyl]-benzamide;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-benzylcarbamoyl-2-(3-
,4-dichloro-phenyl)-ethyl]-4-chloro-benzamide;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-dichlo-
ro-phenyl)-1-(4-fluoro-benzylcarbamoyl)-ethyl]-benzamide;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]--
3-(3,4-dichloro-phenyl)-propionic acid;
(S)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-ben-
zoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(2,4-dichloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(2,4-dichloro-5-fluoro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3-iodo-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(4-chloro-3-iodo-phenyl)-propionic acid methyl ester;
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)--
benzoylamino]-propionic acid methyl ester;
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)--
benzoylamino]-propionic acid;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-dichlo-
ro-phenyl)-1-phenylcarbamoyl-ethyl]-benzamide;
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dichlo-
ro-benzyl)-2-oxo-2-piperidin-1-yl-ethyl]-benzamide;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3,4-dichloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]--
3-(3-bromo-4-chloro-phenyl)-propionic acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]--
3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester;
(Z)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3,4-dichloro-phenyl)-acrylic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3-bromo-4-chloro-phenyl)-propionic acid;
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-chloro-phenyl)-propionic acid;
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylamino-
)-benzoylamino]-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid methyl ester;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid methyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3,4-dichloro-phenyl)-propionic acid methyl ester;
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylamino-
)-benzoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3-bromo-4-fluoro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylamino-
)-benzoylamino]-propionic acid;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid;
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]--
3-(3-bromo-4-chloro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]--
3-(3-bromo-4-fluoro-phenyl)-propionic acid;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid ethyl ester;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3--
bromo-4-chloro-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4--
chloro-3-iodo-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3--
bromo-4-fluoro-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3,3-b-
is-(4-chloro-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4--
chloro-phenyl)-3-methyl-butyric acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-2-hydr-
oxy-1-methyl-ethyl]-4-iodo-benzamide;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-hydro-
xy-1-methyl-ethyl]-4-iodo-benzamide;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3,3-
-bis-(4-chloro-phenyl)-propionic acid;
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(-
4-chloro-phenyl)-3-methyl-butyric acid;
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-hydro-
xy-1-methyl-ethyl]-4-chloro-benzamide;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid tert-butyl ester;
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
2-morpholin-4-yl-ethyl ester; and
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
dimethylcarbamoylmethyl ester.
30. A pharmaceutical composition comprising a pharmaceutically
acceptable carrier and an effective amount of at least one compound
of formula (I): ##STR00179## wherein X is C.sub.1-2alkyl or a bond;
R.sup.1 is selected from the group consisting of a) naphthyl,
phenyl, said phenyl optionally fused at two adjacent carbon atoms
to R.sup.f, R.sup.f is a linear 3- to 5-membered hydrocarbon moiety
having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members
which is a carbonyl, b) Ar.sup.6--, where Ar.sup.6 is a 6-membered
heteroaryl having carbon as a point of attachment, having 1 or 2
heteroatom members which are --N.dbd. and optionally benzo or
pyrido fused, c) Ar.sup.5--, where Ar.sup.5 is a 5-membered
heteroaryl having carbon as a point of attachment, having 1
heteroatom member selected from the group consisting of O, S,
>NH, and >NC.sub.1-4alkyl, having 0 or 1 additional
heteroatom member which is --N.dbd. and optionally benzo or pyrido
fused, d) Ar.sup.6-6--, where Ar.sup.6-6 is phenyl having the point
of attachment and fused to a 6-membered heteroaryl having 1 or 2
heteroatom members which are --N.dbd., e) Ar.sup.6-5--, where
Ar.sup.6-5 is phenyl or pyridyl having the point of attachment and
fused to a 5-membered heteroaryl having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd., where each of a) to e) is substituted with 0, 1,
2, or 3 of R.sup.q, R.sup.q is independently selected from the
group consisting of --C.sub.1-4alkyl, hydroxy, fluoro, chloro,
bromo, iodo, trifluoromethyl, nitro, cyano, aminoC.sub.1-4alkyl,
C.sub.1-4alkoxy, and C.sub.1-4alkylS--; R.sup.2 is selected from
the group consisting of --H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl,
--C.sub.2-6alkynyl, --C.sub.3-7cycloalkyl, and
--C.sub.3-7cycloalkenyl; R.sup.a is, independently, selected from
the group consisting of --C.sub.1-6alkyl, --C.sub.2-6alkenyl,
--C.sub.3-6cycloalkyl, phenyl, furanyl, thiophenyl, benzyl,
pyrrol-1-yl, --OH, --OC.sub.1-6alkyl, --OC.sub.3-6cycloalkyl,
--Ophenyl, --Obenzyl, --SH, --SC.sub.1-6alkyl,
--SC.sub.3-6cycloalkyl, --Sphenyl, --Sbenzyl, cyano, nitro,
--N(R.sup.y)R.sup.z (wherein R.sup.y and R.sup.z are independently
--H, --C.sub.1-4alkyl, or C.sub.1-6cycloalkylC.sub.1-4alkyl),
--(C.dbd.O)C.sub.1-4alkyl, --SCF.sub.3, halo, trifluoromethyl,
--OCF.sub.3, and --COOC.sub.1-4alkyl, --COOH, or, alternatively,
two adjacent R.sup.a, may be taken together with the carbons of
attachment to form a fused ring selected from the group consisting
of phenyl, pyridyl, and pyrimidinyl; alternatively, R.sup.2 and one
of R.sup.a may be taken together as --CH.sub.2-- or >C.dbd.O to
form a fused ring to the phenyl; R.sup.b is selected from the group
consisting of 2,4-difluoro, 2,6-difluoro, or alternatively, two
adjacent R.sup.b substituents at 2- and 3-positions may be taken
together to form a five- or six-membered heterocyclic ring selected
from the group consisting of oxazole, thiazole, thiadiazole,
[1,3]dioxole, and pyrazine; R.sup.c is independently selected from
the group consisting of hydrogen, --C.sub.1-4alkyl,
perhaloC.sub.1-4alkyl, mono- or di-haloC.sub.1-4alkyl,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS--C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.0-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.s)R.sup.t; R.sup.5 and Ware
independently selected from the group consisting of --H,
--C.sub.1-4alkyl, C.sub.1-6cycloalkylC.sub.1-4alkyl, phenyl, phenyl
substituted with halo, benzyl, benzyl substituted with halo, or
alternatively, R.sup.s and R.sup.t taken together with their
nitrogen of attachment form pyrrolidine, piperidine, or morpholine;
ringA is selected from the group consisting of i) a 6-membered
heteroaryl having carbon as a point of attachment and having 1 or 2
heteroatom members which are --N.dbd.; ii) a 5-membered heteroaryl
having carbon as a point of attachment, having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd.; and iii) a 5- or 6-membered non-aromatic
heterocycle having a carbon or nitrogen as a point of attachment,
having 1 or 2 heteroatoms selected from the group consisting of O,
S, and N, having 0 or 1 double bonds, having 0 or 1 carbon member
replaced by a carbonyl, and optionally substituted with
--C.sub.1-4alkyl, --OH, or halo; R.sup.d is independently selected
from the group consisting of hydrogen, --C.sub.1-4alkyl, --OH,
--OC.sub.1-6alkyl, HO--C.sub.1-4alkyl, perhaloC.sub.1-4alkyl, mono-
or di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.c is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; alternatively, one R.sup.c
and one R.sup.d may be taken together to form a double bond; and
enantiomers, diastereomers, hydrates, solvates and pharmaceutically
acceptable salts, esters and amides thereof.
31. A method for the treatment or prevention of pain, drug
dependence, anxiety, panic attack, schizophrenia, pancreatic
disorders, secretory disorders, gastrointestinal motility
disorders, functional bowel disease, biliary colic, and cancer,
eating disorders, reflux diseases, gastroduodenal ulcers, reflux
esophagitis, peptic ulcers, Barrett's esophagus, antral G cell
hyperplasia, pernicious anaemia, and Zollinger-Ellison syndrome, in
mammals comprising the step of administering to a mammal suffering
there from an effective amount of at least one compound of formula
(I): ##STR00180## wherein X is C.sub.1-2alkyl or a bond; R.sup.1 is
selected from the group consisting of a) naphthyl, phenyl, said
phenyl optionally fused at two adjacent carbon atoms to R.sup.f,
R.sup.f is a linear 3- to 5-membered hydrocarbon moiety having 0 or
1 unsaturated bonds and having 0, 1 or 2 carbon members which is a
carbonyl, b) Ar.sup.6--, where Ar.sup.6 is a 6-membered heteroaryl
having carbon as a point of attachment, having 1 or 2 heteroatom
members which are --N.dbd. and optionally benzo or pyrido fused, c)
Ar.sup.5--, where Ar.sup.5 is a 5-membered heteroaryl having carbon
as a point of attachment, having 1 heteroatom member selected from
the group consisting of O, S, >NH, and >NC.sub.1-4alkyl,
having 0 or 1 additional heteroatom member which is --N.dbd. and
optionally benzo or pyrido fused, d) Ar.sup.6-6--, where Ar.sup.6-6
is phenyl having the point of attachment and fused to a 6-membered
heteroaryl having 1 or 2 heteroatom members which are --N.dbd., e)
Ar.sup.6-5--, where Ar.sup.6-5 is phenyl or pyridyl having the
point of attachment and fused to a 5-membered heteroaryl having 1
heteroatom member selected from the group consisting of O, S,
>NH, and >NC.sub.1-4alkyl, and having 0 or 1 additional
heteroatom member which is --N.dbd., where each of a) to e) is
substituted with 0, 1, 2, or 3 of R.sup.q, R.sup.q is independently
selected from the group consisting of --C.sub.1-4alkyl, hydroxy,
fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, cyano,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
C.sub.1-4alkylO--C.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, C.sub.1-4alkoxy, and
C.sub.1-4alkylS--; R.sup.2 is selected from the group consisting of
--H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.2-6alkynyl,
--C.sub.3-7cycloalkyl, and --C.sub.3-7cycloalkenyl; R.sup.a is,
independently, selected from the group consisting of
--C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.3-6cycloalkyl,
phenyl, furanyl, thiophenyl, benzyl, pyrrol-1-yl, --OH,
--OC.sub.1-6alkyl, --OC.sub.3-6cycloalkyl, --Ophenyl, --Obenzyl,
--SH, --SC.sub.1-6alkyl, --SC.sub.3-6cycloalkyl, --Sphenyl,
--Sbenzyl, cyano, nitro, --N(R.sup.y)R.sup.z (wherein R.sup.y and
R.sup.z are independently --H, --C.sub.1-4alkyl, or
C.sub.1-6cycloalkylC.sub.1-4alkyl), --(C.dbd.O)C.sub.1-4alkyl,
--SCF.sub.3, halo, trifluoromethyl, --OCF.sub.3, and
--COOC.sub.1-4alkyl, --COOH, or, alternatively, two adjacent
R.sup.a, may be taken together with the carbons of attachment to
form a fused ring selected from the group consisting of phenyl,
pyridyl, and pyrimidinyl; alternatively, R.sup.2 and one of R.sup.a
may be taken together as --CH.sub.2-- or >C.dbd.O to form a
fused ring to the phenyl; R.sup.b is selected from the group
consisting of 2,4-difluoro, 2,6-difluoro, or alternatively, two
adjacent R.sup.b substituents at 2- and 3-positions may be taken
together to form a five- or six-membered heterocyclic ring selected
from the group consisting of oxazole, thiazole, thiadiazole,
[1,3]dioxole, and pyrazine; R.sup.c is independently selected from
the group consisting of hydrogen, --C.sub.1-4alkyl,
perhaloC.sub.1-4alkyl, mono- or di-haloC.sub.1-4alkyl,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS--C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.0-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.s)R.sup.t; R.sup.s and R.sub.t
independently selected from the group consisting of --H,
--C.sub.1-4alkyl, C.sub.1-6cycloalkylC.sub.1-4alkyl, phenyl, phenyl
substituted with halo, benzyl, benzyl substituted with halo, or
alternatively, R.sup.5 and R.sup.t taken together with their
nitrogen of attachment form pyrrolidine, piperidine, or morpholine;
ringA is selected from the group consisting of i) a 6-membered
heteroaryl having carbon as a point of attachment and having 1 or 2
heteroatom members which are --N.dbd.; ii) a 5-membered heteroaryl
having carbon as a point of attachment, having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd.; and iii) a 5- or 6-membered non-aromatic
heterocycle having a carbon or nitrogen as a point of attachment,
having 1 or 2 heteroatoms selected from the group consisting of O,
S, and N, having 0 or 1 double bonds, having 0 or 1 carbon member
replaced by a carbonyl, and optionally substituted with
--C.sub.1-4alkyl, --OH, or halo; R.sup.d is independently selected
from the group consisting of hydrogen, --C.sub.1-4alkyl, --OH,
--OC.sub.1-6alkyl, HO--C.sub.1-4alkyl, perhaloC.sub.1-4alkyl, mono-
or di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.c is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; alternatively, one R.sup.c
and one R.sup.d may be taken together to form a double bond; and
enantiomers, diastereomers, hydrates, solvates and pharmaceutically
acceptable salts, esters and amides thereof.
32. A method for the treatment or prevention of pancreatic
adenocarcinoma, pain, gastro-esophageal reflux disease, non-erosive
reflux disease, anorexia, pancreatitis, gastroduodenal ulcers,
reflux esophagitis, anxiety, colon cancer, peptic ulcers,
pancreatic tumors and gastric tumors in mammals comprising the step
of administering to a mammal suffering there from an effective
amount of at least one compound of formula (I): ##STR00181##
wherein X is C.sub.1-2alkyl or a bond; R.sup.1 is selected from the
group consisting of a) naphthyl, phenyl, said phenyl optionally
fused at two adjacent carbon atoms to R.sup.f, R.sup.f is a linear
3- to 5-membered hydrocarbon moiety having 0 or 1 unsaturated bonds
and having 0, 1 or 2 carbon members which is a carbonyl, b)
Ar.sup.6--, where Ar.sup.6 is a 6-membered heteroaryl having carbon
as a point of attachment, having 1 or 2 heteroatom members which
are --N.dbd. and optionally benzo or pyrido fused, c) Ar.sup.5--,
where Ar.sup.5 is a 5-membered heteroaryl having carbon as a point
of attachment, having 1 heteroatom member selected from the group
consisting of O, S, >NH, and >NC.sub.1-4alkyl, having 0 or 1
additional heteroatom member which is --N.dbd. and optionally benzo
or pyrido fused, d) Ar.sup.6-6--, where Ar.sup.6-6 is phenyl having
the point of attachment and fused to a 6-membered heteroaryl having
1 or 2 heteroatom members which are --N.dbd., e) Ar.sup.6-5--,
where Ar.sup.6-5 is phenyl or pyridyl having the point of
attachment and fused to a 5-membered heteroaryl having 1 heteroatom
member selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd., where each of a) to e) is substituted with 0, 1,
2, or 3 of R.sup.q, R.sup.q is independently selected from the
group consisting of --C.sub.1-4alkyl, hydroxy, fluoro, chloro,
bromo, iodo, trifluoromethyl, nitro, cyano, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
C.sub.1-4alkylO--C.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, C.sub.1-4alkoxy, and
C.sub.1-4alkylS--; R.sup.2 is selected from the group consisting of
--H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.2-6alkynyl,
--C.sub.3-7cycloalkyl, and --C.sub.3-7cycloalkenyl; R.sup.a is,
independently, selected from the group consisting of
--C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.3-6cycloalkyl,
phenyl, furanyl, thiophenyl, benzyl, pyrrol-1-yl, --OH,
--OC.sub.1-6alkyl, --OC.sub.3-6cycloalkyl, --Ophenyl, --Obenzyl,
--SH, --SC.sub.1-6alkyl, --SC.sub.3-6cycloalkyl, --Sphenyl,
--Sbenzyl, cyano, nitro, --N(R.sup.y)R.sup.z (wherein R.sup.y and
R.sup.z are independently --H, --C.sub.1-4alkyl, or
C.sub.1-6cycloalkylC.sub.1-4alkyl), --(C.dbd.O)C.sub.1-4alkyl,
--SCF.sub.3, halo, trifluoromethyl, --OCF.sub.3, and
--COOC.sub.1-4alkyl, --COOH, or, alternatively, two adjacent
R.sup.a, may be taken together with the carbons of attachment to
form a fused ring selected from the group consisting of phenyl,
pyridyl, and pyrimidinyl; alternatively, R.sup.2 and one of R.sup.a
may be taken together as --CH.sub.2-- or >C.dbd.O to form a
fused ring to the phenyl; R.sup.b is selected from the group
consisting of 2,4-difluoro, 2,6-difluoro, or alternatively, two
adjacent R.sup.b substituents at 2- and 3-positions may be taken
together to form a five- or six-membered heterocyclic ring selected
from the group consisting of oxazole, thiazole, thiadiazole,
[1,3]dioxole, and pyrazine; R.sup.c is independently selected from
the group consisting of hydrogen, --C.sub.1-4alkyl,
perhaloC.sub.1-4alkyl, mono- or di-haloC.sub.1-4alkyl,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS--C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.0-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.5)R.sup.t; R.sup.s and R.sup.t
independently selected from the group consisting of --H,
--C.sub.1-4alkyl, C.sub.16cycloalkylC.sub.1-4alkyl, phenyl, phenyl
substituted with halo, benzyl, benzyl substituted with halo, or
alternatively, R.sup.s and R.sup.t taken together with their
nitrogen of attachment form pyrrolidine, piperidine, or morpholine;
ringA is selected from the group consisting of i) a 6-membered
heteroaryl having carbon as a point of attachment and having 1 or 2
heteroatom members which are --N.dbd.; ii) a 5-membered heteroaryl
having carbon as a point of attachment, having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd.; and iii) a 5- or 6-membered non-aromatic
heterocycle having a carbon or nitrogen as a point of attachment,
having 1 or 2 heteroatoms selected from the group consisting of O,
S, and N, having 0 or 1 double bonds, having 0 or 1 carbon member
replaced by a carbonyl, and optionally substituted with
--C.sub.1-4alkyl, --OH, or halo; R.sup.d is independently selected
from the group consisting of hydrogen, --C.sub.1-4alkyl, --OH,
--OC.sub.16alkyl, perhaloC.sub.1-4alkyl, mono- or
di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.c is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; alternatively, one R.sup.c
and one R.sup.d may be taken together to form a double bond; and
enantiomers, diastereomers, hydrates, solvates and pharmaceutically
acceptable salts, esters and amides thereof.
33. A method for the treatment or prevention of pancreatitis,
non-erosive reflux disease, or gastroesophageal reflux disease in
mammals comprising the step of administering to a mammal suffering
there from an effective amount of at least one compound of formula
(I): ##STR00182## wherein X is C.sub.1-2alkyl or a bond; R.sup.1 is
selected from the group consisting of a) naphthyl, phenyl, said
phenyl optionally fused at two adjacent carbon atoms to R.sup.f,
R.sup.f is a linear 3- to 5-membered hydrocarbon moiety having 0 or
1 unsaturated bonds and having 0, 1 or 2 carbon members which is a
carbonyl, b) Ar.sup.6--, where Ar.sup.6 is a 6-membered heteroaryl
having carbon as a point of attachment, having 1 or 2 heteroatom
members which are --N.dbd. and optionally benzo or pyrido fused, c)
Ar.sup.5--, where Ar.sup.5 is a 5-membered heteroaryl having carbon
as a point of attachment, having 1 heteroatom member selected from
the group consisting of O, S, >NH, and >NC.sub.1-4alkyl,
having 0 or 1 additional heteroatom member which is --N.dbd. and
optionally benzo or pyrido fused, d) Ar.sup.6-6--, where Ar.sup.6-6
is phenyl having the point of attachment and fused to a 6-membered
heteroaryl having 1 or 2 heteroatom members which are --N.dbd., e)
Ar.sup.6-5--, where Ar.sup.6-5 is phenyl or pyridyl having the
point of attachment and fused to a 5-membered heteroaryl having 1
heteroatom member selected from the group consisting of O, S,
>NH, and >NC.sub.1-4alkyl, and having 0 or 1 additional
heteroatom member which is --N.dbd., where each of a) to e) is
substituted with 0, 1, 2, or 3 of R.sup.q, R.sup.q is independently
selected from the group consisting of --C.sub.1-4alkyl, hydroxy,
fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, cyano,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
C.sub.1-4alkylO--C.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, C.sub.1-4alkoxy, and
C.sub.1-4alkylS--; R.sup.2 is selected from the group consisting of
--H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.2-6alkynyl,
--C.sub.3-7cycloalkyl, and --C.sub.3-7cycloalkenyl; R.sup.a is,
independently, selected from the group consisting of
--C.sub.1-6alkyl, --C.sub.2-6alkenyl, --C.sub.3-6cycloalkyl,
phenyl, furanyl, thiophenyl, benzyl, pyrrol-1-yl, --OH,
--OC.sub.1-6alkyl, --OC.sub.3-6cycloalkyl, --Ophenyl, --Obenzyl,
--SH, --SC.sub.1-6alkyl, --SC.sub.3-6cycloalkyl, --Sphenyl,
--Sbenzyl, cyano, nitro, --N(R.sup.y)R.sup.z (wherein R.sup.y and
R.sup.z are independently --H, --C.sub.1-4alkyl, or
C.sub.1-6cycloalkylC.sub.1-4alkyl), --(C.dbd.O)C.sub.1-4alkyl,
--SCF.sub.3, halo, trifluoromethyl, --OCF.sub.3, and
--COOC.sub.1-4alkyl, --COOH, or, alternatively, two adjacent
R.sup.a, may be taken together with the carbons of attachment to
form a fused ring selected from the group consisting of phenyl,
pyridyl, and pyrimidinyl; alternatively, R.sup.2 and one of R.sup.a
may be taken together as --CH.sub.2-- or >C.dbd.O to form a
fused ring to the phenyl; R.sup.b is selected from the group
consisting of 2,4-difluoro, 2,6-difluoro, or alternatively, two
adjacent R.sup.b substituents at 2- and 3-positions may be taken
together to form a five- or six-membered heterocyclic ring selected
from the group consisting of oxazole, thiazole, thiadiazole,
[1,3]dioxole, and pyrazine; R.sup.b is independently selected from
the group consisting of hydrogen, --C.sub.1-4alkyl,
perhaloC.sub.1-4alkyl, mono- or di-haloC.sub.1-4alkyl,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS-C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.o-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.5)R.sup.t; R.sup.s and R.sup.t
independently selected from the group consisting of --H,
--C.sub.1-4alkyl, C.sub.1-6cycloalkylC.sub.1-4alkyl, phenyl, phenyl
substituted with halo, benzyl, benzyl substituted with halo, or
alternatively, R.sup.5 and R.sup.t taken together with their
nitrogen of attachment form pyrrolidine, piperidine, or morpholine;
ringA is selected from the group consisting of i) a 6-membered
heteroaryl having carbon as a point of attachment and having 1 or 2
heteroatom members which are --N.dbd.; ii) a 5-membered heteroaryl
having carbon as a point of attachment, having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd.; and iii) a 5- or 6-membered non-aromatic
heterocycle having a carbon or nitrogen as a point of attachment,
having 1 or 2 heteroatoms selected from the group consisting of O,
S, and N, having 0 or 1 double bonds, having 0 or 1 carbon member
replaced by a carbonyl, and optionally substituted with
--C.sub.1-4alkyl, --OH, or halo; R.sup.d is independently selected
from the group consisting of hydrogen, --C.sub.1-4alkyl, --OH,
--OC.sub.1-6alkyl, HO--C.sub.1-4alkyl, perhaloC.sub.1-4alkyl, mono-
or di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS--C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.b is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; alternatively, one R.sup.b
and one R.sup.d may be taken together to form a double bond; and
enantiomers, diastereomers, hydrates, solvates and pharmaceutically
acceptable salts, esters and amides thereof.
Description
FIELD OF THE INVENTION
[0001] There is provided by the present invention compounds that
are dual CCK1/CCK2 receptor modulators. More particularly, there is
provided by the present invention sulfonamides that are dual
CCK1/CCK2 receptor antagonists useful for the treatment of disease
states mediated by CCK1/CCK2 receptor activity.
BACKGROUND OF THE INVENTION
[0002] This invention relates to cholecystokinin (CCK) receptor
ligands. The invention also relates to methods for preparing such
ligands and to compounds that are useful intermediates in such
methods. The invention further relates to pharmaceutical
compositions comprising such ligands and methods for preparing such
pharmaceutical compositions.
[0003] The gastrins and cholecystokinins are structurally related
neuropeptides that exist in gastrointestinal tissue, gastrinomas
and, in the case of the cholecystokinins, the central nervous
system (J. H. Walsh, Gastrointestinal Hormones, L. R. Johnson, ed.,
Raven Press, New York, 1994, p. 1).
[0004] The actions of CCK are mediated by two G-protein coupled
receptors: CCK-1 (formerly CCK-A) and CCK-2 (formerly
CCK-B/gastrin). These CCK receptors are expressed throughout the
gastrointestinal system and in different parts of the central
nervous system including the cortex, the striatum, the
hypothalamus, the hippocampus, the olfactory bulb, the vagal
afferent neurones, in different enteric nerves, and in the genital
tract.
[0005] Several forms of gastrin are found including 34-, 17- and
14-amino acid species with the minimum active fragment being the
C-terminal tetrapeptide (TrpMetAspPhe-NH.sub.2), which is reported
in the literature to have full pharmacological activity (H. J.
Tracy and R. A. Gregory, Nature (London), 1964, 204:935-938). Much
effort has been devoted to the synthesis of analogs of this
tetrapeptide (and the N-protected derivative Boc-TrpMetAspPhe-NH2)
in an attempt to elucidate the relationship between structure and
activity.
[0006] Natural cholecystokinin is a 33 amino acid peptide (CCK-33),
the C-terminal 5 amino acids of which are identical to those of
gastrin. Also found naturally is the C-terminal octapeptide (CCK-8)
of CCK-33. A review of CCK receptors, ligands and the activities
thereof may be found in P. de Tullio et al. (Exp. Opin. Invest.
Drugs, 2000, 9(1):129-146).
[0007] Gastrin and cholecystokinin are key regulators of
gastrointestinal function. In addition, cholecystokinin is a
neurotransmitter in the brain. Gastrin is one of the three primary
stimulants of gastric acid secretion. In addition to the acute
stimulation of gastric acid, gastrin has a trophic effect on the
gastrointestinal mucosa and is implicated as a trophic hormone of
several adenocarcinomas, including pancreatic, colorectal,
esophageal and small cell lung.
[0008] Cholecystokinin stimulates intestinal motility, gallbladder
contraction, and biliary and pancreatic enzyme secretion, and is
known to have trophic actions on the pancreas thus increasing,
inter alia, pancreatic enzyme production. Cholecystokinin also
inhibits gastric emptying and has various effects in the central
nervous system, including regulation of appetite and pain. CCK
regulates GI motility and specifically gut and colonic motility.
CCK promotes protein synthesis and cell growth, especially in the
GI system and in the pancreas. CCK is involved in mediating satiety
after a meal. CCK is an important neuromodulator and
neurotransmitter involved in anxiety and panic disorder. CCK
modulates the release of dopamine. CCK is also known to antagonize
morphine and beta-endorphine induced analgesia and the action on
nociception.
[0009] Gastrin acts on CCK2 (otherwise known as gastrin/CCK-B
receptors) whereas cholecystokinin acts on both CCK2 and CCK1
receptors (otherwise known as cholecystokinin/CCK-A receptors).
Compounds that bind to cholecystokinin and/or gastrin receptors are
important because of their potential pharmaceutical use as
antagonists of the natural peptides or mimetics of the natural
peptides acting as partial or full agonists at the cholecystokinin
and/or gastrin receptors. A selective gastrin receptor antagonist
has not yet been marketed. However, several are currently
undergoing clinical evaluation. JB95008 (gastrazole) is being
developed by The James Black Foundation and Johnson & Johnson
Pharmaceutical Research & Development LLC for the potential
treatment of advanced pancreatic cancer (pancreatic
adenocarcinoma), and is currently in Phase II clinical trials. ML
Laboratories and Panos are developing L-365,260 (Colycade), which
is in Phase II clinical trials for pain. Other potential
indications included eating disorders and cancer. YF-476 (formerly
YM-220), under joint development by Yamanouchi and Ferring Research
Institute, is in Phase I clinical trials for gastro-esophageal
reflux disease (GERD). In Phase I trials, Zeria Pharmaceutical is
investigating Z-360, an orally available 1,5-benzodiazepine
derivative (WO-09825911), as a potential treatment for
gastroduodenal ulcers and reflux esophagitis. CR 2945
(itriglumide), an orally active anthranilic acid derivative, has
been investigated by Rotta in Phase I trials for anxiety disorders,
cancer (particularly colon cancer) and peptic ulcer.
[0010] Gastrimmune, Aphton Corporation's anti-gastrin vaccine,
which works by chemical neutralization of the hormone, is
undergoing late stage clinical trials for cancer indications, in
particular, pancreatic and gastric tumors.
[0011] In addition to those indications described above, gastrin
(CCK2) antagonists have been proposed for the following
gastrin-related disorders: gastrointestinal ulcers, Barrett's
esophagus, antral G cell hyperplasia, pernicious anaemia,
Zollinger-Ellison syndrome, and other conditions in which lower
gastrin activity or lower acid secretion is desirable.
[0012] Cholecystokinin (CCK1) receptors have been shown to mediate
cholecystokinin-stimulated gallbladder contraction, pancreatic
enzyme secretion, satiety, gastric emptying inhibition and
regulation of peristalsis, indicating a key role in the integrated
physiological gastrointestinal response to a meal. In addition,
there is evidence that cholecystokinin receptors mediate a
mitogenic action of cholecystokinin on some adenocarcinomas.
Consequently, selective cholecystokinin receptor antagonists, for
example, tarazepide, devazepide (Merck), lorglumide (Rotta), 2-NAP
(JBF), dexloxiglumide (Rotta), and lintitript (Sanofi) have been
examined in the clinic for potential applications in, inter alia,
irritable bowel syndrome, chronic constipation, non-ulcer
dyspepsia, acute and chronic pancreatitis, biliary disease and
pancreatic cancer. Also, Kaken Pharmaceuticals and Mitsubishi-Tokyo
Pharmaceuticals are awaiting registration in Japan on loxiglumide,
a CCK-1 receptor antagonist for the treatment of GI cancers and
pancreatitis. Loxiglumide is the racemate of dexloxiglumide.
[0013] A number of CCK-1 receptor agonists are under preclinical
investigation. Glaxo Smith Kline, Inc. is investigating GW 5823, GW
7854, GW 7178 and GW 8573, 1,5-benzodiaepines for the treatment of
gallstones, gastrointestinal disease and obesity. Also, Pfizer is
investigating the CCK-1 receptor agonist, PD 170292, for
obesity.
[0014] Additional roles of cholecystokinin receptors include the
regulation of appetite and metabolism, indicating potential
therapeutic applications in the treatment of disorders such as
obesity and anorexia nervosa. Other possible uses are in the
potentiation of opiate (for example morphine) analgesia and in the
treatment of cancers, especially of the pancreas. Moreover, ligands
for cholecystokinin/gastrin receptors in the brain have been
claimed to possess anxiolytic activity, and gastrin receptor
antagonists would be expected to act as neurological agents towards
the relief of anxiety and related neuroses and psychoses.
[0015] Non-selective compounds that act as antagonists of both
CCK-1 and CCK-2 receptors are expected to offer the combined
potential therapeutic applications the selective antagonists
described above with the advantage of guaranteed synchronized
action compared to the use of a combination of two selective
compounds. These `dual` or `mixed` CCK receptor antagonists are
important because of their potential pharmaceutical application for
treatments of disorders where both cholecystokinin and gastrin
stimulated effects are implicated. Thus, a combination of the
inhibition of the number of transient lower esophageal sphincter
relaxations, reported to be under the control of CCK-1 receptors
(Boulant, J., et al. Gut, 1997, 40:575-581), together with
inhibition of CCK-2 receptor mediated gastric acid secretion and
gastric mucosal growth might be expected to be valuable for the
treatment of gastrointestinal reflux disease. Similarly, the
concurrent antagonism of cholecystokinin stimulated, CCK-1 receptor
mediated, inhibition of gastric emptying together with inhibition
of transient lower esophageal sphincter relaxations, gastric acid
secretion and gastric mucosal growth might also be expected to be
valuable for the treatment of gastrointestinal or gastroesophageal
reflux disease. Moreover, it has been hypothesized that CCK-1/CCK-2
receptor dual antagonists, such as those described by Fujisawa
Pharmaceutical Co. Ltd. (Tabuchi, S., et al. Chem. Pharm. Bull.
2000, 48(1):1-15), will be more efficacious for the treatment of
pancreatitis than a selective CCK-1 receptor antagonist alone as a
consequence of inhibiting acid secretion induced pancreatic enzyme
release as well as cholecystokinin-stimulated pancreatic enzyme
release.
[0016] The features and advantages of the invention are apparent to
one of ordinary skill in the art. Based on this disclosure,
including the summary, detailed description, background, examples,
and claims, one of ordinary skill in the art will be able to make
modifications and adaptations to various conditions and usages.
Publications described herein are incorporated by reference in
their entirety.
[0017] Described herein is a series of aryl sulfonamide compounds
with the ability to modulate the activity of CCK1 and CCK2
receptors.
SUMMARY OF THE INVENTION
[0018] The invention features an aryl sulfonamide compound of
formula (I):
##STR00001##
wherein X is C.sub.1-2alkyl or a bond; [0019] R.sup.1 is selected
from the group consisting of [0020] a) naphthyl, phenyl, said
phenyl optionally fused at two adjacent carbon atoms to R.sup.f,
[0021] R.sup.f is a linear 3- to 5-membered hydrocarbon moiety
having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members
which is a carbonyl, [0022] b) Ar.sup.6--, where Ar.sup.6 is a
6-membered heteroaryl having carbon as a point of attachment,
having 1 or 2 heteroatom members which are --N.dbd. and optionally
benzo or pyrido fused, [0023] c) Ar.sup.5--, where Ar.sup.5 is a
5-membered heteroaryl having carbon as a point of attachment,
having 1 heteroatom member selected from the group consisting of O,
S, >NH, and >NC.sub.1-4alkyl, having 0 or 1 additional
heteroatom member which is --N.dbd. and optionally benzo or pyrido
fused, [0024] d) Ar.sup.6-6--, where Ar.sup.6 is phenyl having the
point of attachment and fused to a 6-membered heteroaryl having 1
or 2 heteroatom members which are --N.dbd., [0025] e) Ar.sup.6-5--,
where Ar.sup.5 is phenyl or pyridyl having the point of attachment
and fused to a 5-membered heteroaryl having 1 heteroatom member
selected from the group consisting of O, S, >NH, and
>NC.sub.1-4alkyl, and having 0 or 1 additional heteroatom member
which is --N.dbd., [0026] where each of a) to e) is substituted
with 0, 1, 2, or 3 of R.sup.q, [0027] R.sup.q is independently
selected from the group consisting of --C.sub.1-4alkyl, hydroxy,
fluoro, chloro, bromo, iodo, trifluoromethyl, nitro, cyano,
aminoC.sub.1-4alkyl, C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
C.sub.1-4alkylO-C.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS-C.sub.1-4alkyl, C.sub.1-4alkoxy, and
C.sub.1-4alkylS--; [0028] R.sup.2 is selected from the group
consisting of --H, --C.sub.1-6alkyl, --C.sub.2-6alkenyl,
--C.sub.2-6alkynyl, --C.sub.3-7cycloalkyl, and
--C.sub.3-7cycloalkenyl; [0029] R.sup.a is, independently, selected
from the group consisting of --C.sub.1-6alkyl, --C.sub.2-6alkenyl,
--C.sub.3-6cycloalkyl, phenyl, furanyl, thiophenyl, benzyl,
pyrrol-1-yl, --OH, --OC.sub.1-6alkyl, OC.sub.3-6cycloalkyl,
--Ophenyl, --Obenzyl, --SH, --SC.sub.1-6alkyl,
--SC.sub.3-6cycloalkyl, --Sphenyl, --Sbenzyl, cyano, nitro,
--N(R.sup.y)R.sup.z (wherein R.sup.y and R.sup.z are independently
--H, --C.sub.1-4alkyl, or C.sub.1-6cycloalkylC.sub.1-4alkyl),
--(C.dbd.O)C.sub.1-4alkyl, --SCF.sub.3, halo, trifluoromethyl,
--OCF.sub.3, and --COOC.sub.1-4alkyl, --COOH, or, alternatively,
two adjacent R.sup.a, may be taken together with the carbons of
attachment to form a fused ring selected from the group consisting
of phenyl, pyridyl, and pyrimidinyl; [0030] alternatively, R.sup.2
and one of R.sup.a may be taken together as --CH.sub.2-- or
>C.dbd.O to form a fused ring to the phenyl; [0031] R.sup.b is
selected from the group consisting of 2,4-difluoro, 2,6-difluoro,
or alternatively, two adjacent R.sup.b substituents at 2- and
3-positions may be taken together to form a five- or six-membered
heterocyclic ring selected from the group consisting of oxazole,
thiazole, thiadiazole, [1,3]dioxole, and pyrazine; [0032] R.sup.c
is independently selected from the group consisting of hydrogen,
--C.sub.1-4alkyl, perhaloC.sub.1-4alkyl, mono- or
di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HO--C.sub.1-4alkyl,
HS--C.sub.1-4alkyl, C.sub.1-4alkylS-C.sub.1-4alkyl,
--C.sub.0-2alkylCOOC.sub.1-4alkyl, --C.sub.0-2alkylCOOH, and
--C.sub.0-2alkylCON(R.sup.s)R.sup.t; --COO--C.sub.0-2alkyl-ringA,
and --COO--C.sub.1-2alkyl-CON(R.sup.s)R.sup.t; [0033] R.sup.s and
R.sup.t are independently selected from the group consisting of
--H, --C.sub.1-4alkyl, C.sub.1-6cycloalkylC.sub.1-4alkyl, phenyl,
phenyl substituted with halo, benzyl, benzyl substituted with halo,
[0034] or alternatively, R.sup.s and R.sup.t taken together with
their nitrogen of attachment form pyrrolidine, piperidine, or
morpholine; [0035] ringA is selected from the group consisting of
[0036] i) a 6-membered heteroaryl having carbon as a point of
attachment and having 1 or 2 heteroatom members which are --N.dbd.;
[0037] ii) a 5-membered heteroaryl having carbon as a point of
attachment, having 1 heteroatom member selected from the group
consisting of O, S, >NH, and >NC.sub.1-4alkyl, and having 0
or 1 additional heteroatom member which is --N.dbd.; and [0038]
iii) a 5- or 6-membered non-aromatic heterocycle having a carbon or
nitrogen as a point of attachment, having 1 or 2 heteroatoms
selected from the group consisting of O, S, and N, having 0 or 1
double bonds, having 0 or 1 carbon member replaced by a carbonyl,
and optionally substituted with --C.sub.1-4alkyl, --OH, or halo;
[0039] R.sup.d is independently selected from the group consisting
of hydrogen, --C.sub.1-4alkyl, --OH, --OC.sub.1-6alkyl,
HO--C.sub.1-4alkyl, perhaloC.sub.1-4alkyl, mono- or
di-haloC.sub.1-4alkyl, aminoC.sub.1-4alkyl,
C.sub.1-4alkylaminoC.sub.1-4alkyl,
diC.sub.1-4alkylaminoC.sub.1-4alkyl, HS--C.sub.1-4alkyl,
C.sub.1-4alkylS-C.sub.1-4alkyl, and optionally substituted phenyl;
or two R.sup.d together can be .dbd.O where at least one R.sup.c is
selected from the group consisting of --COOC.sub.1-4alkyl,
--COO-ringA, --COOH, --CON(R.sup.s)R.sup.t, and
--COOC.sub.1-2alkylCON(R.sup.s)R.sup.t; [0040] alternatively, one
R.sup.c and one R.sup.d may be taken together to form a double
bond; [0041] and enantiomers, diastereomers, hydrates, solvates and
pharmaceutically acceptable salts, esters and amides thereof.
[0042] Isomeric forms of the compounds of formula (I), and of their
pharmaceutically acceptable salts, esters, and amides, are
encompassed within the present invention, and reference herein to
one of such isomeric forms is meant to refer to at least one of
such isomeric forms. One of ordinary skill in the art will
recognize that compounds according to this invention may exist, for
example in a single isomeric form whereas other compounds may exist
in the form of a regioisomeric or stereoisomeric mixture.
[0043] The present invention provides methods of treating or
preventing diseases and conditions mediated by the CCK1 and CCK2
receptors. The invention also features pharmaceutical compositions
containing such compounds and methods of using such compositions in
the treatment or prevention of disease states mediated by dual
CCK1/CCK2 receptor antagonist activity.
[0044] Additional features and advantages of the invention will
become apparent from the detailed description and examples below,
and the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0045] Particular preferred compounds of the invention comprise a
compound of Formula (I), or an enantiomer, diastereomer, hydrate,
solvate thereof, or a pharmaceutically acceptable salt, amide or
ester thereof, wherein R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.c,
and R.sup.d have any of the meanings defined hereinabove and
equivalents thereof, or at least one of the following assignments
and equivalents thereof. Such assignments may be used where
appropriate with any of the definitions, claims or embodiments
defined herein:
[0046] Preferably, X is a bond.
[0047] Preferably, R.sup.1 is selected from the group consisting
of
[0048] a) phenyl, naphthyl,
6,7,8,9-tetrahydro-5H-benzocyclohepten-1,2,3 or 4-yl, optionally
5,6,7,8 or 9 oxo substituted, 5,6,7,8-tetrahydro-naphthalen-1,2,3
or 4-yl, optionally 5,6,7 or 8 oxo substituted,
[0049] b) pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,
quinolin-2,3 or 4-yl, isoquinolin-1,3 or 4-yl, quinazolin-2 or
4-yl, quinoxalin-2 or 3-yl, naphthyridinyl,
[0050] c) furanyl, thiophenyl, 1-(H or C.sub.1-4alkyl)pyrrolyl,
oxazolyl, thiazolyl, pyrazolyl, imidazolyl, isoxazolyl,
isothiazolyl, benzofuran-2 or 3-yl, benzothiophen-2 or 3-yl, 1-(H
or C.sub.1-4alky)-1H-indol-2 or 3-yl, 1-(H or
C.sub.1-4alkyl)-1H-benzimidazol-2-yl, benzooxazol-2-yl,
benzothiazol-2-yl, 1H-pyrrolopyridin-2 or 3-yl,
[0051] d) quinolin-5,6,7 or 8-yl, isoquinolin-5,6,7 or 8-yl,
quinazolin-5,6,7 or 8-yl, quinoxalin-5,6,7 or 8-yl, and
[0052] e) benzofuran-4,5,6 or 7-yl, benzothiophen-4,5,6 or 7-yl,
1-(H or C.sub.1-4alkyl)-1H-indol-4,5,6 or 7-yl, 1-(H or
C.sub.1-4alkyl)-1H-benzimidazol-4,5,6 or 7-yl, benzooxazol-4,5,6 or
7-yl, benzothiazol-4,5,6 or 7-yl, 1H-pyrrolopyridin-4,5,6 or 7-yl,
where each of a) to e) is substituted with 0, 1, 2, or 3 of
R.sup.q.
[0053] Most preferably, R.sup.1 is selected from the group
consisting of phenyl, 6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl
optionally 5,6,7,8 or 9 oxo substituted, naphthyl, pyridyl,
furanyl, thiophenyl, and benzothiophenyl, where each member is
substituted with 0, 1, 2, or 3 of R.
[0054] Specific R.sup.1 are selected from the group consisting of
phenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl,
2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl,
3,4-dichlorophenyl, 2,6-dichlorophenyl, 2,4,6-trichlorophenyl,
2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl,
3,4-difluorophenyl, 2,6-difluorophenyl, 2,4,6-trifluorophenyl,
2-chloro-4-fluorophenyl, 2-fluoro-4-bromophenyl,
2-fluoro-4-chlorophenyl, 3-bromo-4-chlorophenyl,
3-bromo-4-fluorophenyl, 4-chloro-3-iodophenyl, 2-methylphenyl,
4-methylphenyl, 4-methoxyphenyl, 4-dimethylaminophenyl,
2-methylsulfanylphenyl, 2-trifluoromethylphenyl,
4-trifluoromethylphenyl, 4-nitrophenyl, 3-cyanophenyl,
4-cyanophenyl, naphthyl, thiophen-3-yl, 5-bromothiophen-3-yl, and
benzothiophen-3-yl.
[0055] Preferably, R.sup.f is selected from the group consisting of
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2-- and
--(C.dbd.O)CH.sub.2CH.sub.2CH.sub.2--.
[0056] Preferably, R.sup.q is selected from the group consisting of
methyl, ethyl, propyl, t-butyl, hydroxy, fluoro, chloro, bromo,
iodo, trifluoromethyl, nitro, cyano, aminomethyl,
methylaminomethyl, dimethylaminomethyl, hydroxymethyl,
methoxymethyl, methylsulfanyl, methylsulfanylmethyl, methoxy,
ethoxy, mercaptomethyl, and mercaptoethyl.
[0057] Most preferably, R.sup.q is selected from the group
consisting of methyl, fluoro, chloro, bromo, iodo, trifluoromethyl,
nitro, and cyano.
[0058] Preferably, R.sup.2 is selected from the group consisting of
--H, methyl, ethyl, i-propyl, t-butyl, allyl, propargyl,
cyclopropyl, cyclohexyl, and cyclopentenyl.
[0059] Preferably, R.sup.2 and one of R.sup.a are taken together as
--CH.sub.2-- or >C.dbd.O to form a fused ring to the phenyl.
[0060] More preferably, R.sup.2 is --H or methyl.
[0061] Preferably, each R.sup.a is independently selected from the
group consisting of methyl, ethyl, propyl, i-propyl, ethenyl,
propenyl, cyclopropyl, cyclobutyl, phenyl, furanyl, thiophenyl,
pyrrol-1-yl, benzyl, methoxy, ethoxy, propoxy, cyclopropoxy,
cyclobutoxy, cyclopentoxy, phenoxy, benzoxy, mercapto,
methylsulfanyl, ethylsulfanyl, t-butylsulfanyl,
cyclopropylsulfanyl, phenylsulfanyl, nitro, cyano, amino,
dimethylamino, (cyclohexylmethyl)amino, acetyl, --SCF.sub.3, iodo,
fluoro, chloro, bromo, trifluoromethyl, --OCF.sub.3, and
methoxycarbonyl.
[0062] Preferably, there is one R.sup.a. More preferably, there is
one R.sup.a positioned on the ring para to the amide substituent.
Preferably, there are two R.sup.a substituents.
[0063] Preferably, where two adjacent R.sup.a are taken together
with the carbons of attachment to form a fused ring, the fused ring
is phenyl.
[0064] Most preferably, each R.sup.a is independently selected from
the group consisting of methyl, i-propyl, ethenyl, 2-propenyl,
cyclopropyl, phenyl, thiophenyl, methoxy, ethoxy, propoxy,
i-propoxy, nitro, cyano, dimethylamino, (cyclohexylmethyl)amino,
acetyl, fluoro, chloro, bromo, iodo, --CF.sub.3, and fused
phenyl.
[0065] Preferably, two R.sup.b are 2,6-difluoro or
2,4-difluoro.
[0066] Preferably, two adjacent R.sup.b substituents at 2- and
3-positions are taken with the benzene ring of attachment to form
benzothiazole, benzothiadiazole, or quinoxaline.
[0067] Preferably, R.sup.c is selected from the group consisting of
hydrogen, methyl, ethyl, i-propyl, hydroxymethyl, methoxymethyl,
dimethylaminomethyl, methylsulfanylmethyl, methoxycarbonyl,
ethoxycarbonyl, tert-butoxycarbonyl, methoxycarbonylmethyl,
carboxy, carboxymethyl, carbamoyl, carbamoylmethyl,
dimethylcarbamoyl, piperidine-1-carbonyl,
5-methyl-2-oxo-[1,3]dioxol-4-yl-methoxycarbonyl,
3-pyridylmethoxycarbonyl, 3-chlorobenzylcarbamoyl,
4-fluorobenzylcarbamoyl, benzylcarbamoyl, phenylcarbamoyl,
dimethylcarbamoylmethoxycarbonyl, and
2-morpholin-4-ylethoxycarbonyl.
[0068] More preferably, R.sup.c is selected from the group
consisting of hydrogen, methyl, hydroxymethyl, methoxycarbonyl,
methoxycarbonylmethyl, carboxy, carboxymethyl, carbamoyl, and
carbamoylmethyl.
[0069] Preferably, the carbon to which the two R.sup.c groups are
attached is in the (S) configuration.
[0070] Preferably, R.sup.d is selected from the group consisting of
hydrogen, methyl, ethyl, i-propyl, hydroxy, hydroxymethyl,
methoxymethyl, dimethylaminomethyl, phenyl, 4-chlorophenyl, and
methylsulfanylmethyl.
[0071] Preferably, two R.sup.d together form .dbd.O.
[0072] More preferably, R.sup.d is selected from the group
consisting of hydrogen, methyl, phenyl, and hydroxy.
[0073] Compounds of Formula (I) comprise compounds that satisfy any
one of the combinations of definitions given herein and equivalents
thereof.
[0074] It is understood that some compounds referred to herein are
chiral and/or have geometric isomeric centers, for example E- and
Z-isomers. The present invention encompasses all such optical
isomers, including diastereomers and racemic mixtures,
atropisomers, and geometric isomers, and mixtures thereof, that
possess the activity that characterizes the compounds of this
invention. In addition, certain compounds referred to herein can
exist in solvated as well as unsolvated forms. It is understood
that this invention encompasses all such solvated and unsolvated
forms that possess the activity that characterizes the compounds of
this invention.
[0075] Compounds according to the present invention that have been
modified to be detectable by some analytic technique are also
within the scope of this invention. The compounds of the present
invention may be labeled with radioactive elements such as
.sup.125I, .sup.18F, .sup.11C, .sup.64Cu, .sup.3H, .sup.14C, and
the like for use in imaging or for radioactive treatment of
patients. An example of such compounds is an isotopically labeled
compound, such as an .sup.18F isotopically labeled compound that
may be used as a probe in detection and/or imaging techniques, such
as positron emission tomography (PET) and single-photon emission
computed tomography (SPECT). Preferably, compounds of the present
invention labeled with .sup.18F or .sup.11C may be used as a
positron emission tomography (PET) molecular probe for studying
CCK-mediated disorders. Alternatively, compounds of the present
invention labeled with .sup.14C may be used in metabolic studies.
Another example of such compounds is an isotopically labeled
compound, such as a deuterium and/or tritium labeled compound that
may be used in reaction kinetic studies. The compounds described
herein may be reacted with an appropriate functionalized
radioactive reagents using conventional chemistry to provide
radiolabeled compounds.
[0076] Preferred compounds of the present invention are selected
from the group consisting of:
TABLE-US-00001 EX Chemical Name 1
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chlo-
ro- phenyl)-propyl]-benzamide; 2
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]--
3- (3,4-dichloro-phenyl)-propionic acid; 3
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylamino-
]-3- phenyl-propionic acid; 4
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]--
3- (3-bromo-phenyl)-propionic acid; 5
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(3,4-dichloro-
phenyl)-propyl]-benzamide; 6
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2,2-bis-(4-chloro-phenyl)-
- ethyl]-4-chloro-benzamide; 7
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-phen-
yl)- 2-methyl-propyl]-benzamide; 8
(S)-3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino-
)- benzoylamino]-propionic acid methyl ester; 9
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-naphthal-
en- 2-yl-propionic acid; 10
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,4-
difluorobenzenesulfonylamino)-benzamide; 11
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-carbamoyl-2-(4-chl-
oro- phenyl)-ethyl]-4,5-dichloro-benzamide; 12
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-pheny-
l)-1- hydroxymethyl-ethyl]-4-methyl-benzamide; 13
(S)-Benzo[1,2,5]thiadiazole-4-sulfonic acid
[6-bromo-1,3-dioxo-2-(2-phenyl-
propyl)-2,3-dihydro-1H-isoindol-4-yl]-amide; 14
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(4-chloro-phenyl)-propionic acid; 15
(R)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-propionic acid; 16
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[2-(3,4-d-
ichloro- phenyl)-propyl]-benzamide; 17
(R)-2-[2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoylamino]-3-phe-
nyl- propionic acid; 18
(.+-.)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3,4-
- dichloro-phenyl)-3-oxo-propionic acid methyl ester; 19
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-
- (3,4-dichloro-phenyl)-3-hydroxy-propionic acid; 20
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-phenethy-
l- benzamide; 21
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro-phen-
yl)- propyl]-benzamide; 22
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-1-me-
thyl- ethyl]-4-trifluoromethyl-benzamide; 23
2-(Benzothiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro-phenyl)-1-meth-
yl- ethyl]-benzamide; 24
4-Bromo-N-[2-(4-chloro-phenyl)-propyl]-2-(2,6-difluoro-
benzenesulfonylamino)-benzamide; 25
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino]-3-
phenyl-propionic acid; 26
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethyl-
benzoylamino]-3-phenyl-propionic acid; 27
2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phenyl-propio-
nic acid; 28
2-[2-(Benzothiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-phenyl-
propionic acid; 29
2-[4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phenyl-
propionic acid; 30
4-Bromo-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-
benzenesulfonylamino)-benzamide; 31
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-propyl)-
- benzamide; 32
3-(3,4-Dichloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-
- benzoylamino]-propionic acid; 33
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(-
4- chloro-phenyl)-propionic acid; 34
3-(4-Chloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-
benzoylamino]-propionic acid; 35
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-pro-
pyl)- benzamide; 36
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-pro-
pyl)- benzamide; 37
(S)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-propyl)-
benzamide; 38
(R)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-propyl)-
benzamide; 39
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phenyl)-
propyl]-4-iodo-benzamide; 40
N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-sulfonylamin-
o)- benzamide; 41
2-[4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(2,4-
dichloro-phenyl)-propionic acid; 42
N-[2-(3,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonylamino-
)-4- iodo-benzamide; 43
4-Chloro-N-[2-(2,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-
benzenesulfonylamino)-benzamide; 44
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-nitro-phenyl)-pr-
opyl]- benzamide; 45
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-trifluoromethyl-
phenyl)-propyl]-benzamide; 46
2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(2,4-
dichloro-phenyl)-propionic acid; 47
N-[2-(2,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonylamino-
)-4- iodo-benzamide; 48
2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-N-[2-(4-nitro-phenyl)-prop-
yl]- benzamide; 49
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-((2S,1R)-2-hydro-
xy-1- methyl-2-phenyl-ethyl)-benzamide; 50
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-indan-2-yl-
benzamide; 51
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(2-pyri-
din-2- yl-ethyl)-benzamide hydrochloride; 52
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chl-
oro- phenyl)-1-hydroxymethyl-ethyl]-benzamide; 53
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chlo-
ro- phenyl)-1-methyl-ethyl]-benzamide; 54
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-pheny-
l)- propyl]-4-methyl-benzamide; 55
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[(1R,2S)-2-(4-ch-
loro- phenyl)-2-hydroxy-1-methyl-ethyl]-benzamide; 56
(2S,3R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-
benzoylamino]-3-(3,4-dichloro-phenyl)-butyric acid; 57
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-d-
ichloro- phenyl)-propyl]-benzamide; 58
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-N-[2-(3-
,4- dichloro-phenyl)-propyl]-benzamide; 59
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(quinoxaline-5-
sulfonylamino)-benzamide; 60
(R)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-propionic acid; 61
(.+-.)-N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-sulfo-
nylamino)- benzamide; 62
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoylamin-
o]-3- (4-chloro-phenyl)-propionic acid; 63
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3-cyan-
o- phenyl)-propionic acid; 64
(S)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,4-
dichloro-phenyl)-butyric acid; 65
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
- benzoylamino]-propionic acid methyl ester; 66
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
- benzoylamino]-propionic acid; 67
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(4-chloro-phenyl)-propionic acid methyl ester; 68
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(4-chloro-phenyl)-propionic acid; 69
(R)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-3-(-
4- chloro-phenyl)-propionic acid methyl ester; 70
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(2,4-dichloro-
- phenyl)-ethyl]-benzamide; 71
(S)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-3-(-
4- chloro-phenyl)-propionic acid methyl ester; 72
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-prop-
yl]-4- iodo-benzamide; 73
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-
- methyl-2,2-diphenyl-ethyl)-benzamide; 74
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydroxy-1-
- methyl-2,2-diphenyl-ethyl)-benzamide; 75
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(2,4-dichloro-phenyl)--
ethyl]- benzamide; 76
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamin-
o]-3- (4-fluoro-phenyl)-propionic acid; 77
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamin-
o]-3- thiophen-3-yl-propionic acid; 78
(S)-3-(3-Chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-propionic acid; 79
(S)-2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-p-tolyl-
propionic acid; 80
N-[2-(4-Bromo-phenyl)-ethyl]-4-chloro-2-(2,6-difluoro-benzenesulfonylam-
ino)- benzamide; 81
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-6-chloro-N-[2-(3,4-dichloro-
- phenyl)-propyl]-benzamide; 82
(R)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,4-
dichloro-phenyl)-butyric acid; 83
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoylamin-
o]-3- (4-chloro-phenyl)-propionic acid; 84
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3-nitr-
o- phenyl)-propionic acid; 85
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3,4-
difluoro-phenyl)-propionic acid; 86
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(4-cyan-
o- phenyl)-propionic acid; 87
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-thiophe-
n-3- yl-propionic acid; 88
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-butyric acid methyl ester; 89
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-butyric acid; 90
(S)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-propionic acid; 91
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3- (3-bromo-4-chloro-phenyl)-propionic acid;
92
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3- (4-chloro-3-iodo-phenyl)-propionic acid; 93
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3- (3-bromo-4-fluoro-phenyl)-propionic acid; 94
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3,3- bis-(4-chloro-phenyl)-propionic acid; 95
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3- (4-chloro-phenyl)-3-methyl-butyric acid; 96
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(-
4- chloro-phenyl)-2-methyl-propionic acid; 97
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(-
3- bromo-phenyl)-propionic acid; 98
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(-
4- chloro-phenyl)-3-hydroxy-propionic acid; 99
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(4-chloro-phen-
yl)- 2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide; 100
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phenyl)-
-2- hydroxy-1-methyl-ethyl]-4-iodo-benzamide; 101
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-phen-
yl)- 2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide; 102
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(3,4- dichloro-phenyl)-3-hydroxy-propionic acid; 103
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(3- bromo-phenyl)-butyric acid; 104
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-prop-
yl]-4- iodo-benzamide; 105
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(3,4- dichloro-phenyl)-acrylic acid; 106
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]- 3,3-bis-(4-chloro-phenyl)-propionic acid; 107
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (4-chloro-phenyl)-3-methyl-butyric acid; 108
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-phen-
yl)- 2-hydroxy-1-methyl-ethyl]-4-chloro-benzamide; 109
2-[2-(Benzooxazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-3-(4-ch-
loro- phenyl)-propionic acid; 110
2-[2-(Benzooxazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,4-dichlo-
ro- phenyl)-propionic acid; 111
2-[2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,4-
dichloro-phenyl)-propionic acid; 112
2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-phenyl)--
2- hydroxy-1-methyl-ethyl]-benzamide; 113
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylami-
no]-3- (3-bromo-4-fluoro-phenyl)-propionic acid
5-methyl-2-oxo-[1,3]dioxol-4- ylmethyl ester; 114
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylami-
no]-3- (3-bromo-4-fluoro-phenyl)-propionic acid pyridin-3-ylmethyl
ester; 115
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (3-bromo-phenyl)-propionic acid; 116
(2S,3R)-3-(3,4-Dichloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamin-
o)-4- iodo-benzoylamino]-butyric acid methyl ester; 117
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (3,4-dichloro-phenyl)-propionic acid; 118
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (3,4-dichloro-phenyl)-propionic acid; 119
(S)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3--
(3,4- dichloro-phenyl)-propionic acid; 120
(R)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3--
(3,4- dichloro-phenyl)-propionic acid; 121
anti-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylam-
ino]- 3-(3,4-dichloro-phenyl)-3-hydroxy-propionic acid; 122
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (3-bromo-4-chloro-phenyl)-propionic acid methyl ester; 123
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (3-bromo-4-fluoro-phenyl)-propionic acid methyl ester; 124
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylami-
no)- benzoylamino]-propionic acid methyl ester; 125
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamin-
o)-4- iodo-benzoylamino]-propionic acid methyl ester; 126
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylami-
no)- benzoylamino]-propionic acid; 127
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamin-
o)-4- iodo-benzoylamino]-propionic acid; 128
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3-chlor-
o- benzylcarbamoyl)-2-(3,4-dichloro-phenyl)-ethyl]-benzamide; 129
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-benzylcarbamoyl-2-
-(3,4- dichloro-phenyl)-ethyl]-4-chloro-benzamide; 130
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-dic-
hloro- phenyl)-1-(4-fluoro-benzylcarbamoyl)-ethyl]-benzamide; 131
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamin-
o]-3- (3,4-dichloro-phenyl)-propionic acid; 132
(S)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-
benzoylamino]-propionic acid; 133
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (2,4-dichloro-phenyl)-propionic acid; 134
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (2,4-dichloro-5-fluoro-phenyl)-propionic acid; 135
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (3-iodo-phenyl)-propionic acid; 136
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (4-chloro-3-iodo-phenyl)-propionic acid methyl ester; 137
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamin-
o)- benzoylamino]-propionic acid methyl ester; 138
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamin-
o)- benzoylamino]-propionic acid; 139
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4-dic-
hloro- phenyl)-1-phenylcarbamoyl-ethyl]-benzamide; 140
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4-dic-
hloro- benzyl)-2-oxo-2-piperidin-1-yl-ethyl]-benzamide; 141
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3,4-dichloro-phenyl)-propionic acid; 142
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamin-
o]-3- (3-bromo-4-chloro-phenyl)-propionic acid methyl ester; 143
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamin-
o]-3- (3-bromo-4-fluoro-phenyl)-propionic acid methyl ester; 144
(Z)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3,4-dichloro-phenyl)-acrylic acid; 145
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (3-bromo-4-chloro-phenyl)-propionic acid; 146
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonyla-
mino)- benzoylamino]-propionic acid; 147
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-chloro-phenyl)-propionic acid; 148
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-
sulfonylamino)-benzoylamino]-propionic acid; 149
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (3-bromo-4-fluoro-phenyl)-propionic acid methyl ester; 150
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl
ester; 151
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylam-
ino)- benzoylamino]-propionic acid methyl ester; 152
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonyla-
mino)- benzoylamino]-propionic acid methyl ester; 153
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-
sulfonylamino)-benzoylamino]-propionic acid methyl ester; 154
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino-
]-3- (3,4-dichloro-phenyl)-propionic acid methyl ester; 155
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylam-
ino)- benzoylamino]-propionic acid; 156
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylami-
no]-3- (3-bromo-4-fluoro-phenyl)-propionic acid; 157
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid; 158
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfonylam-
ino)- benzoylamino]-propionic acid; 159
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonyla-
mino)- benzoylamino]-propionic acid; 160
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-
sulfonylamino)-benzoylamino]-propionic acid; 161
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamin-
o]-3- (3-bromo-4-chloro-phenyl)-propionic acid; 162
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamin-
o]-3- (3-bromo-4-fluoro-phenyl)-propionic acid; 163
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid ethyl
ester; 164
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(3- bromo-4-chloro-phenyl)-propionic acid; 165
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(4- chloro-3-iodo-phenyl)-propionic acid; 166
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(3- bromo-4-fluoro-phenyl)-propionic acid; 167
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3,-
3-bis- (4-chloro-phenyl)-propionic acid; 168
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3--
(4- chloro-phenyl)-3-methyl-butyric acid; 169
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-2-
hydroxy-1-methyl-ethyl]-4-iodo-benzamide; 170
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-
hydroxy-1-methyl-ethyl]-4-iodo-benzamide; 171
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]--
3,3- bis-(4-chloro-phenyl)-propionic acid; 172
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]--
3-(4- chloro-phenyl)-3-methyl-butyric acid; 173
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-
hydroxy-1-methyl-ethyl]-4-chloro-benzamide; 174
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid tert-butyl
ester; 175
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
2-morpholin-4-yl- ethyl ester; and 176
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
dimethylcarbamoylmethyl ester.
[0077] The compounds as described above may be made according to
processes within the skill of the art and/or that are described in
the schemes and examples that follow. To obtain the various
compounds herein, starting materials may be employed that carry the
ultimately desired substituents though the reaction scheme with or
without protection as appropriate. This may be achieved by means of
conventional protecting groups, such as those described in
"Protective Groups in Organic Chemistry", ed. J. F. W. McOmie,
Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts,
"Protective Groups in Organic Synthesis", 3.sup.rd ed., John Wiley
& Sons, 1999. The protecting groups may be removed at a
convenient subsequent stage using methods known from the art.
Alternatively, it may be necessary to employ, in the place of the
ultimately desired substituent, a suitable group that may be
carried through the reaction scheme and replaced as appropriate
with the desired substituent. Such compounds, precursors, or
prodrugs are also within the scope of the invention. Reactions may
be performed between the melting point and the reflux temperature
of the solvent, and preferably between 0.degree. C. and the reflux
temperature of the solvent.
[0078] The compounds of Formula (I) may be prepared by a number of
reaction schemes. Persons skilled in the art will recognize that
certain compounds are more advantageously produced by one scheme as
compared to another.
TABLE-US-00002 Table of Acronyms Term Acronym Tetrahydrofuran THF
N,N-Dimethylformamide DMF Dimethyl sulfoxide DMSO
tert-Butylcarbamoyl Boc High-pressure liquid chromatography HPLC
Acetyl Ac Ethyl acetate EtOAc Trifluoroacetic acid TFA
Methanesulfonyl chloride MsCl Dichloromethane DCM
O-(7-Azabenzotriazol-1-yl)-N,N,N',N'- HATU tetramethyluronium
hexafluorophosphate 1,5,7-Triazabicyclo[4.4.0]dec-5-ene TBD
4-(Dimethylamino)pyridine DMAP
##STR00002##
[0079] Referring to Scheme A, commercially available aminobenzoic
acid A1 is reacted with triphosgene and Hunig's base to produce the
benzofused isatoic anhydride species of the genus A2. Various
isatoic anhydrides A2 are available commercially. An amine is
acylated with the isatoic anhydride A2 to produce a benzamide A5.
Benzamide A5 may also be obtained from commercially available
anthranilic acid A3 through peptide coupling with amines A7.
Benzamide A5 may additionally be obtained from commercially
available nitrobenzoic acid A4 through peptide coupling with amines
A7, followed by reduction of the nitro group. Benzamide A5 is
sulfonylated with aryl sulfonyl chloride A6 to produce aryl
sulfonamide compounds (I).
##STR00003##
[0080] Referring to Scheme B, methyl anthranilate B1 is
sulfonylated to sulfonamide B2. The methyl (or other alkyl) ester
is hydrolyzed to the acid B3. Acid B3 undergoes peptide coupling
with amine A7 under standard conditions to produce compounds of
Formula (I).
##STR00004##
[0081] Referring to Scheme C, phenol C1 is acylated with
thionocarbamoyl chloride producing a thionocarbamate. The
thionocarbamate is isomerized by heating to thiocarbamate C3, where
good yields are obtained with heating to 240 C for about 45
minutes. Finally, the thiocarbamate is saponified to the
corresponding thiol and immediately thereafter oxidized to the
sulfonylchloride A6. Additionally, some sulfonyl chlorides may be
commercially available.
[0082] Amines of Formula A7 may be commercially available or may be
prepared according to methods described in Schemes D-1.
##STR00005##
[0083] Referring to Scheme D, a carboxylic acid or derivative of
type D1 (where X' is OH, OC.sub.1-4alkyl, a protecting group, or a
chiral auxiliary) is singly or multiply alkylated with an activated
halide containing group R.sup.d and subsequently converted to an
amine D3 by methods well known in the art. Where X' is a chiral
auxiliary, and where the R.sup.d substituents differ from one
another, particular non-racemic products are obtained.
##STR00006##
[0084] Referring to Scheme E, an amine of type E1 is converted to
E3 via alkylation with an R.sup.d-containing electrophile, followed
by removal of X'', if necessary. X'' is absent or is a protecting
group or a chiral auxiliary. The amine group "N.dbd.PG" may be a
free amine, a suitably protected amine such as a Boc-protected
amine or other carbamate, or an imine such as that derived from
benzophenone. In the case where X'' is a chiral directing group,
non-racemic E2 and E3 may also be produced. Where R.sup.c-X'' is a
t-butyl ester, alkylation may be performed in the presence of a
chiral catalyst to produce non-racemic E2 and E3. A particular
embodiment is described in Example 174. Preferably, said alkylation
is performed in the presence of
O-allyl-N-(9-anthracenylmethyl)-cinchonidinium bromide, at reduced
temperature, and with a suitable base such as CsOH.H.sub.2O.
Alternatively, alkene E4 is converted directly to E3 via addition
of the groups R.sup.d and ammonia or an ammonia equivalent across
the double bond. Alternatively, alkene E4 is converted in a similar
manner to alcohol E5, and subsequently to an amine E3 using methods
known to those skilled in the art.
##STR00007##
[0085] Referring to Scheme F, R.sup.d is introduced to an
unsaturated aldehyde (F1) by 1,4-addition to provide F2. An
aldehyde of formula F2 is then electrophilically aminated to form
an amino aldehyde F3. Oxidation and functionalization of the
aldehyde produces a carboxylic acid or a carboxylate derivative
such as F4, where Y is OH, OC.sub.1-4alkyl, or N(R.sup.y)(R.sup.z).
A carboxylic acid analog of formula F4 may be subsequently reduced
to the corresponding primary alcohol F5.
##STR00008##
[0086] Referring to Scheme G, a carboxylic acid derivative such as
an acid halide G1, where Hal is preferably chloride, reacts with an
isonitrile to provide oxazole G2. Oxazole G2 is then hydrolyzed to
an amino ketone of formula G3, where X is a bond. G3, in turn, is
modified via addition of R.sup.d to the carbonyl to form G4, or
reduced to G6 (where X is a bond) using methods well known in the
art. Alternatively, the reduction of a ketone of type G3 to an
alcohol of type G6 is performed after keto amine G3 is coupled to
the anthranilic portion as described in Schemes A and B. An amine
of type G5, or a nitrogen-protected analog, is condensed with a
suitable aldehyde (where X is C.sub.1-2alkyl or a bond) to form an
amino alcohol G6. An alkene G7 may be prepared by dehydration of
amine G6 or by condensation of an aldehyde with an appropriately
derivatized amine, or nitrogen-protected analog, of the type G8
(preferably, where G8 is a phosphorous ylid).
##STR00009##
[0087] Referring to Scheme H, single or multiple alkylation of
carboxylic acid derivative H1 provides H2, which is converted to
amine H3 using methods known to those skilled in the art.
Substituent X' is as defined above. Alternatively, carboxylic acid
derivative H1 is aminated to provide amine H4 using methods well
known in the art. Conversion of H4 to amino acid derivative H5
gives compounds of Formula (I) where Y is defined previously. Where
X' is a chiral auxiliary, certain non-racemic products may be
obtained.
##STR00010##
[0088] Referring to Scheme 1, alkylation of a protected 2-amino
malonic acid derivative 12 with an alkyl chloride or other
alkylating agent 11, in the presence of a base such as NaOEt,
provides diesters 15. Hydrolysis and decarboxylation using standard
methods gives amino acids 14. Selective deacetylization with a
suitable enzyme, such as acylase from Asperigillus genus, allows
for the isolation of non-racemic I5 and I6. The desired material
may be further processed according to the preceding schemes to
provide compounds of Formula (I). A particular embodiment is shown
in Intermediate Example 1. Enzymatic resolution is preferably
performed with the following conditions: in water, at a pH of
approximately 8, in the presence of CoCl.sub.2, and at 40.degree.
C. Preferably, the "L" enantiomer (I6) is obtained in greater than
90% ee. More preferably, the "L" enantiomer (I6) is obtained in
greater than 95% ee. Even more preferably the "L" enantiomer (I6)
is obtained in greater than 99% ee.
[0089] Compounds of Formula (I) may be converted to their
corresponding salts using methods known to those skilled in the
art. For example, amines of Formula (I) may be treated with
trifluoroacetic acid, HCl, or citric acid in a solvent such as MeOH
to provide the corresponding salt forms. Acids of Formula (I) may
be treated with NaOH or KOH to provide the corresponding salt
forms.
[0090] Compounds prepared according to the schemes described above
may be obtained as single enantiomers, diastereomers, or
regioisomers, or as racemic mixtures or mixtures of enantiomers,
diastereomers, or regioisomers. Where regioisomeric or
diastereomeric mixtures are obtained, isomers may be separated
using conventional methods such as chromatography or
crystallization. Where racemic (1:1) and non-racemic (not 1:1)
mixtures of enantiomers are obtained, single enantiomers may be
isolated using conventional separation methods known to one skilled
in the art. Particularly useful separation methods may include
chiral chromatography, recrystallization, resolution,
diastereomeric salt formation, or derivatization into
diastereomeric adducts followed by separation.
[0091] The present invention includes within its scope prodrugs of
the compounds of this invention. In general, such prodrugs will be
functional derivatives of the compounds that are readily
convertible in vivo into the required compound. Thus, in the
methods of treatment of the present invention, the term
"administering" shall encompass the treatment of the various
disorders described with a compound of Formula (I) or with a
compound that converts to a compound of Formula (I) in vivo after
administration to the patient. Conventional procedures for the
selection and preparation of suitable prodrug derivatives are
described, for example, in "Design of Prodrugs", ed. H. Bundgaard,
Elsevier, 1985; Beaumont; K.; Webster, R.; Gardner, I.; Dack, K.
Curr. Drug Metab. 2003, 4, 461-485; Mizen, L; Burton, G. Pharm.
Biotechnol. 1998, 11, 345-365. In addition to prodrugs, the
invention provides the salts, esters, amides, and other protected
or derivatized forms of the described compounds.
[0092] For therapeutic use, salts of the compounds of the present
invention are those that are pharmaceutically acceptable. However,
salts of acids and bases that are non-pharmaceutically acceptable
may also find use, for example, in the preparation or purification
of a pharmaceutically acceptable compound. All salts, whether
pharmaceutically acceptable or not are included within the ambit of
the present invention.
[0093] Pharmaceutically acceptable salts, esters, and amides of
compounds according to the present invention refer to those salt,
ester, and amide forms of the compounds of the present invention
which would be apparent to the pharmaceutical chemist, i.e., those
that are non-toxic and that would favorably affect the
pharmacokinetic properties of said compounds of the present
invention. Those compounds having favorable pharmacokinetic
properties would be apparent to the pharmaceutical chemist, i.e.,
those which are non-toxic and which possess such pharmacokinetic
properties to provide sufficient palatability, absorption,
distribution, metabolism and excretion. Other factors, more
practical in nature, which are also important in the selection, are
cost of raw materials, ease of crystallization, yield, stability,
hygroscopicity and flowability of the resulting bulk drug.
[0094] Examples of acids that may be used in the preparation of
pharmaceutically acceptable salts include the following: acetic
acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid,
alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid,
benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric
acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid,
capric acid, caproic acid, caprylic acid, cinnamic acid, citric
acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric
acid, ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid,
galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic
acid, D-glucuronic acid, L-glutamic acid, .alpha.-oxo-glutaric
acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric
acid, hydroiodic acid, (+)-L-lactic acid, (.+-.)-DL-lactic acid,
lactobionic acid, lauric acid, maleic acid, (-)-L-malic acid,
malonic acid, (.+-.)-DL-mandelic acid, methanesulfonic acid,
naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid,
1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic
acid, orotic acid, oxalic acid, palmitic acid, pamoic acid,
perchloric acid, phosphoric acid, L-pyroglutamic acid, saccharic
acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic
acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric
acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid,
and valeric acid.
[0095] Compounds of the present invention containing acidic protons
may be converted into their therapeutically active non-toxic metal
or amine addition salt forms by treatment with appropriate organic
and inorganic bases. Appropriate base salt forms comprise, for
example, the ammonium salts; the alkali and earth alkaline metal
salts (e.g. lithium, sodium, potassium, magnesium, calcium salts,
which may be prepared by treatment with, for example, magnesium
hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide,
or sodium hydroxide); and amine salts made with organic bases (e.g.
primary, secondary and tertiary aliphatic and aromatic amines such
as L-arginine, benethamine, benzathine, choline, deanol,
diethanolamine, diethylamine, dimethylamine, dipropylamine,
diisopropylamine, 2-(diethylamino)-ethanol, ethanolamine,
ethylamine, ethylenediamine, isopropylamine, N-methyl-glucamine,
hydrabamine, 1H-imidazole, L-lysine, morpholine,
4-(2-hydroxyethyl)-morpholine, methylamine, piperidine, piperazine,
propylamine, pyrrolidine, 1-(2-hydroxyethyl)-pyrrolidine, pyridine,
quinuclidine, quinoline, isoquinoline, secondary amines,
triethanolamine, trimethylamine, triethylamine,
N-methyl-D-glucamine, 2-amino-2-(hydroxymethyl)-1,3-propanediol,
and tromethamine). See, e.g., S. M. Berge, et al., "Pharmaceutical
Salts", J. Pharm. Sci., 1977, 66:1-19, and Handbook of
Pharmaceutical Salts, Propertions, Selection, and Use; Stahl, P.
H., Wermuth, C. G., Eds.; Wiley-VCH and VHCA: Zurich, 2002, which
are incorporated herein by reference.
[0096] Pharmaceutically acceptable esters and amides are those that
are within a reasonable benefit/risk ratio, pharmacologically
effective and suitable for contact with the tissues of patients
without undue toxicity, irritation, or allergic response.
Representative pharmaceutically acceptable amides of the invention
include those derived from ammonia, primary C.sub.1-6alkyl amines
and secondary di(C.sub.1-6alkyl) amines. Secondary amines include
5- or 6-membered heterocyclic or heteroaromatic ring moieties
containing at least one nitrogen atom and optionally between 1 and
2 additional heteroatoms. Preferred amides are derived from
ammonia, C.sub.1-3alkyl primary amines, and
di(C.sub.1-2alkyl)amines.
[0097] Representative pharmaceutically acceptable esters of the
invention include C.sub.1-7alkyl, C.sub.5-7cycloalkyl, phenyl,
substituted phenyl, and phenylC.sub.1-6alkyl-esters. Preferred
esters include methyl esters. Furthermore, examples of suitable
esters include such esters where one or more carboxyl substituents
is replaced with p-methoxybenzyloxy-carbonyl,
2,4,6-trimethylbenzyloxy-carbonyl, 9-anthryloxycarbonyl,
CH.sub.3SCH.sub.2COO--, tetrahydrofur-2-yloxycarbonyl,
tetrahydropyran-2-yloxy-carbonyl, fur-2-yloxycarbonyl,
benzoylmethoxy-carbonyl, p-nitrobenzyloxy-carbonyl,
4-pyridylmethoxycarbonyl, 2,2,2-trichloro-ethoxycarbonyl,
2,2,2-tribromoethoxycarbonyl, t-butyloxycarbonyl,
t-amyloxy-carbonyl, diphenylmethoxycarbonyl,
triphenylmethoxycarbonyl, adamantyloxy-carbonyl,
2-benzyloxyphenyloxycarbonyl, 4-methylthiophenyloxycarbonyl, or
tetrahydropyran-2-yloxycarbonyl.
[0098] The compounds of the present invention are dual CCK1/CCK2
antagonists. A dual CCK1/CCK2 antagonist is useful in methods for
treating a disorder mediated by the CCK1 or CCK2 receptor.
Compounds of the present invention therefore may be useful in
methods for treating or preventing pain, drug dependence, anxiety,
panic attack, schizophrenia, pancreatic disorders, secretory
disorders, gastrointestinal motility disorders, functional bowel
disease, biliary colic, cancer, eating disorders (including, for
example, anorexia), reflux diseases (including, for example,
gastro-esophageal reflux disease and non-erosive reflux disease),
gastroduodenal ulcers, reflux esophagitis, peptic ulcers, Barrett's
esophagus, antral G cell hyperplasia, pernicious anaemia and
Zollinger-Ellison syndrome. Cancer includes, for example, colon
cancer, pancreatic adenocarcinoma, pancreatic tumors, and gastric
tumors.
[0099] Particularly, dual CCK1/CCK2 antagonists are useful in
methods for treating or preventing pancreatic adenocarcinoma, pain,
gastro-esophageal reflux disease, non-erosive reflux disease,
anorexia, pancreatitis, gastroduodenal ulcers, reflux esophagitis,
anxiety, colon cancer, peptic ulcers, pancreatic tumors and gastric
tumors.
[0100] Said methods of treating and preventing comprise the step of
administering to a mammal suffering therefrom an effective amount
of at least one compound of the present invention.
[0101] Compounds of the present invention may be administered in
pharmaceutical compositions to treat patients (humans and other
mammals) with disorders mediated by the CCK1 and CCK2 receptors.
Thus, the invention features pharmaceutical compositions containing
at least one compound of the present invention and a
pharmaceutically acceptable carrier. A composition of the invention
may further include at least one other therapeutic agent (for
example, a combination formulation or combination of differently
formulated active agents for use in a combination therapy
method).
[0102] The present invention also features methods of using or
preparing or formulating such pharmaceutical compositions. The
pharmaceutical compositions can be prepared using conventional
pharmaceutical excipients and compounding techniques known to those
skilled in the art of preparing dosage forms. It is anticipated
that the compounds of the invention can be administered by oral,
parenteral, rectal, topical, or ocular routes, or by inhalation.
Preparations may also be designed to give slow release of the
active ingredient. The preparation may be in the form of tablets,
capsules, sachets, vials, powders, granules, lozenges, powders for
reconstitution, liquid preparations, or suppositories. Preferably,
compounds may be administered by intravenous infusion or topical
administration, but more preferably by oral administration.
[0103] For oral administration, the compounds of the invention can
be provided in the form of tablets or capsules, or as a solution,
emulsion, or suspension. Tablets for oral use may include the
active ingredient mixed with pharmaceutically acceptable excipients
such as inert diluents, disintegrating agents, binding agents,
lubricating agents, sweetening agents, flavoring agents, coloring
agents and preservatives. Suitable inert fillers include sodium and
calcium carbonate, sodium and calcium phosphate, lactose, starch,
sugar, glucose, methyl cellulose, magnesium stearate, mannitol,
sorbitol, and the like; typical liquid oral excipients include
ethanol, glycerol, water and the like. Starch,
polyvinyl-pyrrolidone, sodium starch glycolate, microcrystalline
cellulose, and alginic acid are suitable disintegrating agents.
Binding agents may include starch and gelatin. The lubricating
agent, if present, will generally be magnesium stearate, stearic
acid or talc. If desired, the tablets may be coated with a material
such as glyceryl monostearate or glyceryl distearate to delay
absorption in the gastrointestinal tract, or may be coated with an
enteric coating. Capsules for oral use include hard gelatin
capsules in which the active ingredient is mixed with a solid,
semi-solid, or liquid diluent, and soft gelatin capsules wherein
the active ingredient is mixed with water, an oil such as peanut
oil or olive oil, liquid paraffin, a mixture of mono and
di-glycerides of short chain fatty acids, polyethylene glycol 400,
or propylene glycol.
[0104] Liquids for oral administration may be suspensions,
solutions, emulsions or syrups or may be presented as a dry product
for reconstitution with water or other suitable vehicles before
use. Compositions of such liquid may contain
pharmaceutically-acceptable excipients such as suspending agents
(for example, sorbitol, methyl cellulose, sodium alginate, gelatin,
hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate
gel and the like); non-aqueous vehicles, which include oils (for
example, almond oil or fractionated coconut oil), propylene glycol,
ethyl alcohol or water; preservatives (for example, methyl or
propyl p-hydroxybenzoate or sorbic acid); wetting agents such as
lecithin; and, if needed, flavoring or coloring agents.
[0105] The compounds of this invention may also be administered by
non-oral routes. The compositions may be formulated for rectal
administration as a suppository. For parenteral use, including
intravenous, intramuscular, intraperitoneal, or subcutaneous
routes, the compounds of the invention will generally be provided
in sterile aqueous solutions or suspensions, buffered to an
appropriate pH and isotonicity or in parenterally acceptable oil.
Suitable aqueous vehicles include Ringer's solution and isotonic
sodium chloride. Such forms will be presented in unit dose form
such as ampules or disposable injection devices, in multi-dose
forms such as vials from which the appropriate dose may be
withdrawn, or in a solid form or pre-concentrate that can be used
to prepare an injectable formulation. Another mode of
administration of the compounds of the invention may utilize a
patch formulation to affect transdermal delivery. The compounds of
this invention may also be administered by inhalation, via the
nasal or oral routes using a spray formulation consisting of the
compound of the invention and a suitable carrier.
[0106] Methods are known in the art for determining effective doses
for therapeutic (treatment) and prophylactic (preventative)
purposes for the pharmaceutical compositions or the drug
combinations of the present invention, whether or not formulated in
the same composition. The specific dosage level required for any
particular patient will depend on a number of factors, including
severity of the condition being treated, the route of
administration, and the weight of the patient. For therapeutic
purposes, "effective dose" or "effective amount" refers to that
amount of each active compound or pharmaceutical agent, alone or in
combination, that elicits the biological or medicinal response in a
tissue system, animal, or human that is being sought by a
researcher, veterinarian, medical doctor, or other clinician, which
includes alleviation of the symptoms of the disease or disorder
being treated. For prophylactic purposes (i.e., preventing or
inhibiting the onset or progression of a disorder), the term
"effective dose" or "effective amount" refers to that amount of
each active compound or pharmaceutical agent, alone or in
combination, that inhibits in a subject the onset or progression of
a disorder as being sought by a researcher, veterinarian, medical
doctor, or other clinician, the delaying of which disorder is
mediated, at least in part, by the modulation of the CCK1 and CCK2
receptors. Methods of combination therapy include co-administration
of a single formulation containing all active agents; essentially
contemporaneous administration of more than one formulation; and
administration of two or more active agents separately
formulated.
[0107] It is anticipated that the daily dose (whether administered
as a single dose or as divided doses) will be in the range 0.01 to
1000 mg per day, more usually from 1 to 500 mg per day, and most
usually from 10 to 200 mg per day. Expressed as dosage per unit
body weight, a typical dose will be expected to be between 0.0001
mg/kg and 15 mg/kg, especially between 0.01 mg/kg and 7 mg/kg, and
most especially between 0.15 mg/kg and 2.5 mg/kg.
[0108] Preferably, oral doses range from about 0.05 to 200 mg/kg,
daily, taken in 1 to 4 separate doses. Some compounds of the
invention may be orally dosed in the range of about 0.05 to about
50 mg/kg daily, others may be dosed at 0.05 to about 20 mg/kg
daily, while still others may be dosed at 0.1 to about 10 mg/kg
daily. Infusion doses can range from about 1 to 1000 pg/kg/min of
inhibitor, admixed with a pharmaceutical carrier over a period
ranging from several minutes to several days. For topical
administration compounds of the present invention may be mixed with
a pharmaceutical carrier at a concentration of about 0.1% to about
10% of drug to vehicle.
EXAMPLES
[0109] In order to illustrate the invention, the following examples
are included. These examples do not limit the invention. They are
only meant to suggest a method of practicing the invention. Those
skilled in the art may find other methods of practicing the
invention, which are obvious to them. However, those methods are
deemed to be within the scope of this invention.
[0110] Preparative reversed-phase HPLC was performed on a
Gilson.RTM. instrument, using a YMC-Pack ODS-A, 5 .mu.m,
75.times.30 mm column, with a flow rate of 10 mL/min, and detection
at .lamda. 220 and 254 nm. The gradient was 20 to 99%
acetonitrile/water/0.05% TFA over 20 min.
[0111] For analytical reversed-phase HPLC, a Hewlett Packard Series
1100 was used, with an Agilent ZORBAX.RTM. C8, 5 .mu.m,
4.6.times.150 mm column, a flow rate of 1 mL/min, and detection at
.lamda. 220 and 254 nm. The gradient was 1 to 99%
acetonitrile/water/0.05% TFA over 8 min.
[0112] Mass spectra were obtained on an Agilent series 1100 MSD
using electrospray ionization (ESI) in either positive or negative
modes as indicated. The calculated (calcd.) mass corresponds to the
exact mass.
[0113] NMR spectra were obtained on either a Bruker model DPX400
(400 MHz) or DPX500 (500 MHz) spectrometer. The format of the
.sup.1H NMR data below is: chemical shift in ppm down field of the
tetramethylsilane reference (multiplicity, coupling constant J in
Hz, integration).
[0114] Normal phase flash chromatography was performed using
Isco.RTM. RediSep.TM. 4, 12, 40 or 120 g cartridges under medium
pressure.
[0115] Elemental analyses were performed by NuMega Resonance Labs,
Inc., San Diego, Calif.
[0116] Where solutions were "concentrated", they were concentrated
under reduced pressure using a rotary evaporator.
Example 1
##STR00011##
[0117]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-
-chloro-phenyl)-propyl]-benzamide
[0118] A.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
methyl ester. To a solution of methyl 2-amino-4-chlorobenzoate (7.0
g, 37.7 mmol) in DCM (75 mL) at room temperature (rt) was added
4-chlorosulfonyl-2,1,3-benzothiadiazole (9.45 g, 39.6 mmol),
pyridine (9.1 mL, 112 mmol), and DMAP (0.23 g, 1.88 mmol). The
mixture was stirred at rt overnight, poured into 1 N HCl (200 mL),
and extracted with DCM (2.times.100 mL). The combined organic
layers were dried (Na.sub.2SO.sub.4) and concentrated. The crude
residue was purified by flash chromatography (hexanes/EtOAc) to
afford the title sulfonamide as a tan solid (11.65 g, 80%). MS
(ESI-): mass calcd. for C.sub.14H.sub.10ClN.sub.3O.sub.4S.sub.2,
383.8; m/z found, 382 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.38 (s, 1H), 8.40 (dd, J=7.2, 1.2, 1H), 8.24 (dd,
J=8.8, 1.2, 1H), 7.80 (d, J=8.4, 1H), 7.76 (d, J=2.0, 1H), 7.74
(dd, J=8.8, 7.2, 1H), 6.94 (dd, J=8.4, 2.0, 1H), 3.92 (s, 3H).
Anal. calcd. for C.sub.14H.sub.10ClN.sub.3O.sub.4S.sub.2: C, 43.81;
H, 2.63; N, 10.95. Found: C, 44.19; H, 3.00; N, 11.23.
[0119] B.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid.
To a stirred suspension of
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
methyl ester (2.0 g, 5.2 mmol) in THF (12 mL) at rt was added LiOH
(2 M in water, 10 mL). The resulting orange mixture was stirred
overnight at rt then poured into 0.5 M HCl (150 mL) causing
precipitation of the desired benzoic acid. After stirring the
mixture several minutes to complete precipitation, the product was
collected by suction filtration and air-dried to afford the acid as
a tan solid (1.87 g, 97%). MS (ESI-): mass calcd. for
C.sub.13H.sub.8ClN.sub.3O.sub.4S.sub.2, 369.8; m/z found, 368
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.22 (br s, 1H),
8.43 (dd, J=7.2, 1.0, 1H), 8.26 (dd, J=8.8, 1.0, 1H), 7.90 (d,
J=8.8, 1H), 7.80 (d, J=2.0, 1H), 7.75 (dd, J=8.8, 7.2, 1H), 6.99
(dd, J=8.8, 2.0, 1H). Anal. calcd. for
C.sub.13H.sub.8ClN.sub.3O.sub.4S.sub.2: C, 42.22; H, 2.18; N,
11.36. Found: C, 41.92; H, 2.50; N, 11.38.
[0120] C.
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-
-(4-chloro-phenyl)-propyl]-benzamide. To a solution of
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
(0.030 g, 0.081 mmol) in a mixture of THF (0.12 mL) and DMF (0.60
mL) at rt was added pyridine (0.020 mL, 0.25 mmol) followed by HATU
(0.062 g, 0.17 mmol). The reaction mixture was agitated for 1 h on
a shaker. (.+-.)-2-(4-Chlorophenyl)-propylamine hydrochloride
(0.035 g, 0.17 mmol) and N,N-diisopropylethylamine (Hunig's base;
0.030 mL, 0.17 mmol) were added. (Hunig's base may be omitted when
using the free base form of the amine.) The reaction mixture was
agitated for 1 h. TFA (0.050 mL) was added to quench the reaction.
The mixture was diluted with DMF (1 mL), and the product amide was
obtained by purification of the resulting mixture by preparative
reverse-phase HPLC. The title amide was obtained as a solid (27 mg,
64%). HPLC: R.sub.T=10.60 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.18Cl.sub.2N.sub.4O.sub.3S, 520.02; m/z found, 519/521
[M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.53 (s, 1H), 8.35
(dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0, 1H), 7.71 (dd, J=8.8,
7.0, 1H), 7.70 (d, J=2.0, 1H), 7.32-7.27 (m, 2H), 7.16-7.09 (m,
2H), 6.95 (d, J=8.4, 1H), 6.88 (dd, J=8.4, 2.0, 1H), 5.79-5.74 (br
m, 1H), 3.76-3.68 (m, 1H), 3.33-3.25 (m, 1H), 3.05-2.95 (m, 1H),
1.31 (d, J=7.0, 3H).
Example 2
##STR00012##
[0121]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3,4-dichloro-phenyl)-propionic acid
[0122] A. 2-Amino-3-(3,4-dichloro-phenyl)-propionic acid methyl
ester hydrochloride. To a stirred solution of
(S)-2-tert-butoxycarbonylamino-3-(3,4-dichloro-phenyl)-propionic
acid (0.67 g, 2.00 mmol) in MeOH (13 mL) at 0.degree. C. was added
SOCl.sub.2 (0.29 mL, 4.00 mmol). The reaction mixture was allowed
to stir and warm to rt overnight. The mixture was concentrated to
provide the product as a white solid (0.56 g, 99%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6): 8.66 (br s, 2H), 7.65-7.60 (m, 2H), 7.26
(dd, J=8.2, 1.9, 1H), 4.37 (br s, 1H), 3.72 (s, 3H), 3.18-3.14 (m,
2H).
[0123] B.
(S)-2-(2-Amino-4-iodo-benzoylamino)-3-(3,4-dichloro-phenyl)-prop-
ionic acid methyl ester. A solution of 4-iodo-2-nitrobenzoic acid
(0.35 g, 1.20 mmol) dissolved in SOCl.sub.2 (5 mL) was heated at
reflux for 2 h. The mixture was concentrated and the resulting
liquid was dissolved in DMF (5 mL). DMAP (161 mg, 1.32 mmol) and
2-amino-3-(3,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride (0.37 g, 1.32 mmol) were added and the solution was
stirred overnight at rt. The mixture was poured into water and
extracted with EtOAc (3.times.). The organic layers were combined,
dried (MgSO.sub.4), and concentrated to provide the crude product
as a yellow oil. The oil was purified by flash chromatography
(hexanes/EtOAc) to provide the product as a colorless oil (50%, 313
mg). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.59 (d, J=8.1, 2H), 7.37
(d, J=8.2, 1H), 7.28 (d, J=2.0, 1H), 7.18 (d, J=8.0, 1H), 7.04 (dd,
J=8.2, 2.0, 1H), 6.49 (d, J=7.4, 1H), 5.10-5.04 (m, 1H), 3.81 (s,
3H), 3.33-3.17 (m, 2H).
[0124] C.
(S)-2-(2-Amino-4-iodo-benzoylamino)-3-(3,4-dichloro-phenyl)-prop-
ionic acid methyl ester.
(S)-2-(2-Amino-4-iodo-benzoylamino)-3-(3,4-dichloro-phenyl)-propionic
acid methyl ester (313 mg, 0.60 mmol) was dissolved in 1:1
EtOAc/DCM (6 mL) and SnCl.sub.2.2H.sub.2O (0.68 g, 2.99 mmol) was
added. The mixture was stirred overnight at rt and then satd. aq.
NaHCO.sub.3 was added (10 mL). The mixture was filtered through a
pad of diatomaceous earth and rinsed with copious water and DCM.
The organic layer was separated, dried (MgSO.sub.4), and
concentrated to provide the desired product as a colorless oil (187
mg, 63%). MS (ESI-): mass calcd. for
C.sub.17H.sub.15Cl.sub.2IN.sub.2O.sub.3, 493.1; m/z found, 492
[M-H].sup.-, 531 [M+K].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
7.36 (d, J=8.2, 1H), 7.22 (d, J=1.9, 1H), 7.09-7.07 (m, 1H),
6.99-6.94 (m, 3H), 6.48 (d, J=7.1, 1H), 4.98 (q, J=5.6, 1H), 3.80
(s, 3H), 3.25-3.11 (m, 2H).
[0125] D.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3-(3,4-dichloro-phenyl)-propionic acid methyl ester. To a
solution of
(S)-2-(2-amino-4-iodo-benzoylamino)-3-(3,4-dichloro-phenyl)-propionic
acid methyl ester (39 mg, 0.079 mmol) in DCM (1 mL) was added
4-chlorosulfonyl-2,1,3-benzothiadiazole (37 mg, 0.158 mmol) and
pyridine (30 .mu.L, 0.371 mmol). The mixture was shaken overnight
at rt, then polymer bound tris(2-aminoethyl)amine resin was added.
The resulting mixture was shaken for 2 h, and the resin was removed
by filtration and rinsed with DCM. TBD methyl polystyrene resin was
then added and the mixture was shaken for 2 h. The liquid was
drained and the resin was washed with DCM (3.times.). A solution of
10% TFA in DCM (3 mL) was added to the resin and the mixture was
shaken for 1.5 h. The resin was removed by filtration, washed with
10% TFA in DCM and the filtrate was concentrated to provide the
desired product as a white solid (55 mg, 99%). .sup.1H NMR (400
MHz, CDCl.sub.3): 11.10 (s, 1H), 8.36 (dd, J=7.0, 0.8, 1H), 8.24
(dd, J=8.8, 0.8, 1H), 8.02 (d, J=1.5, 1H), 7.75 (dd, J=8.8, 7.1,
1H), 7.37-7.32 (m, 2H), 7.16 (d, J=2.0, 1H), 6.96 (d, J=8.3, 1H),
6.92 (dd, J=8.2, 2.0, 1H), 6.67 (d, J=7.3, 1H), 4.96 (q, J=5.7,
1H), 3.83 (s, 3H), 3.20-3.12 (m, 2H).
[0126] E.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3-(3,4-dichloro-phenyl)-propionic acid. To
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
-(3,4-dichloro-phenyl)-propionic acid methyl ester (55 mg, 0.079
mmol) in 2:1 water/THF (3 mL) was added LiOH-2H.sub.2O (7 mg, 0.158
mmol). The yellow solution was stirred for 2 h and then 20% aq. HCl
(2 mL) was added. The mixture was extracted with EtOAc (3.times.).
The organic layers were combined, dried (MgSO.sub.4), and
concentrated to provide the desired product as a white solid (41
mg, 76%). HPLC: R.sub.T=9.77 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.2IN.sub.4O.sub.5S.sub.2, 677.3; m/z found,
676 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.22 (s, 1H),
8.33 (d, J=7.0, 1H), 8.12 (d, J=8.8, 1H), 7.98 (d, J=0.8, 1H), 7.70
(dd, J=8.6, 7.3, 1H), 7.33 (d, J=8.2, 1H), 7.22 (d, J=8.2, 1H),
7.02 (dd, J=8.2, 1.6, 1H), 6.93 (d, J=8.3, 1H), 6.73 (d, J=7.3,
1H), 4.99 (q, J=6.3, 1H), 3.31 (dd, J=14.2, 5.7, 1H), 3.20 (dd,
J=14.2, 5.7).
Example 3
##STR00013##
[0127]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoyl-
amino]-3-phenyl-propionic acid
[0128] A. 4,5-Dichlorophthalic acid monomethyl ester. To a stirred
suspension of 4,5-dichlorophthalic anhydride (15.0 g, 69.1 mmol) in
MeOH (1 L) was added NaOMe (5.40 g, 100 mmol). The mixture was
heated at reflux for 12 h. The mixture was cooled to rt and
concentrated to a volume of .about.100 mL, and then was poured into
0.5 N HCl (1 L) causing precipitation of the product. The resulting
white powder was collected by suction filtration, washed with
water, and dried under vacuum to give 17.1 g (99.5%) of the
monomethyl ester. .sup.1H NMR (400 MHz, CDCl.sub.3): 8.02 (s, 1H),
7.84 (s, 1H), 3.94 (s, 3H).
[0129] B. Methyl 2-amino-4,5-dichlorobenzoate. A suspension of
4,5-dichlorophthalic acid monomethyl ester (17 g, 69 mmol) in
SOCl.sub.2 (100 mL) was heated at reflux for 1 h. The resulting
mixture was cooled and concentrated to give a yellow oil. The oil
was azeotroped with toluene (5.times.5 mL), leaving the acid
chloride as a yellow liquid. .sup.1H NMR (400 MHz, CDCl.sub.3):
7.96 (s, 1H), 7.82 (s, 1H), 3.95 (s, 3H). The crude acid chloride
was stirred in dry acetone (400 mL) at 0.degree. C. as a solution
of NaN.sub.3 (18.0 g, 277 mmol) in water (120 mL) was added
dropwise, maintaining the temperature below 10.degree. C. After
addition was complete, the orange reaction mixture was stirred 1 h
at 0.degree. C. The mixture was concentrated with no external
heating. The residue was partitioned between water and DCM
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated to give the crude acyl azide as
a tan solid. .sup.1H NMR indicated the acyl azide methyl ester was
contaminated with 3 other minor unidentified components. .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.87 (s, 1H), 7.78 (s, 1H), 3.94 (s,
3H). The crude tan solid was suspended in a mixture of acetic acid
(240 mL) and water (120 mL) and heated at reflux for 1 h. Rapid gas
evolution occurred. The suspension was concentrated, and the
resulting solid was collected by suction filtration and washed with
water. The crude solid was stirred in toluene and filtered. The
filtrate was concentrated to a white solid (9.10 g, .about.54%, 91%
pure by .sup.1H NMR). The aminobenzoate was used without further
purification. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.92 (s, 1H), 6.78
(s, 1H), 5.77 (br s, 2H), 3.87 (s, 3H).
[0130] C. 2-Amino-4,5-dichloro-benzoic acid. Methyl
2-amino-4,5-dichlorobenzoate (2.1 g, 9.41 mmol) was dissolved in
THF (15 mL) and water (30 mL) was added. LiOH (0.79 g, 18.8 mmol)
was added the mixture was stirred overnight at rt. The product was
precipitated by addition of 10% aq. HCl (30 mL) and isolated by
suction filtration. The white solid was dried under vacuum (1.6 g,
81%). .sup.1H NMR (400 MHz, DMSO-d.sub.6): 7.78 (s, 1H), 7.01 (s,
1H).
[0131] D. 3,4-Dichloroisatoic anhydride.
2-Amino-4,5-dichloro-benzoic acid (1.5 g, 7.28 mmol) was dissolved
in 1:1 DCM/THF (20 mL) and cooled to 0.degree. C. Phosgene (20% in
toluene, 5.4 mL, 8.00 mmol) and Hunig's base (2.54 mL, 14.6 mmol)
were added and the reaction was stirred overnight and warmed slowly
to rt. The mixture was poured into water and extracted with DCM
(3.times.) and EtOAc (2.times.). The combined organic layers were
dried (MgSO.sub.4), and concentrated to provide the product as a
white solid (1.6 g, 92%). HPLC: R.sub.T=8.10 min. MS (ESI-): mass
calcd. for C.sub.8H.sub.3Cl.sub.2NO.sub.3, 232.0; m/z found, 231
[M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 11.95 (s, 1H),
8.10 (s, 1H), 7.32 (s, 1H).
[0132] E. 2-(2-Amino-4,5-dichloro-benzoylamino)-3-phenyl-propionic
acid methyl ester. 3,4-Dichloroisatoic anhydride (147 mg, 0.634
mmol) was dissolved in DMF (2 mL). (L)-Phenylalanine methyl ester
hydrochloride (150 mg, 0.697 mmol) and DMAP (85 mg, 0.697 mmol)
were added and the mixture was stirred overnight at rt. The mixture
was quenched with water and extracted with EtOAc (3.times.). The
combined organic layers were washed with water, dried (MgSO.sub.4),
filtered and concentrated to provide the crude product. The crude
solid was purified by flash chromatography (hexanes/EtOAc) to
provide the desired product as a white solid (150 mg, 68%). .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.27-7.21 (m, 5H), 7.07-7.05 (m, 2H),
6.30 (d, J=7.2, 1H), 5.44 (br s, 2H), 4.95-4.90 (m, 1H), 3.71 (s,
3H), 3.22-3.09 (m, 2H).
[0133] F.
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benz-
oylamino]-3-phenyl-propionic acid. This compound was prepared from
2-(2-amino-4,5-dichloro-benzoylamino)-3-phenyl-propionic acid
methyl ester and benzo[1,2,5]thiadiazole-4-sulfonyl chloride as in
EXAMPLE 2, Parts D and E. HPLC: R.sub.T=10.10 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.16Cl.sub.2N.sub.4O.sub.5S.sub.2, 551.4;
m/z found, 550 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.11 (s, 1H), 8.33 (dd, J=7.1, 0.9, 1H), 8.20 (dd, J=8.8, 0.8,
1H), 7.83 (s, 1H), 7.70 (dd, J=8.8, 7.1, 1H), 7.28 (m, 3H), 7.20
(s, 1H), 7.13 (dd, J=7.4, 1.7, 2H), 6.42 (d, J=7.5, 1H), 5.00 (dd,
J=13.3, 6.0, 1H), 3.32 (dd, J=14.1, 5.7, 1H), 3.23 (dd, J=14.1,
6.1, 1H).
Example 4
##STR00014##
[0134]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-phenyl)-propionic acid
[0135] A. (1R,2R)-Pseudoephedrine glycinamide hydrate. To a
flame-dried three-necked round bottom flask was added
(1R,2R)-(-)-pseudoephedrine (10 g, 60.5 mmol), glycine methyl ester
hydrochloride (9.9 g, 78.7 mmol), and THF (90 mL). The mixture was
stirred for 15 min at rt and lithium t-butoxide (6.8 g, 84.7 mmol)
was added. The resulting suspension was stirred at rt for 3 h.
Water (150 mL) was added and the THF was removed in vacuo. The
aqueous phase was extracted with DCM (3.times.). The combined
organic layers were dried (K.sub.2CO.sub.3), filtered, and
concentrated. Hot THF (50 mL) was added to dissolve the residue and
water (2 mL) was added. The mixture was allowed to stand overnight.
A white solid formed and was collected by suction filtration. The
product was washed with Et.sub.2O and dried (10.2 g, 70%). .sup.1H
NMR (400 MHz, CDCl.sub.3; 1:1 ratio of rotamers): 7.42-7.28 (m,
5H), 4.65-4.52 (m, 1.5H), 3.95-3.83 (m, 0.5H), 3.71 (d, J=15.6,
0.5H), 3.45 (d, J=16.9, 1H), 3.37 (d, J=17.0, 0.5H), 2.97 (s,
1.5H), 2.79 (s, 1.5H), 1.85 (br s, 3H), 1.09 (d, J=6.8, 1.5H), 0.99
(d, J=6.8, 1.5H).
[0136] B.
2-Amino-3-(3-bromo-phenyl)-N-((2R)-hydroxy-(1R)-methyl-2-phenyl--
ethyl)-N-methyl-propionamide. A flame-dried flask was charged with
LiCl (100 mg, 2.44 mmol). The flask was flushed with N.sub.2 and
(1R,2R)-pseudoephedrine glycinamide hydrate (1.0 g, 4.17 mmol) was
added. The solid reagents were dissolved in THF (20 mL), cooled to
0.degree. C., and lithium bis(trimethylsilyl)amide (LHMDS; 1 M in
THF, 13.3 mL, 13.3 mmol) was added. The bright yellow solution was
stirred for 1 h and then 3-bromobenzyl bromide (1.25, 5.00 mmol)
was added. The mixture was stirred for 2 h at 0.degree. C. and 1 M
HCl (200 mL) was added. The solution was extracted with EtOAc
(3.times.). The organic layers were combined and washed with 1 M
HCl (3.times.). All aqueous layers were combined, cooled to
0.degree. C., and basified to pH 14 with 40% aq. NaOH. The aqueous
layers were extracted with DCM (4.times.). The organic layers were
combined, dried (K.sub.2CO.sub.3), filtered and concentrated to
provide the crude product. The crude product was purified by flash
chromatography (DCM/MeOH) to provide the product as a colorless oil
(232 mg, 14%). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.39 (br s, 1H),
8.17 (br s, 2H), 7.30-7.16 (m, 7H), 7.08-6.97 (m, 2H), 4.88-4.81
(m, 1H), 4.39-4.36 (m, 1H), 4.25 (d, J=9.7, 1H), 3.16-3.13 (m, 1H),
2.96-2.89 (m, 1H), 2.16 (s, 3H), 0.48 (d, J=6.9, 3H).
[0137] C.
(S)-3-(3-Bromo-phenyl)-2-tert-butoxycarbonylamino-propionic acid. A
suspension of
2-amino-3-(3-bromo-phenyl)-N-((2R)-hydroxy-(1R)-methyl-2-phenyl-ethyl)-N--
methyl-propionamide (232 mg, 0.593 mmol) in 1 M NaOH (1.2 mL) and
water (1.2 mL) was heated at reflux for 2 h and then cooled to rt,
whereupon the clear solution became cloudy. Water (10 mL) was added
and the solution was extracted with DCM (2.times.). The combined
organic layers were washed with water. The aqueous layers were
back-extracted with DCM, then combined and concentrated to .about.5
mL. NaHCO.sub.3 (100 mg, 1.19 mmol) and dioxane (10 mL) were added.
The mixture was cooled to 0.degree. C. and di-tert-butyl
dicarbonate (0.24 mL, 1.02 mmol) was added. The reaction mixture
was stirred overnight and allowed to warm to rt. Water (20 mL) was
added and the solution was extracted with EtOAc (3.times.). The
organic layers were combined and washed with 2% aq. NaHCO.sub.3.
The combined aqueous layers were acidified to pH 3.5 with satd. aq.
citric acid and extracted with EtOAc (3.times.). The organic layers
were combined, washed with water, dried (Na.sub.2SO.sub.4), and
concentrated to provide the product as a clear, colorless oil (38
mg, 17%). .sup.1H NMR (400 MHz, CDCl.sub.3; 1.7:1 ratio of
rotamers): 7.40-7.33 (m, 3.2H), 7.12-7.20 (m, 3.2H), 6.69 (d,
J=6.8, 0.6H), 5.00 (d, J=7.8, 1H), 4.62-4.54 (m, 1H), 4.48-4.34 (m,
0.6H), 3.26-3.12 (m, 1.6H), 3.10-2.84 (m, 1.6H), 1.43 (s, 9H), 1.29
(s, 5.4H).
[0138] D. (S)-2-Amino-3-(3-bromo-phenyl)-propionic acid methyl
ester hydrochloride.
(S)-3-(3-Bromo-phenyl)-2-tert-butoxycarbonylamino-propionic acid
was treated as in EXAMPLE 2, Part A, to provide a white solid. MS
(ESI+): mass calcd. for C.sub.10H.sub.12BrNO.sub.2, 258.1; m/z
found, 259 [M+H].sup.+.
[0139] E.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3-(3-bromo-phenyl)-propionic acid.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic acid was
coupled to (S)-2-amino-3-(3-bromo-phenyl)-propionic acid methyl
ester hydrochloride as in EXAMPLE 1, Part C. The methyl ester was
hydrolyzed as in EXAMPLE 2, Part E, to afford the title compound.
HPLC: R.sub.T=9.91 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16BrIN.sub.4O.sub.5S.sub.2, 687.3; m/z found, 686
[M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 13.05 (s, 1H),
11.77 (s, 1H), 9.03 (d, J=7.8, 1H), 8.45-8.35 (m, 2H), 7.92-7.86
(m, 1H), 7.82 (d, J=1.5, 1H), 7.53-7.51 (br m, 1H), 7.47-7.38 (m,
2H), 7.36-7.34 (m, 1H), 7.31-7.19 (m, 2H), 4.65-4.54 (m, 1H), 3.19
(dd, J=14.0, 4.7, 1H), 3.00 (dd, J=13.7, 10.8, 1H).
Example 5
##STR00015##
[0140]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(3,4-dichl-
oro-phenyl)-propyl]-benzamide
[0141] A. 2-(3,4-Dichloro-phenyl)-propionitrile. To a -78.degree.
C. solution of (3,4-dichloro-phenyl)-acetonitrile (5.0 g, 26.9
mmol) in THF (60 mL) was added LHMDS (1 M in THF, 28.2 mL, 28.2
mmol). The reddish orange solution was stirred at -78.degree. C.
for 1 h and MeI (1.76 mL, 28.2 mmol) was added. The mixture was
allowed to warm to rt overnight. The mixture was diluted with 1 M
HCl (20 mL) and extracted with Et.sub.2O (3.times.). The combined
organic layers were dried (MgSO.sub.4) and concentrated to provide
a dark brown oil. The crude product was purified by flash
chromatography (hexanes/EtOAc) to provide a colorless oil (5.0 g,
93%). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.52-7.42 (m, 2H),
7.25-7.18 (m, 1H), 3.88 (q, J=7.3, 1H), 1.64 (d, J=7.3, 3H).
[0142] B. 2-(3,4-Dichloro-phenyl)-propylamine hydrochloride.
2-(3,4-Dichloro-phenyl)-propionitrile (5.0 g, 25.0 mmol) was
dissolved in THF (80 mL). BH.sub.3.THF (1 M in THF, 27.5 mL, 27.5
mmol) was added and the mixture was stirred overnight at rt. EtOH
(10 mL) was added, the mixture was stirred for 20 min, and HCl in
Et.sub.2O (2 M, 12.5 mL) was added. After stirring for 1 h, water
was added, causing precipitation of the product. The product was
collected by suction filtration and dried (4.2 g, 70%). MS (ESI+):
mass calcd. for C.sub.9H.sub.11Cl.sub.2N, 204.1; m/z found, 205
[M+H].sup.+. .sup.1H NMR (400 MHz, CD.sub.3OD): 7.45-7.42 (m, 2H),
7.17-7.15 (m, 1H), 3.05-3.02 (m, 2H), 2.98-2.96 (m, 1H), 1.24 (d,
J=6.5, 3H).
[0143] C.
2-Amino-4-bromo-N-[2-(3,4-dichloro-phenyl)-propyl]-benzamide. The
title compound (68 mg, 27%) was prepared from
4-bromo-2-nitrobenzoic acid as in Example 2, Parts B and C. MS
(ESI-): mass calcd. for C.sub.16H.sub.15BrCl.sub.2N.sub.2O, 402.1;
m/z found, 401 [M-H].sup.-, 440 [M+K].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.39 (d, J=8.2, 1H), 7.33 (d, J=2.0, 1H), 7.07 (dd,
J=8.3, 2.0, 1H), 6.95 (d, J=8.4, 1H), 6.82 (d, J=1.8, 1H), 6.69
(dd, J=8.4, 1.9, 1H), 5.98-5.96 (br m, 1H), 5.58 (br s, 2H),
3.70-3.65 (m, 1H), 3.38-3.31 (m, 1H), 3.04 (sext, J=6.8, 1H), 1.30
(d, J=7.0, 3H).
[0144] D.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(3,4-di-
chloro-phenyl)-propyl]-benzamide. The title compound (45 mg, 99%)
was prepared as in Example 2, Part D. HPLC: R.sub.T=11.06 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.17BrCl.sub.2N.sub.4O.sub.3S.sub.2, 600.3; m/z found,
599 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.47 (s, 1H),
8.36 (dd, J=7.0, 0.9, 1H), 8.23 (dd, J=8.8, 0.9, 1H), 7.86 (d,
J=1.8, 1H), 7.72 (dd, J=8.8, 7.1, 1H), 7.40 (d, J=8.2, 1H), 7.29
(d, J=2.0, 1H), 7.05 (ddd, J=7.6, 5.6, 2.0, 2H), 6.93 (d, J=8.4,
1H), 5.85 (br m, 1H), 3.68 (td, J=13.2, 6.4, 1H), 3.31 (ddd,
J=13.8, 8.7, 5.4, 1H), 3.00 (m, 1H), 1.31 (d, J=7.0, 3H).
Example 6
##STR00016##
[0145]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2,2-bis-(4-chloro-ph-
enyl)-ethyl]-4-chloro-benzamide
[0146] A. 2,2-Bis-(4-chloro-phenyl)-acetamide. A suspension of
2,2-bis-(4-chloro-phenyl)-acetic acid (0.50 g, 1.8 mmol) in
SOCl.sub.2 (5 mL) was heated at reflux for 1 h. The mixture was
concentrated, and the residue was azeotroped with toluene
(3.times.). The crude acid chloride was stirred in DCM (10 mL) at
rt and treated with NH.sub.3 (0.5 M in dioxane, 14 mL, 7.5 mmol).
After 1 h, the reaction mixture was concentrated, and the residue
was diluted with satd. aq. NaHCO.sub.3 and extracted with DCM
(3.times.). The combined organics were dried (Na.sub.2SO.sub.4) and
concentrated to provide the amide as a white solid (0.50 g, 100%).
The amide was used without further purification. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.35-7.28 (m, 4H), 7.23-7.17 (m, 4H), 5.69 (br s,
1H), 5.53 (br s, 1H), 4.87 (s, 1H).
[0147] B. 2,2-Bis-(4-chloro-phenyl)-ethylamine. To a solution of
2,2-bis-(4-chloro-phenyl)-acetamide (0.50 g, 1.8 mmol) in THF (10
mL) at rt was added BH.sub.3-THF (1.0 M in THF, 4.5 mL, 4.5 mmol).
The solution was heated at reflux for 2 h. The mixture was cooled
in an ice bath, and the excess BH.sub.3 was quenched by careful
addition of 10 mL of MeOH. HCl (2.0 M in MeOH, 5 mL) was added, and
the resulting mixture was heated at reflux for 1 h. After cooling,
the mixture was concentrated, and the residue was partitioned
between 1 N HCl and Et.sub.2O. The acidic aqueous layer was
basified with 10 N NaOH and extracted with Et.sub.2O (3.times.).
The combined organic extracts were dried (MgSO.sub.4) and
concentrated to provide the desired amine (181 mg, 38%). The amine
was used without further purification. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.30-7.26 (m, 4H), 7.18-7.12 (m, 4H), 3.94 (t, J=7.5,
1H), 3.28 (d, J=7.6, 2H), 1.06 (br s, 2H).
[0148] C.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2,2-bis-(4-chloro-
-Phenyl)-ethyl]-4-chloro-benzamide.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
was coupled with 2,2-bis-(4-chloro-phenyl)-ethylamine as in EXAMPLE
1, Part C. HPLC: R.sub.T=11.40 min. MS (ESI-): mass calcd. for
C.sub.27H.sub.19Cl.sub.3N.sub.4O.sub.3S.sub.2, 616.00; m/z found,
615/617 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.49 (s,
1H), 8.36 (dd, J=7.1, 1.0, 1H), 8.23 (dd, J=8.8, 1.0, 1H), 7.72
(dd, J=8.8, 7.0, 1H), 7.68 (d, J=1.8, 1H), 7.34-7.30 (m, 4H),
7.18-7.13 (m, 4H), 6.89 (d, J=8.4, 1H), 6.86 (dd, J=8.4, 1.8, 1H),
5.87 (br t, J=5.6, 1H), 4.24 (t, J=8.0, 1H), 3.95 (dd, J=7.9, 5.9,
2H).
Example 7
##STR00017##
[0149]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-
-phenyl)-2-methyl-propyl]-benzamide
[0150] A. 2-(4-Chloro-phenyl)-isobutyramide. Prepared from
2-(4-chloro-phenyl)-2-methyl-propionic acid (0.50 g, 2.5 mmol), as
in EXAMPLE 6, Step A (0.45 g, 92%). .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.34 (s, 4H), 5.26 (br s, 1H), 5.15 (br s, 1H), 1.57
(s, 6H).
[0151] B. 2-(4-Chloro-phenyl)-2-methyl-propylamine. Prepared from
2-(4-chloro-phenyl)-isobutyramide (0.45 g, 2.3 mmol), as in EXAMPLE
6, Step B (310 mg, 73%). .sup.1H NMR (400 MHz, CDCl.sub.3):
7.32-7.24 (m, 4H), 2.78 (s, 2H), 1.29 (s, 6H), 0.97 (br s, 2H).
[0152] C.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-chl-
oro-phenyl)-2-methyl-propyl]-benzamide.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
was coupled with 2-(4-chloro-phenyl)-2-methyl-propylamine as in
EXAMPLE 1, Part C. HPLC: R.sub.T=11.08 min. MS (ESI-): mass calcd.
for C.sub.23H.sub.20Cl.sub.2N.sub.4O.sub.3S.sub.2, 534.04; m/z
found, 533/535 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.53 (s, 1H), 8.35 (dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0,
1H), 7.71 (dd, J=8.8, 7.0, 1H), 7.70 (d, J=1.8, 1H), 7.35-7.31 (m,
2H), 7.30-7.26 (m, 2H), 6.89 (d, J=8.3, 1H), 6.86 (dd, J=8.4, 1.8,
1H), 5.58-5.52 (m, 1H), 3.56 (d, J=6.1, 2H), 1.36 (s, 6H).
Example 8
##STR00018##
[0153]
(S)-3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid methyl ester
[0154] A. Diethylthiocarbamic acid O-quinoxalin-5-yl ester. A
mixture of 5-hydroxyquinoxaline (2.13 g, 14.6 mmol), finely ground
K.sub.2CO.sub.3 (4.0 g, 29 mmol), and DMF (50 mL) was stirred at
23.degree. C. for 1 h. Solid diethylthiocarbamoyl chloride (2.43 g,
16.1 mmol) was then added. The resulting mixture was stirred for 2
h, then was diluted with water (150 mL) and extracted with
Et.sub.2O (2.times.100 mL). The combined organic extracts were
washed with water (100 mL) and brine (100 mL), then dried and
concentrated to a viscous orange oil, which was used without
purification (3.63 g, 95%). MS (ESI+): mass calcd. for
C.sub.13H.sub.15N.sub.3OS, 261.1; m/z found, 262 [M+H].sup.+.
.sup.1H NMR (500 MHz, CDCl.sub.3): 8.85-8.65 (m, 2H), 7.96 (dd,
J=8.5, 1.1, 1H), 7.71 (t, J=7.9, 1H), 7.46 (dd, J=7.6, 1.2, 1H),
3.87 (q, J=7.1, 2H), 3.78 (q, J=7.1, 2H), 1.38 (t, J=7.1, 3H), 1.28
(t, J=7.1, 3H). .sup.13C NMR (125 MHz, CDCl.sub.3): 186.6, 149.4,
144.9, 144.5, 143.4, 137.0, 128.9, 127.0, 123.1, 48.2, 44.5, 13.1,
11.5.
[0155] B. Diethylthiocarbamic acid S-quinoxalin-5-yl ester. Neat
diethylthiocarbamic acid O-quinoxalin-5-yl ester (0.52 g, 2.0 mmol)
was heated at 240.degree. C. for 1 h. The resulting brown oil was
chromatographed (EtOAc/hexanes), providing a pale yellow oil (0.49
g, 94%). MS (ESI+): mass calcd. for C.sub.13H.sub.15N.sub.3OS,
261.1; m/z found, 262 [M+H].sup.+. .sup.1H NMR (500 MHz,
CDCl.sub.3): 8.93 (d, J=1.8, 1H), 8.87 (d, J=1.8, 1H), 8.18 (dd,
J=8.4, 1.2, 1H), 8.13 (dd, J=7.3, 1.2, 1H), 7.81 (dd, J=7.3, 1.0,
1H), 3.61 (br s, 2H), 3.43 (br s, 2H), 1.38 (br s, 3H), 1.16 (br s,
3H).
[0156] C. Quinoxaline-5-sulfonyl chloride. A solution of
diethylthiocarbamic acid S-quinoxalin-5-yl ester (3.20 g, 12.3
mmol), KOH (6.89 g, 123 mmol) and MeOH (100 mL) was heated at
reflux for 16 h. The solution was allowed to cool to rt, and then
acetic acid (7 mL) was added. The mixture was diluted with water
(100 mL) and extracted with EtOAc (2.times.100 mL). The combined
extracts were washed with water (100 mL) and brine (100 mL), then
dried and concentrated to a tan solid (1.90 g). A portion of this
thiol (0.22 g, 1.4 mmol) was combined with DCM (50 mL), formic acid
(25 mL), and water (25 mL), and the resulting biphasic mixture was
cooled to 0.degree. C. Chlorine gas was bubbled through this
mixture with rapid stirring for 5 min. The mixture was transferred
to a separatory funnel, and the organic phase was collected. The
aqueous phase was extracted with DCM (50 mL), and the combined
organic phases were washed with 1 M NaOH (50 mL) and brine (50 mL),
and then dried. The solution was concentrated to afford the title
compound as a light yellow crystalline solid (0.28 g, 86%). .sup.1H
NMR (500 MHz, CDCl.sub.3): 9.17 (d, J=1.8, 1H), 9.07 (d, J=1.8,
1H), 8.60 (dd, J=7.5, 1.4, 1H), 8.53 (dd, J=8.4, 1.4, 1H), 7.96
(dd, J=8.6, 0.8, 1H). .sup.13C NMR (125 MHz, CDCl.sub.3): 146.9,
146.8, 143.7, 140.4, 139.0, 138.4, 132.4, 128.8.
[0157] D. 4-Chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid
methyl ester. A solution of methyl 2-amino-4-chlorobenzoate (0.33
g, 1.8 mmol), quinoxaline-5-sulfonyl chloride (0.40 g, 1.8 mmol),
pyridine (0.71 mL, 8.8 mmol), and DCM (10 mL) was stirred at rt for
16 h. EtOAc (75 mL) was added and the solution was washed with
satd. aq. NaHCO.sub.3 (50 mL), then dried and concentrated.
Chromatographic purification of this residue (EtOAc/hexanes) gave
the title compound as a white solid (0.60 mg, 90%). MS (ESI+): mass
calcd. for C.sub.16H.sub.12ClN.sub.3O.sub.4S, 377.0; m/z found, 378
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.44 (s, 1H), 8.97
(d, J=1.8, 1H), 8.95 (d, J=1.8, 1H), 8.61 (dd, J=7.4, 1.4, 1H),
8.33 (dd, J=8.5, 1.4, 1H), 7.89 (dd, J=8.4, 1.0, 1H), 7.84 (d,
J=2.0, 1H), 7.77 (d, J=8.6, 1H), 6.89 (dd, J=8.6, 2.0, 1H), 3.90
(s, 3H).
[0158] E. 4-Chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid. A
solution of LiOH.H.sub.2O (0.32 g, 7.7 mmol) in water (5 mL) was
added to a solution of
4-chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid methyl ester
(0.58 g, 1.5 mmol) and THF (10 mL). The biphasic mixture was
stirred rapidly at rt for 16 h, then adjusted to pH 5 with 1 M HCl.
The resulting precipitate was collected by filtration to afford the
acid as a white solid (0.51 g, 92%). MS (ESI+): calcd. for
C.sub.15H.sub.10ClN.sub.3O.sub.4S, 363.0; m/z found, 364
[M+H].sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6): 14.20 (br s, 1H),
11.73 (s, 1H), 9.12 (d, J=1.6, 1H), 9.00 (d, J=1.5, 1H), 8.65 (d,
J=7.3, 1H), 8.42 (d, J=8.3, 1H), 8.06 (t, J=7.8, 1H), 7.80 (d,
J=8.5, 1H), 7.63 (d, J=2.0, 1H), 7.07 (dd, J=8.4, 1.9, 1H).
[0159] F. (S)-2-Amino-3-(5-bromo-thiophen-2-yl)-propionic acid
methyl ester hydrochloride.
(S)-2-tert-Butoxycarbonylamino)-3-(5-bromo-thiophen-2-yl)-propionic
acid was treated as in EXAMPLE 2, Part A. .sup.1H NMR (400 MHz,
CD.sub.3OD): 7.02 (d, J=3.6, 1H), 6.79 (d, J=3.6, 1H), 4.35 (t,
J=5.9, 1H), 3.87 (s, 3H), 3.42 (d, J=5.7, 2H).
[0160] G.
(S)-3-(5-Bromo-thiophen-2-yl)-2-[4-chloro-2-(quinoxaline-5-sulfo-
nylamino)-benzoylamino]-propionic acid methyl ester.
4-Chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid was coupled
with (S)-2-amino-3-(5-bromo-thiophen-2-yl)-propionic acid methyl
ester hydrochloride as in EXAMPLE 1, Part C. HPLC: R.sub.T=10.34
min. MS (ESI-): mass calcd. for
C.sub.23H.sub.18BrClN.sub.4O.sub.5S.sub.2, 607.96; m/z found,
607/609 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.31 (s,
1H), 8.94 (d, J=1.8, 1H), 8.91 (d, J=1.8, 1H), 8.59 (dd, J=7.4,
1.4, 1H), 8.32 (dd, J=8.4, 1.3, 1H), 7.89 (dd, J=8.4, 7.4, 1H),
7.80 (d, J=2.0, 1H), 7.27 (d, J=8.4, 1H), 6.96 (dd, J=8.4, 2.0,
1H), 6.86 (d, J=3.7, 1H), 6.57 (br d, J=6.8, 1H), 6.48 (d, J=3.6,
1H), 4.92 (dt, J=7.0, 4.6, 1H), 3.83 (s, 3H), 3.40 (d, J=4.6,
2H).
Example 9
##STR00019##
[0161]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-nap-
hthalen-2-yl-propionic acid
[0162] A. (S)-2-Amino-3-naphthalen-2-yl-propionic acid methyl ester
hydrochloride.
(S)-2-(tert-Butoxycarbonylamino)-3-naphthalen-2-yl-propionic acid
was treated as in EXAMPLE 2, Part A, to give a white solid. .sup.1H
NMR (400 MHz, CD.sub.3OD): 7.91-7.82 (m, 3H), 7.75 (br s, 1H),
7.54-7.47 (m, 2H), 7.38 (dd J=8.4, 1.7, 1H), 4.43 (dd, J=7.7, 6.0,
1H), 3.82 (s, 3H), 3.45 (dd, J=14.4, 5.9, 1H), 3.32 (dd, J=14.4,
7.7, 1H).
[0163] B.
(S)-3-Naphthalene-2-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid methyl ester.
4-Chloro-2-(quinoxaline-5-sulfonylamino)benzoic acid was coupled
with (S)-2-amino-3-naphthalen-2-yl-propionic acid methyl ester
hydrochloride as in EXAMPLE 1, Part C.
[0164] C.
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3--
naphthalen-2-yl-propionic acid.
(S)-3-Naphthalen-2-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoyl-
amino]-propionic acid methyl ester was hydrolyzed as in EXAMPLE 2,
Part E, to provide the title acid as a solid. HPLC: R.sub.T=9.60
min. MS (ESI-): mass calcd. for C.sub.28H.sub.21ClN.sub.4O.sub.5S,
560.09; m/z found, 559 [M-H].sup.-. .sup.1H NMR (400 MHz,
CD.sub.3OD): 8.66 (d, J=1.8, 1H), 8.58 (d, J=1.7, 1H), 8.51 (dd,
J=7.4, 1.3, 1H), 8.26 (dd, J=8.5, 1.3, 1H), 7.90 (dd, J=8.4, 7.4,
1H), 7.85-7.73 (m, 3H), 7.70 (br s, 1H), 7.67 (d, J=2.0, 1H),
7.47-7.38 (m, 3H), 7.35 (d, J=8.5, 1H), 6.89 (dd, J=8.5, 2.0, 1H),
4.97-4.85 (m, 1H), 3.46 (dd, J=13.9, 4.8, 1H), 3.19 (dd, J=13.9,
9.8, 1H).
Example 10
##STR00020##
[0165]
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,4-difluorob-
enzenesulfonylamino)-benzamide
[0166] A. 4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoic
acid methyl ester. To a solution of methyl 4-chloroanthranilate
(0.50 g, 2.7 mmol) and pyridine (0.87 mL, 10.8 mmol) in DCM (10 mL)
at rt was added 2,4-difluorobenzenesulfonyl chloride (0.64 g, 3.0
mmol). The mixture was stirred overnight at rt, poured into 1 N
HCl, and extracted with DCM (3.times.). The combined organic
extracts were dried (Na.sub.2SO.sub.4) and concentrated. The
residue was purified by flash chromatography (EtOAc/hexanes) to
provide 0.69 g (70%) of the desired sulfonamide as a solid. .sup.1H
NMR (400 MHz, CDCl.sub.3): 11.02 (s, 1H), 8.07-8.00 (m, 1H), 7.91
(d, J=8.6, 1H), 7.64 (d, J=2.0, 1H), 7.04-6.98 (m, 1H), 7.02 (dd,
J=8.6, 2.0, 1H), 6.93-6.86 (m, 1H), 3.94 (s, 3H).
[0167] B. 4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoic
acid. The title compound (0.65 g, 98%) was prepared from
4-chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoic acid methyl
ester as in Example 1, Part B. .sup.1H NMR (500 MHz, CD.sub.3OD):
8.08-8.02 (m, 1H), 7.98 (d, J=8.5, 1H), 7.60 (d, J=2.0, 1H),
7.20-7.14 (m, 2H), 7.10 (dd, J=8.5, 2.1, 1H).
[0168] C.
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-Phenyl)-propyl]-2-(2,4-difluo-
robenzenesulfonylamino)-benzamide.
4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoic acid was
coupled with (.+-.)-2-(3,4-dichloro-phenyl)-propylamine
hydrochloride as in EXAMPLE 1, Part C. HPLC: R.sub.T=12.04 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.17Cl.sub.3FN.sub.2O.sub.3S.sub.2, 532.00; m/z found,
531/533 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.41 (s,
1H), 8.00 (ddd, J=8.6, 8.6, 6.0, 1H), 7.61 (d, J=2.0, 1H), 7.42 (d,
J=8.2, 1H), 7.32 (d, J=2.1, 1H), 7.11 (d, J=8.4, 1H), 7.08 (dd,
J=8.2, 2.1, 1H), 7.03-6.97 (m, 1H), 6.97 (dd, J=8.4, 2.0, 1H),
6.92-6.86 (m, 1H), 6.02-5.95 (br m, 1H), 3.76-3.68 (m, 1H),
3.41-3.31 (m, 1H), 3.11-3.01 (m, 1H), 1.32 (d, J=7.0, 3H).
Example 11
##STR00021##
[0169]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-carbamoyl-2-(4-
-chloro-phenyl)-ethyl]-4,5-dichloro-benzamide
[0170] The title compound (3 mg, 20%) was prepared from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylam-
ino]-3-(4-chloro-phenyl)-propionic acid and NH.sub.3 (0.5 M in
dioxane) as in Example 1, Part C. HPLC: R.sub.T=10.08 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.16Cl.sub.3N.sub.5O.sub.4S.sub.2, 582.97; m/z found,
582/584 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.34 (s,
1H), 8.37 (dd, J=7.1, 1.0, 1H), 8.24 (dd, J=8.8, 1.0, 1H), 7.84 (s,
1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.36 (s, 1H), 7.36-7.32 (m, 2H),
7.24-7.20 (m, 2H), 6.84 (br d, J=6.9, 1H), 5.47 (br s, 1H), 5.41
(br s, 1H), 4.68 (ddd, J=8.6, 7.0, 5.0, 1H), 3.18 (dd, J=13.7, 4.9,
1H), 3.01 (dd, J=13.6, 8.6, 1H).
Example 12
##STR00022##
[0171]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-p-
henyl)-1-hydroxymethyl-ethyl]-4-methyl-benzamide
[0172] A.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid
methyl ester.
[0173] The title compound (1.22 g, 53%) was prepared from
benzo[1,2,5]thiadiazole-4-sulfonyl chloride and
2-amino-4-methyl-benzoic acid methyl ester as in Example 10, Part
A. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.28 (s, 1H), 8.36 (dd,
J=7.1, 1.0, 1H), 8.19 (dd, J=8.8, 1.0, 1H), 7.73 (d, J=8.1, 1H),
7.68 (dd, J=8.8, 7.1, 1H), 7.51 (br s, 1H), 6.77 (dd, J=8.1, 0.9,
1H), 3.89 (s, 3H), 2.28 (s, 3H).
[0174] B.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid. A
solution of
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methylbenzoic acid
methyl ester (1.22 g, 3.36 mmol) in 3:1 THF/water (10 mL) was
treated with LiOH.H.sub.2O (1.41 g, 33.6 mmol) and was stirred at
rt for 16 h. The mixture was acidified with 1 N HCl, and the
resulting precipitate was collected by filtration, washing with
water. Drying in air provided the title acid as a tan solid (0.89
g, 2.5 mmol, 74%). .sup.1H NMR (500 MHz, CDCl.sub.3): 11.16 (s,
1H), 8.38 (dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0, 1H), 7.84 (d,
J=8.1, 1H), 7.71 (dd, J=8.8, 7.1, 1H), 7.56 (br s, 1H), 6.83 (br d,
J=8.4, 1H), 2.32 (s, 3H).
[0175] C.
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chlor-
o-phenyl)-1-hydroxymethyl-ethyl]-4-methyl-benzamide.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-benzoic acid
was coupled with (.+-.)-2-amino-3-(4-chloro-phenyl)-propan-1-ol as
in EXAMPLE 1, Part C. HPLC: R.sub.T=9.31 min. MS (ESI-): mass
calcd. for C.sub.23H.sub.21ClN.sub.4O.sub.4S.sub.2, 516.07; m/z
found, 515 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.52
(s, 1H), 8.33 (dd, J=7.0, 1.0, 1H), 8.19 (dd, J=8.8, 1.0, 1H), 7.68
(dd, J=8.8, 7.0, 1H), 7.48 (s, 1H), 7.32-7.27 (m, 2H), 7.21-7.17
(m, 2H), 7.09 (d, J=8.0, 1H), 6.75 (d, J=8.0, 1H), 6.28 (br d,
J=7.4, 1H), 4.32-4.23 (m, 1H), 3.72 (dd, J=10.8, 3.6, 1H), 3.65
(dd, J=10.8, 4.5, 1H), 2.91 (d, J=7.4, 2H), 2.75 (br s, 1H), 2.27
(s, 3H).
Example 13
##STR00023##
[0176] (S)-Benzo[1,2,5]thiadiazole-4-sulfonic acid
[6-bromo-1,3-dioxo-2-(2-phenyl-propyl)-2,3-dihydro-1H-isoindol-4-yl]-amid-
e
[0177] A. Methyl 4,5-dibromo-2-furoate. Neat methyl 2-furoate (20.0
g, 158 mmol), in a 500 mL round bottom three-necked flask fitted
with a mechanical stirrer, was stirred as AlCl.sub.3 (45.0 g, 337
mmol) was carefully added in several portions. A mild exotherm was
observed. Br.sub.2 (54.0 g, 338 mmol) was then added via dropping
funnel over 30 min. The resulting thick mixture was stirred for 30
min. The mixture was cooled in an ice bath and treated slowly with
crushed ice. The resulting mixture was extracted with Et.sub.2O
(3.times.). The combined organic extracts were washed with 10% aq.
Na.sub.2S.sub.2O.sub.3, dried (MgSO.sub.4), and concentrated to
give a yellow solid. The crude product was purified by flash
chromatography (Et.sub.2O/hexanes) to provide 26.19 g (58%) of the
desired dibromofuroate as a pale yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.18 (s, 1H), 3.90 (s, 3H).
[0178] B. 4,5-Dibromo-2-furoic acid. To a suspension of methyl
4,5-dibromo-2-furoate (26.19 g, 92.2 mmol) in THF (60 mL) at rt was
added LiOH (3 M in water, 60 mL, 180 mmol). The biphasic mixture
was stirred for 4 h. The mixture was poured into 1 N HCl (500 mL)
and extracted with DCM (3.times.). The combined organic layers were
dried (Na.sub.2SO.sub.4) and concentrated to provide 24.59 g (99%)
of the acid as an off-white solid. .sup.1H NMR (400 MHz,
CD.sub.3OD): 7.30 (s, 1H).
[0179] C. 4-Bromo-2-furoic acid. 4,5-Dibromo-2-furoic acid (24.51
g, 90.8 mmol) was dissolved in a mixture of water (280 mL) and aq.
NH.sub.4OH (33% NH.sub.3; 80 mL) and cooled in an ice bath. The
mixture was stirred rapidly as zinc dust (6.23 g, 95.3 mmol) was
added in portions while keeping the internal temperature below
7.degree. C. The mixture was stirred at 0.degree. C. for 30 min.
HPLC analysis of an aliquot of the reaction mixture indicated some
starting material remaining. An additional portion of zinc dust
(0.5 g, 7.6 mmol) was added and the mixture was stirred at
0.degree. C. for 30 min. HPLC analysis of an aliquot indicated only
a trace of starting material as well as formation of a small amount
of 2-furoic acid from over-reduction. The mixture was acidified to
pH 1 with conc. HCl causing precipitation of the product. The
mixture was cooled to 10.degree. C., and the product was collected
by suction filtration, washed with water, and air dried to provide
8.0 g (46%) of the desired acid. Additional product could be
obtained by extraction of the filtrate with DCM and
recrystallization of the crude extract from water. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.76 (d, J=0.8, 1H), 7.14 (d, J=0.8, 1H).
[0180] D. 4-Bromo-furan-2-carbonyl azide. A suspension of
4-bromo-2-furoic acid (1.87 g, 9.8 mmol) was heated at reflux in
SOCl.sub.2 (5 mL) for 1 h. The mixture was concentrated, and the
residue was azeotroped with toluene (3.times.). The crude acid
chloride was stirred in acetone (15 mL) at 0.degree. C., and a
solution of NaN.sub.3 (702 mg, 10.8 mmol) in water (5 mL) was added
dropwise via pipet. The mixture was stirred for 1 h at 0.degree. C.
then was concentrated without external heating. The residue was
diluted with satd. aq. NaHCO.sub.3 and extracted with DCM
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated without heating to give 1.85 g
(87%) of the acyl azide as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.65 (d, J=0.9, 1H), 7.26 (d, J=0.9, 1H).
[0181] E. (S)-E-3-(2-Phenyl-propylcarbamoyl)-acrylic acid. To a
solution of maleic anhydride (765 mg, 7.8 mmol) in acetic acid (20
mL) at rt was added (S)-2-phenylpropylamine. The mixture was
stirred overnight then was partially concentrated. Water (50 mL)
was added causing precipitation of the product acid. The white
solid was collected by suction filtration, washed with water, and
dried to provide 1.44 g (79%) of the pure acid. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.38-7.32 (m, 2H), 7.29-7.24 (m, 1H), 7.24-7.20
(m, 2H), 6.68 (br m, 1H), 6.29 (d J=12.7, 1H), 6.18 (d, J=12.7,
1H), 3.78-3.69 (m, 1H), 3.47-3.38 (m, 1H), 3.11-3.00 (m, 1H), 1.33
(d, J=7.0, 3H).
[0182] F. (S)--N-2-Phenylpropyl maleimide. A mixture of
(S)-E-3-(2-phenyl-propylcarbamoyl)-acrylic acid (1.44 g, 6.2 mmol),
NaOAc (305 mg, 3.7 mmol), and Ac.sub.2O (6 mL) was heated at
120.degree. C. for 5 h. The mixture was concentrated, and the
residue was stirred vigorously with satd. aq. NaHCO.sub.3. The
resulting mixture was extracted with DCM (3.times.). The combined
organic layers were dried (Na.sub.2SO.sub.4) and concentrated. The
crude product was purified by flash chromatography (EtOAc/hexanes)
to provide 340 mg (26%) of the desired maleimide as a white solid.
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.32-7.26 (m, 2H), 7.24-7.17 (m,
3H), 6.60 (s, 2H), 3.70 (dd, J=13.7, 8.2, 1H), 3.61 (dd, J=13.7,
7.8, 1H), 3.23 (app. sextet, J=7.7, 1H), 1.26 (d, J=7.0, 3H).
[0183] G.
(S)-[6-Bromo-1,3-dioxo-2-(2-phenyl-propyl)-2,3-dihydro-1H-isoind-
ol-4-yl]-carbamic acid tert-butyl ester. A solution of
4-bromo-furan-2-carbonyl azide (444 mg, 2.06 mmol) and
(S)--N-2-phenylpropyl maleimide (340 mg, 1.58 mmol) in degassed
tert-butanol (3 mL) was heated under N.sub.2 at 70.degree. C. for
24 h. The resulting dark red solution was concentrated, and the
residue was adsorbed onto SiO.sub.2 and purified by flash
chromatography (EtOAc/hexanes) to give a pale yellow foam (160 mg,
22%). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.72 (d, J=1.3, 1H), 8.69
(br s, 1H), 7.51 (d, J=1.5, 1H), 7.33-7.18 (m, 5H), 3.81 (dd,
J=13.6, 7.8, 1H), 3.73 (dd, J=13.6, 8.1, 1H), 3.36-3.24 (m, 1H),
1.54 (s, 9H), 1.26 (d, J=7.0, 3H).
[0184] H.
(S)-4-Amino-6-bromo-2-(2-phenyl-propyl)-isoindole-1,3-dione.
(S)-[6-Bromo-1,3-dioxo-2-(2-phenyl-propyl)-2,3-dihydro-1H-isoindol-4-yl]--
carbamic acid tert-butyl ester (160 mg, 0.35 mmol) was stirred in a
mixture of DCM (2 mL) and TFA (1 mL) for 3 h at rt. The mixture was
concentrated, and the residue was diluted with satd. aq.
NaHCO.sub.3 and extracted with DCM (3.times.). The combined organic
layers were dried (Na.sub.2SO.sub.4) and concentrated to give a
yellow oil. Purification by flash chromatography (EtOAc/hexanes)
gave 110 mg (87%) of the desired amine as a yellow foam. .sup.1H
NMR (500 MHz, CDCl.sub.3): 7.31-7.23 (m, 4H), 7.22-7.17 (m, 2H),
6.81 (d, J=1.5, 1H), 5.19 (br s, 2H), 3.78 (dd, J=13.6, 7.6, 1H),
3.71 (dd, J=13.6, 8.2, 1H), 3.30 (app sextet, J.sub.app=7.5, 1H),
1.29 (d, J=7.0, 3H).
[0185] I. (S)-Benzo[1,2,5]thiadiazole-4-sulfonic acid
[6-bromo-1,3-dioxo-2-(2-phenyl-propyl)-2,3-dihydro-1H-isoindol-4-yl]-amid-
e. A mixture of
(S)-4-amino-6-bromo-2-(2-phenyl-propyl)-isoindole-1,3-dione (30 mg,
0.08 mmol) and benzo[1,2,5]thiadiazole-4-sulfonyl chloride (150 mg,
0.64 mmol) was heated to 170.degree. C. forming a melt and stirred
for 2 h. The mixture was allowed to cool, and the solidified
residue was dissolved in EtOAc, and the solution was washed with
satd. aq. NaHCO.sub.3, dried (Na.sub.2SO.sub.4), and concentrated.
Purification by flash chromatography (EtOAc/hexanes) gave the
desired sulfonamide as a tan solid (30 mg, 64%). HPLC:
R.sub.T=11.01 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17BrN.sub.4O.sub.4S.sub.2, 555.99; m/z found, 555/557
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 9.59 (br s, 1H),
8.39 (dd, J=7.0, 1.0, 1H), 8.27 (dd, J=8.8, 1.0, 1H), 8.08 (d,
J=1.4, 1H), 7.75 (dd, J=8.8, 7.1, 1H), 7.47 (d, J=1.3, 1H),
7.27-7.22 (m, 2H), 7.21-7.17 (m, 3H), 3.78 (dd, J=13.6, 8.1, 1H),
3.68 (dd, J=13.6, 7.81, 1H), 3.26 (sextet, J=7.4, 1H), 1.26 (d,
J=7.0, 3H).
Example 14
##STR00024##
[0186]
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(4-chloro-phenyl)-propionic acid
[0187] A.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid methyl ester.
[0188] The title compound (0.95 g, 50%) was prepared from methyl
2-amino-4,5-dichlorobenzoate and
4-chlorosulfonyl-2,1,3-benzothiadiazole as in Example 1, Part A
(without DMAP). .sup.1H NMR (500 MHz, CDCl.sub.3): 11.21 (s, 1H),
8.39 (dd, J=7.1, 1.0, 1H), 8.25 (dd, J=8.8, 1.0, 1H), 7.94 (s, 1H),
7.91 (s, 1H), 7.74 (dd, J=8.8, 7.1, 1H), 3.93 (s, 3H).
[0189] B.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid. To a solution of
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid methyl ester (0.95 g, 2.3 mmol) in THF (21 mL) and water (7
mL) was added LiOH.H.sub.2O (0.38 g, 9.1 mmol). The biphasic
mixture was stirred overnight at rt. The mixture was acidified with
conc. HCl and extracted with DCM (3.times.). The combined organic
layers were dried (MgSO.sub.4) and concentrated to provide 0.80 g
(88%) of the pure acid as a white solid. .sup.1H NMR (500 MHz,
CDCl.sub.3): 11.07 (s, 1H), 8.41 (dd, J=7.0, 1.0, 1H), 8.27 (dd,
J=8.8, 1.0, 1H), 8.01 (s, 1H), 7.94 (s, 1H), 7.75 (dd, J=8.8, 7.0,
1H).
[0190] C.
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro--
benzoylamino]-3-(4-chloro-phenyl)-propionic acid.
(R)-2-(tert-Butoxycarbonylamino)-3-(4-chloro-phenyl)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-(4-chloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This salt was then coupled with
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid as in EXAMPLE 1, Part C. The resulting methyl ester was
hydrolyzed as in EXAMPLE 2, Part E, to afford the title compound.
HPLC: R.sub.T=10.35 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 583.95; m/z found,
583/585 [M-H]. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.07 (s, 1H),
8.34 (d, J=7.1, 1H), 8.23 (d, J=8.8, 1H), 7.84 (s, 1H), 7.74-7.70
(m, 1H), 7.30-7.26 (m, 2H), 7.24 (s, 1H), 7.07 (d, J=8.3, 2H), 6.38
(d, J=7.4, 1H), 5.00-4.97 (m, 1H), 3.30 (dd, J=14.1, 5.9, 1H), 3.21
(dd, J=14.1, 5.9, 1H).
Example 15
##STR00025##
[0191]
(R)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-b-
enzoylamino]-propionic acid
[0192] A. 4-Iodo-2-nitro-benzoic acid. In a 1 L three-neck
round-bottom flask equipped with an internal thermometer, a reflux
condenser, and an addition funnel,
Bu.sub.4N.sup.+MnO.sub.4.sup.-(124 g, 343 mmol) was dissolved in
pyridine (200 mL). The solution was heated to 60.degree. C., and
then the heating source was removed. A solution of
4-iodo-2-nitrotoluene (43.0 g, 163 mmol) in pyridine (60 mL) was
added through the additional funnel over 2 h. The reaction
temperature was maintained at 60.degree. C. by adjusting the
addition rate. When the addition was complete, the reaction mixture
was cooled to rt. The solution was concentrated, diluted with EtOAc
(300 mL) and water (200 mL), and stirred at rt for 30 min. The
precipitated brown solid was filtered off and washed with EtOAc.
The clear organic layer was washed with 5% aq. H.sub.2SO.sub.4 (200
mL) and brine (200 mL), dried (MgSO.sub.4), and concentrated to
afford a thick, brown oil. The crude product was dissolved in EtOAc
(200 mL) and then a solution of KOH (9.1 g, 163 mmol) in MeOH (ca.
30 mL) was added dropwise. The mixture was stirred at rt for 1 h,
and the precipitated solid was collected by filtration and washed
with EtOAc. The filtrate was concentrated and the precipitation was
repeated with KOH in MeOH. The two crops were combined and
dissolved in water (ca. 250 mL) and acidified with conc. HCl to
pH<2. The precipitated white solid was collected by filtration
and dried under vacuum to give the desired product (40 g, 136 mmol,
83%, >98% purity by HPLC). .sup.1H NMR (400 MHz, CD.sub.3OD):
8.13 (d, J=1.6, 1H), 8.01 (dd, J=8.1, 1.6, 1H), 7.50 (d, J=8.1,
1H).
[0193] B. 2-Amino-4-iodo-benzoic acid. 4-Iodo-2-nitro-benzoic acid
(20 g, 68 mmol, 1.0 equiv.) was dissolved in 200 mL of EtOAc and
then SnCl.sub.2.2H.sub.2O (46 g, 204 mmol, 3.0 equiv.) was added in
three portions. The reaction mixture was stirred at rt for 16 h.
Satd. aq. NaHCO.sub.3 was carefully added to adjust the mixture to
pH=9. The precipitated solid was removed by filtration through
diatomaceous earth, washing with water. The aqueous layer in the
filtrate was separated and acidified with conc. HCl to pH=2. The
precipitated solid was collected by filtration and dried to afford
the title compound as white solid (19 g, 68 mmol, 100%). .sup.1H
NMR (400 MHz, CD.sub.3OD): .sup.1H NMR (500 MHz, CDCl.sub.3): 7.56
(d, J=8.5, 1H), 7.08 (s, 1H), 6.99 (d, J=8.5, 1H), 5.71 (br s,
2H).
[0194] C. 4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid. A
mixture of 2-amino-4-iodo-benzoic acid (10 g, 38 mmol, 1.0 equiv.)
and quinoxaline-5-sulfonyl chloride (8.7 g, 38 mmol) in 100 mL of
water was basified with satd. aq. Na.sub.2CO.sub.3, with stirring,
to adjust the pH to 8.0. As the reaction progressed, the pH was
maintained at 8.0.+-.0.2 by adding satd. aq. Na.sub.2CO.sub.3.
After 3 h, no further pH changes were observed. The reaction
mixture was stirred at rt for another 16 h. Conc. HCl was added to
adjust the pH to <2. The precipitated solid was collected by
filtration, washed with water and dried to afford the title
compound as white solid (17 g, 37.4 mmol, 98%). MS (ESI+): calcd.
for C.sub.15H.sub.10IN.sub.3O.sub.4S, 455.0; m/z found, 456
[M+H].sup.+. .sup.1H NMR (500 MHz, DMSO-d.sub.6): 14.0 (br s, 1H),
11.6 (s, 1H), 9.10 (d, J=1.5, 1H), 9.97 (d, J=1.5, 1H), 8.60 (d,
J=7.4, 1H), 8.42 (d, J=8.4, 1H), 8.06 (t, J=7.5, 1H), 7.95 (d,
J=1.2, 1H), 7.51 (d, J=8.3, 1H), 7.37 (dd, J=8.3, 1.2, 1H).
[0195] D.
(R)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino-
)-benzoylamino]-propionic acid.
(R)-2-(tert-Butoxycarbonylamino)-3-(4-chloro-phenyl)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-(4-chloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled with
4-iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in EXAMPLE
1, Part C. The resulting methyl ester was hydrolyzed as in EXAMPLE
2, Part E. HPLC: R.sub.T=9.74 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.18ClIN.sub.4O.sub.5S, 635.97; m/z found, 635/637
[M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.93 (d, J=12.8,
1H), 8.99 (d, J=1.6, 1H), 8.92 (s, 1H), 8.54 (d, J=7.4, 1H), 8.31
(d, J=8.5, 1H), 8.10 (s, 1H), 7.90-7.87 (m, 1H), 7.30-7.22 (m, 3H),
7.05 (d, J=8.4, 2H), 6.84 (d, J=8.2, 1H), 6.29 (d, J=7.9, 1H),
4.93-4.80 (m, 1H), 3.24 (dd, J=14.3, 5.8, 1H), 3.16 (dd, J=14.2,
5.9, 1H).
Example 16
##STR00026##
[0196]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[2-(3-
,4-dichloro-phenyl)-propyl]-benzamide
[0197] A.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoic acid
methyl ester.
[0198] The title compound (1.56 g, 75%) was prepared from
benzo[1,2,5]thiadiazole-4-sulfonyl chloride and
2-amino-5-chloro-benzoic acid methyl ester as in Example 1, Part A.
HPLC: R.sub.T=10.77 min. MS (ESI+): mass calcd. for
C.sub.14H.sub.10ClN.sub.3O.sub.4S.sub.2, 382.98; m/z found, 406
[M+Na].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.16 (s, 1H),
8.35 (dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0, 1H), 7.82 (d,
J=2.5, 1H), 7.72-7.68 (m, 2H), 7.34 (dd, J=9.0, 2.5, 1H), 3.92 (s,
3H).
[0199] B.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoic acid.
LiOH.H.sub.2O (0.68 g, 16.2 mmol) was added to a stirred solution
of 2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoic
acid methyl ester (1.56 g, 4.06 mmol) in THF (15 mL) and water (5
mL). After 18 h, the solution was acidified to pH 2 with conc. HCl,
diluted with water, and extracted with DCM (3.times.). The combined
organic layers were dried (MgSO.sub.4), and concentrated to provide
the title compound (1.50 g, 100%). HPLC: R.sub.T=9.48 min. MS
(ESI-): mass calcd. for C.sub.13H.sub.8ClN.sub.3O.sub.4S.sub.2,
368.96; m/z found, 368/370 [M-H]. .sup.1H NMR (500 MHz,
CDCl.sub.3): 11.07 (s, 1H), 8.38 (dd, J=7.0, 1.0, 1H), 8.24 (dd,
J=8.8, 1.0, 1H), 7.92 (d, J=2.5, 1H), 7.75 (d, J=9.0, 1H),
7.71-7.69 (m, 1H), 7.40 (dd, J=9.0, 2.6, 1H).
[0200] C.
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-N-[2-
-(3,4-dichloro-Phenyl-propyl]-benzamide. The title compound was
prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoic acid
and (.+-.)-2-(3,4-dichloro-phenyl)-propylamine hydrochloride as in
EXAMPLE 1, Part C. HPLC: R.sub.T=11.76 min. MS (ESI-): mass calcd.
for C.sub.22H.sub.17Cl.sub.3N.sub.4O.sub.3S.sub.2, 553.98; m/z
found, 553/555 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.05 (s, 1H), 8.30 (dd, J=7.0, 1.0, 1H), 8.21 (d, 8.0, 1H),
7.70-7.66 (m, 1H), 7.65-7.63 (m, 1H), 7.41 (d, J=8.2, 1H), 7.29
(dd, J=4.6, 2.1, 2H), 7.05 (dd, J=9.6, 2.1, 2H), 5.80 (s, 1H),
3.67-3.60 (m, 1H), 3.32-3.26 (m, 1H), 3.02-2.97 (m, 1H), 1.30 (d,
J=7.0, 3H).
Example 17
##STR00027##
[0201]
(R)-2-[2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoylamino]-3-
-phenyl-propionic acid
[0202] A. 2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoic
acid. 2-Amino-4-iodo-benzoic acid was sulfonylated with
2,6-difluorobenzenesulfonyl chloride as in EXAMPLE 1, Part A.
.sup.1H NMR (500 MHz, CD.sub.3OD): 8.05 (d, J=1.6, 1H), 7.72 (d,
J=8.4, 1H), 7.68-7.60 (m, 1H), 7.48 (dd, J=8.4, 1.6, 1H), 7.16-7.09
(m, 2H).
[0203] B.
(R)-2-[2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoylamino-
]-3-phenyl-propionic acid.
(R)-2-(tert-Butoxycarbonylamino)-3-phenyl-propionic acid was
treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-phenyl-propionic acid methyl ester hydrochloride as a
white solid. This ester was coupled with
2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-benzoic acid as in
EXAMPLE 1, Part C. The resulting methyl ester was hydrolyzed as in
EXAMPLE 2, Part E, to afford the title compound. HPLC: R.sub.T=9.27
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.17F.sub.2IN.sub.2O.sub.5S, 585.99; m/z found, 584/586
[M-H]. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.32 (s, 1H), 8.11 (s,
1H), 7.50-7.46 (m, 1H), 7.38-7.28 (m, 4H), 7.16-7.15 (m, 2H),
7.00-6.96 (m, 3H), 6.51 (d, J=7.6, 1H), 5.07-5.03 (m, 1H), 3.34
(dd, J=14.0, 5.6, 1H), 3.25 (dd, J=14.3, 5.3, 1H).
Example 18
##STR00028##
[0204]
(.+-.)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3--
(3,4-dichloro-phenyl)-3-oxo-propionic acid methyl ester
[0205] A. 5-(3,4-Dichloro-phenyl)-oxazole-4-carboxylic acid methyl
ester. A solution of methyl isocyanoacetate (5.0 g, 50.0 mmol),
3,4-dichlorobenzoyl chloride (10.6 g, 50.0 mmol), and Et.sub.3N
(20.9 mL, 150 mmol) was stirred in THF (20 mL) for 48 h at rt. The
solution was concentrated, diluted with EtOAc, washed with water,
dried (MgSO.sub.4), and concentrated to afford a solid. The solid
was washed with hexanes and collected by filtration to provide 8.7
g (64%) of the desired product. HPLC: R.sub.T=9.68 min. MS (ESI+):
mass calcd. for C.sub.11H.sub.7Cl.sub.2NO.sub.3, 270.98; m/z found,
272/274 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 8.29 (d,
J=2.1, 1H), 8.03 (dd, J=8.5, 2.1, 1H), 7.94 (s, 1H), 7.56 (d,
J=8.5, 1H), 3.98 (s, 3H).
[0206] B. (.+-.)-2-Amino-3-(3,4-dichloro-phenyl)-3-oxo-propionic
acid methyl ester hydrochloride. A suspension of
5-(3,4-dichloro-phenyl)-oxazole-4-carboxylic acid methyl ester (1.5
g, 5.51 mmol), 3 N HCl (10 mL), and MeOH (15 mL) was heated at
50.degree. C. for 4 h. The mixture was concentrated, diluted with
water, and washed with Et.sub.2O. The aqueous layer was
concentrated and Et.sub.2O was added, causing precipitation of a
white solid. The precipitate was collected by filtration to provide
1.0 g (63%) of the desired product as an apparent 10:1 mixture of
keto-enol tautomers. MS (ESI+): mass calcd. for
C.sub.10H.sub.9Cl.sub.2NO.sub.3, 261.00; m/z found, 262/264
[M+H].sup.+. Major tautomer: .sup.1H NMR (500 MHz, CDCl.sub.3):
8.32 (d, J=2.1, 1H), 8.09 (dd, J=8.4, 2.1, 1H), 7.79 (d, J=8.5,
1H), 3.80 (s, 3H). Minor tautomer: .sup.1H NMR (500 MHz,
CDCl.sub.3): 8.19 (d, J=2.0, 1H), 7.96 (dd, J=8.4, 2.1, 1H), 7.76
(d, J=8.4, 1H), 6.18 (s, 1H).
[0207] C.
(.+-.)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-
-3-(3,4-dichloro-phenyl)-3-oxo-propionic acid methyl ester.
4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid was coupled
to (.+-.)-2-amino-3-(3,4-dichloro-phenyl)-3-oxo-propionic acid
methyl ester hydrochloride as in EXAMPLE 1, Part C. HPLC:
R.sub.T=10.65 min. MS (ESI+): mass calcd. for
C.sub.25H.sub.17Cl.sub.3N.sub.4O.sub.6S, 605.99; m/z found, 607/609
[M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.23 (s, 1H), 8.88
(d, J=1.8, 1H), 8.85 (d, J=1.8, 1H), 8.58 (dd, J=7.4, 1.4, 1H),
8.32 (dd, J=8.5, 1.4, 1H), 8.24 (d, 2.1, 1H), 8.03 (dd, J=8.4, 2.1,
1H), 7.89-7.86 (m, 1H), 7.79 (d, J=2.0, 1H), 7.69 (d, J=8.4, 1H),
7.45 (d, J=8.5, 1H), 7.30 (d, J=6.9, 1H), 6.97 (dd, J=8.4, 2.0,
1H), 6.19 (d, J=6.9, 1H), 3.78 (s, 3H).
Example 19
##STR00029##
[0208]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamin-
o]-3-(3,4-dichloro-phenyl)-3-hydroxy-propionic acid
[0209]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamin-
o]-3-(3,4-dichloro-phenyl)-3-oxo-propionic acid methyl ester was
prepared as in EXAMPLE 18, substituting
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
in Part C. A suspension of the methyl ester (34 mg, 0.055 mmol) in
EtOH (0.6 mL) was treated with NH.sub.4Cl (59 mg, 1.11 mmol), water
(0.2 mL), and NaBH.sub.4 (10 mg, 0.277 mmol). The resulting yellow,
homogenous suspension was stirred at rt for 1 h. The mixture was
diluted with water and extracted with DCM (3.times.). The combined
organic layers were dried (MgSO.sub.4) and concentrated to provide
the crude product. The crude product was dissolved in DMF (.about.1
mL) and purified by preparative reversed-phase HPLC to provide the
desired product as a white solid as a 9:1 mixture of diastereomers
(11 mg, 33%). HPLC: R.sub.T=10.16 min (major diastereomer) and
10.26 min (minor diastereomer). MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.6S.sub.2, 601.9; m/z found,
601 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): Major
diastereomer: 11.41 (s, 1H), 8.33 (d, J=6.9, 1H), 8.18 (d, J=8.8,
1H), 7.73-7.68 (m, 1H), 7.58 (br s, 1H), 7.44 (br s, 1H), 7.38-7.34
(m, 1H), 7.23-7.16 (m, 2H), 7.03 (br d, J=6.6, 1H), 6.83 (br d,
J=7.9, 1H), 5.83 (br d, J=3.9, 1H), 5.16-5.09 (br m, 1H); Minor
diastereomer: 11.01 (s, 1H), 8.29 (d, J=6.9, 1H), 8.14 (d, J=9.4,
1H), 7.70-7.63 (m, 1H), 7.53-7.49 (br m, 2H), 7.34-7.30 (m, 1H),
7.18-7.10 (m, 2H), 7.02-7.00 (m, 1H), 6.82-6.78 (m, 1H), 5.61-5.56
(br m, 1H), 5.06-5.02 (br m, 1H).
Example 20
##STR00030##
[0210]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-phen-
ethyl-benzamide
[0211] A. 4-Bromo-2-nitrobenzoic acid. A mixture of
4-bromo-2-nitrotoluene (5.0 g, 23 mmol), KMnO.sub.4 (10.9 g, 69
mmol), and water (250 mL) was heated at reflux overnight. The
mixture was filtered through a pad of diatomaceous earth, washing
with water. The basic filtrate was acidified to pH .about.1 with
conc. HCl and extracted with EtOAc (3.times.300 mL). The combined
organic layers were dried (MgSO.sub.4) and concentrated to provide
the desired benzoic acid (1.22 g, 22%). MS (ESI-): mass calcd. for
C.sub.7H.sub.4BrNO.sub.4, 244.9; m/z found, 244 [M-H].sup.-.
.sup.1H NMR (400 MHz, CD.sub.3OD): 8.07 (d, J=1.9, 1H), 7.85 (dd,
J=8.2, 1.9, 1H), 7.65 (d, J=8.2, 1H).
[0212] B. Methyl 2-amino-4-bromobenzoate. To a stirred solution of
4-bromo-2-nitrobenzoic acid (3.81 g, 15 mmol) in DMF (30 mL) at
0.degree. C. was added 1,8-diazabicycloundecane (DBU; 10.3 mL, 75
mmol) followed by MeI (4.67 mL, 75 mmol). The mixture was stirred
for 15 min at 0.degree. C., then was allowed to warm to rt and was
stirred overnight. The mixture was poured into water and extracted
with EtOAc (2.times.). The combined organic extracts were washed
with water (2.times.), dried (MgSO.sub.4), and concentrated. The
residue was purified by flash chromatography (hexanes/EtOAc) to
afford methyl 4-bromo-2-nitrobenzoate as a pale yellow solid (3.52
g, 90%). To a solution of the nitrobenzoate (3.52 g, 13.5 mmol) in
1:1 EtOAc/DCM (30 mL) at rt was added SnCl.sub.2.2H.sub.2O (15.27
g, 67 mmol). After 18 h, the mixture was concentrated, diluted with
satd. aq. NaHCO.sub.3, and extracted with DCM (3.times.). The
combined organic layers were dried (MgSO.sub.4) and concentrated to
provide the desired aminobenzoate as a white solid (2.89 g, 93%).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.70 (d, J=8.6, 1H), 6.84 (d,
J=1.9, 1H), 6.75 (dd, J=8.6, 1.9, 1H), 5.78 (br s, 2H), 3.86 (s,
3H).
[0213] C.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid
methyl ester.
[0214] The title compound (3.95 g, 75%) was prepared from methyl
2-amino-4-bromobenzoate and 4-chlorosulfonyl-2,1,3-benzothiadiazole
as in Example 1, Part A. MS (ESI-): mass calcd. for
C.sub.14H.sub.10BrN.sub.3O.sub.4S.sub.2, 426.9; m/z found, 426
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.34 (br s, 1H),
8.40 (dd, J=7.0, 0.9, 1H), 8.24 (dd, J=8.8, 0.9, 1H), 7.92 (d,
J=1.8, 1H), 7.74 (dd, J=8.8, 7.0, 1H), 7.72 (d, J=8.5, 1H), 7.10
(dd, J=8.5, 1.8, 1H), 3.92 (s, 3H).
[0215] D.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid.
The title compound (2.79 g, 98%) was prepared as in Example 1, Part
B. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.14 (br s, 1H), 8.42 (dd,
J=7.2, 1.1, 1H), 8.26 (dd, J=8.8, 1.1, 1H), 7.98 (d, J=1.6, 1H),
7.82 (d, J=8.5, 1H), 7.75 (dd, J=8.8, 7.2, 1H), 7.16 (dd, J=8.5,
1.6, 1H).
[0216] E.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-methyl-N-P-
henethyl-benzamide.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid was
coupled with N-methylphenethylamine as in EXAMPLE 1, Part C. HPLC:
R.sub.T=9.90 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrN.sub.4O.sub.3S.sub.2, 530.01; m/z found, 529/531
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3; rotameric
broadening): 8.95-8.80 (br s, 0.6H), 8.57-8.43 (br s, 0.4H), 8.27
(dd, J=7.0, 0.9, 1H), 8.23 (br d, J=8.8, 1H), 7.80-7.64 (m, 2H),
7.37-6.85 (br m, 6H), 6.73-6.62 (br m, 0.6H), 6.55-6.40 (br m,
0.4H), 3.68-3.35 (br m, 1.3H), 3.35-3.07 (br m, 0.7H), 3.07-2.25
(br m, 5H).
Example 21
##STR00031##
[0218]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro--
phenyl)-propyl]-benzamide
[0219] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting 4-chloro-.beta.-methyl phenethylamine hydrochloride in
Part C. HPLC: R.sub.T=10.82 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.18BrClN.sub.4O.sub.3S.sub.2, 565.9; m/z found, 565
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.49 (s, 1H), 8.34
(dd, J=7.0, 0.6, 1H), 8.22 (dd, J=8.8, 0.7, 1H), 7.86 (d, J=1.7,
1H), 7.72 (dd, J=8.8, 7.0, 1H), 7.31-7.29 (m, 2H), 7.14-7.11 (m,
2H), 7.03 (dd, J=8.4, 1.8, 1H), 6.88 (d, J=8.4, 1H), 5.82-5.79 (br
m, 1H), 3.72 (td, J=13.1, 6.4, 1H), 3.30 (ddd, J=13.7, 8.9, 5.2,
1H), 3.03-2.98 (m, 1H), 1.30 (d, J=7.0, 3H).
Example 22
##STR00032##
[0220]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)--
1-methyl-ethyl]-4-trifluoromethyl-benzamide
[0221] This compound was prepared as in EXAMPLE 3, Parts A and B,
and EXAMPLE 5, Part D. HPLC (reversed-phase): R.sub.T=11.00 min. MS
(ESI-): mass calcd. for
C.sub.23H.sub.18ClF.sub.3N.sub.4O.sub.3S.sub.2, 555.0; m/z found,
554 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.25 (s, 1H),
8.37 (dd, J=7.0, 0.8, 1H), 8.23 (dd, J=8.8, 0.9, 1H), 7.94 (s, 1H),
7.72 (dd, J=8.8, 7.1, 1H), 7.30-7.28 (m, 3H), 7.20 (d, J=8.2, 1H),
7.13 (d, J=8.3, 2H), 5.95 (d, J=7.9, 1H), 4.40-4.35 (m, 1H), 2.84
(ddd, J=20.7, 13.6, 6.5, 2H), 1.21 (d, J=6.7, 3H).
Example 23
##STR00033##
[0222]
2-(Benzothiazole-4-sulfonylamino)-4-bromo-N-[2-(4-chloro-phenyl)-1--
methyl-ethyl]-benzamide
[0223] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting 4-chloro-.beta.-methyl phenethylamine hydrochloride in
Part C. HPLC: R.sub.T=10.62 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.19BrClN.sub.3O.sub.3S.sub.2, 564.9; m/z found, 564
[M-H].sup.-. .sup.1H NMR (400 mHz, CDCl.sub.3): 11.19 (s, 1H), 9.16
(s, 1H), 8.93 (d, J=4.1, 1H), 8.20 (dd, J=17.0, 7.3, 2H), 7.91-7.89
(m, 1H), 7.81 (s, 1H), 7.60-7.56 (m, 1H), 7.11 (d, J=7.6, 2H), 7.04
(s, 1H), 5.79-5.82 (m, 1H), 4.37-4.34 (m, 1H), 2.78-2.73 (m, 1H),
2.89-2.86 (m, 1H), 1.17 (d, J=6.1, 3H).
Example 24
##STR00034##
[0224]
4-Bromo-N-[2-(4-chloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfo-
nylamino)-benzamide
[0225] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting 4-chloro-.beta.-methyl phenethylamine hydrochloride in
Part C. HPLC: R.sub.T=10.85 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.18BrClF.sub.2N.sub.2O.sub.3S, 543.8; m/z found, 543
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.59 (s, 1H), 7.85
(d, J=1.7, 1H), 7.52-7.44 (m, 1H), 7.32-7.28 (m, 2H), 7.19-7.14 (m,
2H), 7.13-7.10 (m, 1H), 7.05-6.96 (m, 3H), 6.14-6.12 (m, 1H), 3.73
(td, J=13.1, 6.4, 1H), 3.38 (ddd, J=13.8, 8.8, 5.3, 1H), 3.07 (m,
1H), 1.31 (d, J=6.98, 3H).
Example 25
##STR00035##
[0226]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoylamino-
]-3-phenyl-propionic acid
[0227] This compound was prepared as in EXAMPLE 2, Parts B-E,
substituting 4-bromo-2-nitrobenzoic acid and (L)-phenylalanine
methyl ester hydrochloride in Part B. HPLC: R.sub.T=9.55 min. MS
(ESI-): mass calcd. for C.sub.22H.sub.17BrN.sub.4O.sub.5S.sub.2,
561.4; m/z found, 560 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.35 (s, 1H), 8.35 (dd, J=7.1, 0.9, 1H), 8.20 (dd,
J=8.8, 0.9, 1H), 7.89 (d, J=1.7, 1H), 7.71 (dd, J=8.8, 7.1, 1H),
7.31-7.26 (m, 3H), 7.14-7.11 (m, 2H), 7.06-7.04 (m, 1H), 7.03-6.98
(m, 1H), 6.34 (d, J=7.3, 1H), 5.01 (dd, J=13.1, 5.8, 1H), 3.32 (dd,
J=14.1, 5.8, 1H), 3.24 (dd, J=14.1, 5.8, 1H).
Example 26
##STR00036##
[0228]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-trifluoromethyl-be-
nzoylamino]-3-phenyl-propionic acid
[0229] This compound was prepared as in EXAMPLE 3, Parts C-F,
substituting 2-amino-4-trifluoromethyl-benzoic acid in Part B.
HPLC: R.sub.T=9.70 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17F.sub.3N.sub.4O.sub.5S.sub.2, 550.5; m/z found, 550
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.21 (s, 1H), 8.36
(dd, J=7.1, 1.0), 8.19 (dd, J=8.8, 0.9, 1H), 7.99 (s, 1H), 7.70
(dd, J=8.8, 7.1, 1H), 7.29 (m, 4H), 7.15 (dt, J=7.3, 1.3, 3H), 6.44
(d, J=7.4, 1H), 5.04 (dd, J=13.2, 5.8, 1H), 3.35 (dd, J=14.2, 5.7,
1H), 3.26 (dd, J=14.1, 5.9, 1H).
Example 27
##STR00037##
[0230]
2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phenyl-pr-
opionic acid
[0231] This compound was prepared as in EXAMPLE 2, Parts B-E,
substituting (L)-phenylalanine methyl ester hydrochloride in Part
B. HPLC: R.sub.T=9.33 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.19IN.sub.4O.sub.5S, 602.4; m/z found, 601
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.00 (s, 1H), 8.99
(d, J=1.7, 1H), 8.89 (d, J=1.7, 1H), 8.54 (dd, J=7.4, 1.3, 1H),
8.30 (dd, J=8.5, 1.3, 1H), 8.13 (d, J=1.5, 1H), 7.87 (dd, J=8.4,
7.5, 1H), 7.29 (m, 2H), 7.11 (dd, J=7.3, 2.0, 1H), 6.80 (d, J=8.3,
1H), 6.24 (d, J=7.4, 1H), 4.92 (dd, J=13.4, 5.9, 1H), 3.26 (dd,
J=14.1, 5.8, 1H), 3.19 (dd, J=14.1, 6.0, 1H).
Example 28
##STR00038##
[0232]
2-[2-(Benzothiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-phenyl--
propionic acid
[0233] This compound was prepared as in EXAMPLE 2, Parts B-E,
substituting (L)-phenylalanine methyl ester hydrochloride in Part
B, benzothiazole-4-sulfonyl chloride in Part D. HPLC: R.sub.T=9.42
min. MS (ESI-): mass calcd. for
C.sub.23H.sub.18IN.sub.3O.sub.5S.sub.2, 607.4; m/z found, 606
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.01 (s, 1H), 9.20
(s, 1H), 8.23 (d, J=7.6, 1H), 8.17 (d, J=8.0, 1H), 8.01 (d, J=1.2,
1H), 7.58 (t, J=7.9, 1H), 7.25 (m, 2H), 7.15 (m, 2H), 6.85 (d,
J=8.2, 1H), 6.47 (d, J=6.8, 1H), 5.04 (dd, J=12.7, 6.0, 1H), 3.33
(dd, J=14.2, 5.5, 1H), 3.25 (dd, J=14.0, 6.0, 1H).
Example 29
##STR00039##
[0235]
2-[4,5-Dichloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-phe-
nyl-propionic acid This compound was prepared as in EXAMPLE 3,
substituting quinoxaline-5-sulfonyl chloride in Part F. HPLC:
R.sub.T=9.46 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.18Cl.sub.2N.sub.4O.sub.5S, 545.4; m/z found, 544
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 10.90 (s, 1H), 8.99
(d, J=1.2, 1H), 8.90 (d, J=1.0, 1H), 8.52 (dd, J=7.3, 0.9, 1H),
8.30 (dd, J=8.5, 0.8, 1H), 7.86 (m, 2H), 7.28 (m, 1H), 7.21 (m,
1H), 7.12 (dd, J=7.6, 1.8, 2H), 6.36 (d, J=7.4, 1H), 4.90 (dd,
J=13.5, 6.1, 1H), 3.25 (dd, J=14.0, 5.6, 1H), 3.17 (dd, J=14.0,
6.3, 1H).
Example 30
##STR00040##
[0236]
4-Bromo-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenes-
ulfonylamino)-benzamide
[0237] This compound was prepared as in EXAMPLE 5, substituting
2,6-difluoro-benzenesulfonyl chloride in Part D. HPLC:
R.sub.T=11.05 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.17BrCl.sub.2F.sub.2N.sub.2O.sub.3S, 578.3; m/z found,
577 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.58 (s, 1H),
7.88 (d, J=1.8, 1H), 7.54-7.46 (m, 1H), 7.41 (d, J=8.3, 1H), 7.32
(d, J=2.1, 1H), 7.15-7.12 (m, 1H), 7.10-7.05 (m, 1H), 7-02-6.96 (m,
2H), 6.07 (br m, 1H), 3.73 (td, J=13.1, 6.4, 1H), 3.38 (ddd,
J=13.8, 8.7, 5.5, 1H), 3.12-3.01 (m, 1H), 1.32 (d, J=7.0, 3H).
Example 31
##STR00041##
[0238]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-pro-
pyl)-benzamide
[0239] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting (.+-.)-.beta.-methylphenethylamine hydrochloride in
Part C. HPLC: R.sub.T=10.17 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrN.sub.4O.sub.3S.sub.2, 531.5; m/z found, 530
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.51 (s, 1H), 8.32
(dd, J=7.0, 0.8, 1H), 8.20 (dd, J=8.8, 0.8, 1H), 7.83 (d, J=1.8,
1H), 7.70 (dd, J=8.8, 7.1, 1H), 7.34-7.31 (m, 2H), 7.26-7.18 (m,
3H), 7.00 (dd, J=8.4, 1.8, 1H), 6.85 (d, J=8.4, 1H), 5.90 (br m,
1H), 3.77-3.70 (m, 1H), 3.30 (ddd, J=13.6, 9.0, 4.9, 1H), 3.04-2.96
(m, 1H), 1.32 (d, J=7.0, 3H).
Example 32
##STR00042##
[0240]
3-(3,4-Dichloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)-4--
iodo-benzoylamino]-propionic acid
[0241] This compound was prepared as in EXAMPLE 2, substituting
2,6-difluoro-benzenesulfonyl chloride in Part D. HPLC: R.sub.T=9.94
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.2F.sub.2IN.sub.2O.sub.5S, 655.2; m/z found,
654 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.29 (s, 1H),
8.05 (d, J=1.4, 1H), 7.53-7.45 (m, 1H), 7.39-7.36 (m, 2H),
7.27-7.26 (m, 1H), 7.07-6.96 (m, 3H), 6.77 (d, J=7.3, 1H), 5.00 (q,
J=6.0, 1H), 3.32 (dd, J=14.2, 5.7, 1H), 3.19 (dd, J=14.2, 6.2,
1H).
Example 33
##STR00043##
[0242]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(4-chloro-phenyl)-propionic acid
[0243] This compound was prepared as in EXAMPLE 2, substituting
(S)-2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid
in Part A. HPLC: R.sub.T=9.72 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16ClIN.sub.4O.sub.5S.sub.2, 642.9; m/z found, 642
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.31 (s, 1H), 8.37
(dd, J=6.9, 0.6, 1H), 8.22 (d, J=8.8, 1H), 8.08 (d, J=1.4, 1H),
7.73 (dd, J=8.8, 7.1, 1H), 7.33-7.19 (m, 3H), 7.05 (d, J=8.4, 2H),
6.88 (d, J=8.3, 1H), 6.40 (d, J=7.3, 1H), 4.99 (q, J=5.7, 1H), 3.30
(dd, J=14.2, 5.6), 3.21 (dd, J=14.3, 5.4, 1H).
Example 34
##STR00044##
[0244]
3-(4-Chloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-
-benzoylamino]-propionic acid
[0245] This compound was prepared as in EXAMPLE 2, substituting
(S)-2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid
in Part A and 2,6-difluoro-benzenesulfonyl chloride in Part D.
HPLC: R.sub.T=9.71 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16ClF.sub.2IN.sub.2O.sub.5S, 620.8; m/z found, 620
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.33 (s, 1H), 8.06
(d, J=1.4, 1H), 7.53-7.46 (m, 1H), 7.36 (dd, J=8.3, 1.4, 1H),
7.27-7.25 (m, 2H), 7.10 (d, J=8.4, 2H), 7.05-6.96 (m, 2H), 6.72 (d,
J=7.4, 1H), 6.32 (br s, 1H), 4.99 (q, J=6.0, 1H), 3.31 (dd, J=14.2,
5.7, 1H), 3.19 (dd, J=14.2, 6.2, 1H).
Example 35
##STR00045##
[0246]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-
-propyl)-benzamide
[0247] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting (R)-1-methyl phenethylamine in Part C. HPLC:
R.sub.T=11.06 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrN.sub.4O.sub.3S.sub.2, 531.5; m/z found, 530
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.43 (s, 1H), 8.33
(dd, J=7.1, 0.9, 1H), 8.21 (dd, J=8.8, 0.9, 1H), 7.84 (d, J=1.8,
1H), 7.70 (dd, J=8.8, 7.1, 1H), 7.35-7.31 (m, 2H), 7.26-7.23 (m,
1H), 7.20-7.18 (m, 2H), 7.00 (dd, J=8.4, 1.8, 1H), 6.84 (d, J=8.4,
1H), 5.85 (br m, 1H), 4.50 (br s, 1H), 3.78-3.72 (m, 1H), 3.30
(ddd, J=13.7, 9.1, 4.9, 1H), 3.06-2.95 (m, 1H), 1.33 (d, J=7.0,
3H).
Example 36
##STR00046##
[0248]
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-(2-phenyl-
-propyl)-benzamide
[0249] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting (S)-.beta.-methyl phenethylamine in Part C. HPLC:
R.sub.T=11.05 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrN.sub.4O.sub.3S.sub.2, 531.5; m/z found, 530
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.41 (s, 1H), 8.33
(dd, J=7.1, 0.9, 1H), 8.21 (dd, J=8.8, 0.9, 1H), 7.84 (d, J=1.8,
1H), 7.70 (dd, J=8.8, 7.1, 1H), 7.35-7.31 (m, 2H), 7.26-7.23 (m,
1H), 7.20-7.18 (m, 2H), 7.01 (dd, J=8.4, 1.8, 1H), 6.83 (d, J=8.4,
1H), 5.86 (br m, 1H), 4.68 (br s, 1H), 3.72-3.78 (m, 1H), 3.30
(ddd, J=13.6, 9.1, 4.9, 1H), 3.04-2.95 (m, 1H), 1.33 (d, J=7.0,
3H).
Example 37
##STR00047##
[0250]
(S)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-propy-
l)-benzamide
[0251] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting (R)-1-methyl phenethylamine in Part C,
2,6-difluoro-benzenesulfonyl chloride in Part D. HPLC:
R.sub.T=11.11 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrF.sub.2N.sub.2O.sub.3S, 509.4; m/z found, 508
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.44 (s, 1H), 7.86
(d, J=1.8, 1H), 7.53-7.45 (m, 1H), 7.37-7.34 (m, 2H), 7.29-7.22 (m,
3H), 7.10 (dd, J=8.4, 1.8, 1H), 7.01-6.95 (m, 3H), 6.06-6.04 (br m,
1H), 5.50 (br s, 1H), 3.84-3.77 (m, 1H), 3.40-3.33 (m, 1H),
3.13-3.02 (m, 1H), 1.34 (d, J=7.0, 3H).
Example 38
##STR00048##
[0252]
(R)-4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-N-(2-phenyl-propy-
l)-benzamide
[0253] This compound was prepared as in EXAMPLE 5, Parts C and D,
substituting (S)-.beta.-methyl phenethylamine in Part C,
2,6-difluoro-benzenesulfonyl chloride in Part D. HPLC:
R.sub.T=11.11 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19BrF.sub.2N.sub.2O.sub.3S, 509.4; m/z found, 508
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.49 (s, 1H), 7.86
(d, J=1.8, 1H), 7.45-7.52 (m, 1H), 7.40-7.33 (m, 2H), 7.28-7.22 (m,
3H), 7.10 (dd, J=8.4, 1.8, 1H), 7.01-6.96 (m, 3H), 6.05 (br m, 1H),
5.21 (br s, 1H), 3.84-3.77 (m, 1H), 3.37 (ddd, J=13.7, 9.1, 5.0,
1H), 3.08-3.04 (m, 1H), 1.34 (d, J=7.0, 3H).
Example 39
##STR00049##
[0254]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phen-
yl)-propyl]-4-iodo-benzamide
[0255] This compound was prepared as in EXAMPLE 5, substituting
4-iodo-2-nitrobenzoic acid in Part C. HPLC: R.sub.T=11.97 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.17Cl.sub.2IN.sub.4O.sub.3S.sub.2, 647.3; m/z found,
646 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.40 (s, 1H),
8.34 (dd, J=7.0, 0.9, 1H), 8.23 (dd, J=8.8, 0.9, 1H), 8.04 (d,
J=1.6, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.39 (d, J=8.2, 1H),
7.29-7.25 (m, 2H), 7.04 (dd, J=8.3, 2.1, 1H), 6.77 (d, J=8.3, 1H),
5.92-5.90 (br m, 1H), 3.71-3.64 (m, 1H), 3.30 (ddd, J=13.7, 8.6,
5.4, 1H), 3.04-2.98 (m, 1H), 1.30 (d, J=7.0, 3H).
Example 40
##STR00050##
[0256]
N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-sulfonyl-
amino)-benzamide
[0257] This compound was prepared as in EXAMPLE 5, substituting
quinoxaline-5-sulfonyl chloride in Part D. HPLC: R.sub.T=11.49 min.
MS (ESI-): mass calcd. for
C.sub.24H.sub.19Cl.sub.2IN.sub.4O.sub.3S, 641.3; m/z found, 640
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.13 (s, 1H), 9.01
(d, J=1.7, 1H), 8.95 (d, J=1.7, 1H), 8.54 (dd, J=7.4, 1.3, 1H),
8.33 (dd, J=8.5, 1.3, 1H), 8.03 (d, J=1.6, 1H), 7.89 (dd, J=8.4,
7.5, 1H), 7.38 (d, J=8.23, 1H), 7.28 (d, J=2.0, 1H), 7.23 (dd,
J=8.2, 1.6, 1H), 7.03 (dd, J=8.3, 2.1, 1H), 6.77 (d, J=8.3, 1H),
5.96-5.94 (br m, 1H), 3.60-3.56 (m, 1H), 3.29 (ddd, J=13.7, 8.5,
5.5, 1H), 3.01-2.95 (m, 1H), 1.29 (d, J=7.0, 1H).
Example 41
##STR00051##
[0258]
2-[4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(2-
,4-dichloro-phenyl)-propionic acid
[0259] A. 2-(2,6-Difluoro-benzenesulfonylamino)-4-bromo-benzoic
acid. Methyl 2-amino-4-bromobenzoate was sulfonylated with
2,6-difluorobenzenesulfonyl chloride and hydrolyzed as in EXAMPLE
1, Part B. .sup.1H NMR (400 MHz, acetone-d.sub.6): 11.65 (s, 1H),
8.02 (d, J=8.5, 1H), 7.93 (d, J=1.8, 1H), 7.74-7.82 (m, 1H), 7.38
(dd, J=8.5, 1.9, 1H), 7.28-7.23 (m, 2H).
[0260] B.
2-[4-Bromo-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-
-(2,4-dichloro-phenyl)-propionic acid.
(S)-2-Amino-3-(2,4-dichloro-phenyl)-propionic acid was treated as
in EXAMPLE 2, Part A, to produce
(S)-2-amino-3-(2,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled with
4-bromo-2-(2,6-difluoro-benzenesulfonylamino)-benzoic acid as in
EXAMPLE 1, Part C. The resulting methyl ester was hydrolyzed as in
EXAMPLE 2, Part E, to afford title compound. HPLC: R.sub.T=10.26
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrCl.sub.2F.sub.2N.sub.2O.sub.5S, 608.2; m/z found,
607 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.36 (s, 1H),
7.87 (d, J=1.8, 1H), 7.52-7.44 (m, 1H), 7.39 (d, J=1.6, 1H),
7.27-7.25 (m, 1H), 7.25-7.22 (m, 1H), 7.18-7.15 (m, 1H), 6.97 (t,
J=8.7, 2H), 6.79 (d, J=7.7, 1H), 5.05-5.00 (m, 1H), 3.50 (dd,
J=14.2, 5.5, 1H), 3.29 (dd, J=14.2, 8.1, 1H).
Example 42
##STR00052##
[0261]
N-[2-(3,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzamide
[0262] This compound was prepared from
2-(2,6-difluorobenzenesulfonylamino)-4-iodo-benzoic acid and
2-(3,4-dichloro-phenyl)-propylamine as in EXAMPLE 1, Part C. HPLC:
R.sub.T=11.98 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.17Cl.sub.2F.sub.2IN.sub.2O.sub.3S, 625.3; m/z found,
624 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.63 (s, 1H),
8.02 (d, J=1.5, 1H), 7.54-7.45 (m, 1H), 7.39 (d, J=8.2, 1H), 7.34
(d, J=1.6, 1H), 7.32 (d, J=1.8, 1H), 7.09 (dd, J=8.3, 2.1, 1H),
7.02-6.94 (m, 3H), 6.34-6.32 (br m, 1H), 3.74-3.65 (m, 1H), 3.40
(ddd, J=13.7, 8.5, 5.6, 1H), 3.14-3.04 (m, 1H), 1.30 (d, J=7.0,
3H).
Example 43
##STR00053##
[0263]
4-Chloro-N-[2-(2,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzene-
sulfonylamino)-benzamide
[0264] A. 2-(2,6-Difluoro-benzenesulfonylamino)-4-chloro-benzoic
acid. Methyl 2-amino-4-chlorobenzoate was sulfonylated with
2,6-difluorobenzenesulfonyl chloride and hydrolyzed as in EXAMPLE
1, Parts A and B.
[0265] B.
4-Chloro-N-[2-(2,4-dichloro-phenyl)-propyl]-2-(2,6-difluoro-benz-
enesulfonylamino)-benzamide. The title compound was prepared from
2-(2,6-difluoro-benzenesulfonylamino)-4-chloro-benzoic acid and
2-(2,4-dichloro-phenyl)-propylamine hydrochloride (prepared as in
EXAMPLE 5, substituting 2,4-dichlorophenyl-acetonitrile in Part A)
as in Example 1, Part C. HPLC: R.sub.T=11.20 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.17Cl.sub.3F.sub.2N.sub.2O.sub.3S, 533.8;
m/z found, 533 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.62 (s, 1H), 7.73 (d, J=1.9, 1H), 7.52-7.45 (m, 1H), 7.40 (d,
J=1.8, 1H), 7.28-7.25 (m, 2H), 7.18 (d, J=8.5, 1H), 7.01-6.96 (m,
3H), 6.05 (br m, 1H), 3.76-3.70 (m, 1H), 3.68-3.57 (m, 1H),
3.57-3.49 (m, 1H), 1.32 (d, J=6.8, 3H).
Example 44
##STR00054##
[0266]
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-nitro-phenyl-
)-propyl]-benzamide
[0267] This compound was prepared from
4-chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoic acid and
2-(4-nitro-phenyl)-propylamine hydrochloride (prepared as in
EXAMPLE 5, substituting 4-nitrophenylacetonitrile in Part A) as in
Example 1, Part C. HPLC: R.sub.T=10.37 min. MS (ESI-): mass calcd.
for C.sub.22H.sub.18ClF.sub.2N.sub.3O.sub.5S, 509.9; m/z found, 509
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.63 (s, 1H), 8.18
(d, J=8.6, 1H), 7.69 (d, J=1.7, 1H), 7.56-7.46 (m, 1H), 7.42 (d,
J=8.6, 2H), 7.15 (d, J=8.5, 1H), 7.02-6.94 (m, 1H), 6.19-6.17 (br
m, 1H), 3.79-3.70 (m, 1H), 3.57-3.49 (m, 1H), 3.33-3.23 (m, 1H),
1.38 (d, J=6.9, 3H).
Example 45
##STR00055##
[0268]
4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-N-[2-(4-trifluoromet-
hyl-phenyl)-propyl]-benzamide
[0269] This compound was prepared from
4-chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoic acid and
2-(4-trifluoro-phenyl)-propylamine hydrochloride (prepared as in
EXAMPLE 5, substituting 4-trifluorophenyl-acetonitrile in Part A)
as in Example 1, Part C. HPLC: R.sub.T=10.93 min. MS (ESI-): mass
calcd. for C.sub.23H.sub.18ClF.sub.5N.sub.2O.sub.3S, 532.9; m/z
found, 532 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.64
(s, 1H), 7.72 (d, J=2.0, 1H), 7.61 (d, J=8.1, 2H), 7.53-7.46 (m,
1H), 7.36 (d, J=8.1, 2H), 7.10 (d, J=8.5, 1H), 7.01-6.94 (m, 3H),
6.02 (br m, 1H), 3.83-3.74 (m, 1H), 3.45 (ddd, J=13.8, 8.7, 5.4,
1H), 3.23-3.13 (m, 1H), 1.36 (d, J=7.0, 1H).
Example 46
##STR00056##
[0270]
2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-3-(-
2,4-dichloro-phenyl)-propionic acid
[0271] (R)-2-Amino-3-(2,4-dichloro-phenyl)-propionic acid was
treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-(2,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled with
4-chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoic acid as in
EXAMPLE 1, Part C. The resulting methyl ester was hydrolyzed as in
EXAMPLE 2, Part E, to afford title compound. HPLC: R.sub.T=10.20
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3F.sub.2N.sub.2O.sub.5S, 563.8; m/z found,
563 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6): 8.56 (d,
J=8.1, 1H), 7.82 (d, J=8.6, 1H), 7.77-7.71 (m, 1H), 7.70 (d, J=2.0,
1H), 7.50-7.48 (m, 2H), 7.31 (dd, J=8.3, 2.1, 1H), 7.22-7.14 (m,
3H), 5.08-5.00 (m, 1H), 3.62-3.51 (m, 1H), 3.34-3.21 (m, 1H).
Example 47
##STR00057##
[0272]
N-[2-(2,4-Dichloro-phenyl)-propyl]-2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzamide
[0273] This compound was prepared from
2-(2,6-difluoro-benzenesulfonylamino)-4-iodo-benzoic acid and
2-(2,4-dichloro-phenyl)-propylamine hydrochloride (prepared as in
EXAMPLE 5, substituting 2,4-dichloro-phenyl)-acetonitrile in Part
A) as in Example 1, Part C. HPLC: R.sub.T=11.10 min. MS (ESI-):
mass calcd. for C.sub.22H.sub.17Cl.sub.2F.sub.2IN.sub.2O.sub.3S,
625.3; m/z found, 624 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.51 (s, 1H), 8.06 (d, J=1.6, 1H), 7.52-7.45 (m, 1H),
7.39 (d, J=1.8, 1H), 7.35 (dd, J=8.3, 1.6, 1H), 7.27 (d, J=1.9,
2H), 7.04-6.93 (m, 3H), 6.09 (br m, 1H), 3.77-3.69 (m, 1H),
3.69-3.58 (m, 1H), 3.57-3.47 (m, 1H), 1.31 (d, J=6.8, 3H).
Example 48
##STR00058##
[0274]
2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-N-[2-(4-nitro-phenyl)--
propyl]-benzamide
[0275] This compound was prepared from
2-(2,6-difluorobenzenesulfonylamino)-4-iodo-benzoic acid and
2-(4-nitrophenyl)-propylamine hydrochloride (prepared as in EXAMPLE
5, substituting 4-nitro-phenyl)-acetonitrile in Part A) as in
Example 1, Part C. HPLC: R.sub.T=10.30 min. MS (ESI-): mass calcd.
for C.sub.22H.sub.18F.sub.2IN.sub.3O.sub.5S, 601.4; m/z found, 600
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 8.19 (d, J=8.7,
2H), 8.05 (d, J=1.5, 1H), 7.56-7.46 (m, 1H), 7.41 (d, J=8.7, 2H),
7.33 (dd, J=8.3, 1.5, 1H), 7.00 (t, J=8.6, 2H), 6.89 (d, J=8.3,
1H), 6.13 (br m, 1H), 3.74 (td, J=12.9, 6.3, 1H), 3.51 (ddd,
J=14.0, 8.5, 5.9, 1H), 3.26 (m, 1H), 1.38 (d, J=7.0, 3H).
Example 49
##STR00059##
[0276] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-((2S,
1R)-2-hydroxy-1-methyl-2-phenyl-ethyl)-benzamide
[0277] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic
acid was coupled with (1S,2R)-(+)-norephedrine as in EXAMPLE 1,
Part C. HPLC: R.sub.T=10.13 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.19ClN.sub.4O.sub.4S.sub.2, 502.05; m/z found, 501
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.69 (s, 1H), 8.37
(dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0, 1H), 7.73 (d, J=2.0,
1H), 7.72 (dd, J=8.8, 7.0, 1H), 7.41-7.29 (m, 5H), 7.24 (d, J=8.4,
1H), 6.93 (dd, J=8.4, 2.0, 1H), 6.28 (br d, J=8.3, 1H), 4.98 (d,
J=3.0, 1H), 4.45 (dd q, J=8.3, 6.9, 3.0, 1H), 2.60 (br s, 1H), 1.05
(d, J=6.9, 3H).
Example 50
##STR00060##
[0278]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-indan-2-yl-b-
enzamide
[0279] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic
acid was coupled with 2-aminoindane as in EXAMPLE 1, Part C. HPLC:
R.sub.T=10.24 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.17ClN.sub.4O.sub.3S.sub.2, 484.04; m/z found, 483
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.64 (s, 1H), 8.37
(dd, J=7.0, 1.0, 1H), 8.23 (dd, J=8.8, 1.0, 1H), 7.72 (dd, J=8.8,
7.0, 1H), 7.72 (d, J=2.0, 1H), 7.28-7.19 (m, 4H), 7.14 (d, J=8.4,
1H), 6.89 (dd, J=8.4, 2.0, 1H), 6.12 (br d, J=7.5, 1H), 4.87-4.80
(m, 1H), 3.41 (dd, J=16.3, 7.0, 2H), 2.83 (dd, J=16.3, 3.9,
2H).
Example 51
##STR00061##
[0280]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-methyl-N-(2--
pyridin-2-yl-ethyl)-benzamide hydrochloride
[0281] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic
acid was coupled with N-methyl-2-pyridin-2-ylethylamine as in
EXAMPLE 1, Part C. The hydrochloride salt was isolated as a white
solid after repeated concentration from methanolic HCl. HPLC:
R.sub.T=7.10 min. MS (ESI-): mass calcd. for
C.sub.21H.sub.18ClN.sub.5O.sub.3S.sub.2, 487.05; m/z found, 486
[M-H].sup.-. .sup.1H NMR (500 MHz, CD.sub.3OD): rotameric
broadening, 8.79 (br d, J=4.7, 1H), 8.61-8.52 (br m, 1H), 8.33 (br
d, J=8.8, 1H), 8.24-8.16 (br m, 1H), 8.16-8.10 (br m, 1H),
7.98-7.90 (br m, 1H), 7.82-7.75 (br m, 1H), 7.23-7.15 (br m, 1H),
7.00-6.90 (br m, 1H), 3.95-3.83 (br m, 2H), 3.49-3.38 (br m, 2H),
2.92 (br s, 3H).
Example 52
##STR00062##
[0282]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(4-
-chloro-phenyl)-1-hydroxymethyl-ethyl]-benzamide
[0283] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic
acid was coupled with
(.+-.)-2-amino-3-(4-chloro-phenyl)-propan-1-ol as in EXAMPLE 1,
Part C. HPLC: R.sub.T=9.71 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.18Cl.sub.2N.sub.4O.sub.4S.sub.2, 536.01; m/z found,
535/537 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.57 (s,
1H), 8.38 (br d, J=6.2, 1H), 8.22 (br d, J=8.4, 1H), 7.71 (br m,
2H), 7.35-7.10 (br m, 5H), 6.92 (br d, J=6.0, 1H), 6.30 (br m, 1H),
4.36-4.27 (br m, 1H), 3.76-3.62 (br m, 2H), 2.98-2.85 (br m, 2H),
1.92 (br s, 1H).
Example 53
##STR00063##
[0284]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-N-[2-(4--
chloro-phenyl)-1-methyl-ethyl]-benzamide
[0285] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic
acid was coupled with (.+-.)-2-(4-chlorophenyl)-1-methylethylamine
as in EXAMPLE 1, Part C. HPLC: R.sub.T=10.50 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.18BrClN.sub.4O.sub.3S.sub.2, 563.97; m/z
found, 563/565 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.61 (s, 1H), 8.37 (dd, J=7.0, 1.2, 1H), 8.22 (dd, J=8.8, 1.0,
1H), 7.88 (d, J=1.8, 1H), 7.72 (dd, J=8.8, 7.0, 1H), 7.32-7.25 (m,
2H), 7.13-7.05 (m, 2H), 7.07 (dd, J=8.4, 1.8, 1H), 7.01 (d, J=8.4,
1H), 5.74 (br d, J=7.8, 1H), 4.40-4.28 (m, 1H), 2.88 (dd, J=13.6,
5.6, 1H), 2.75 (dd, J=13.6, 7.1, 1H), 1.17 (d, J=6.7, 3H).
Example 54
##STR00064##
[0286]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-p-
henyl)-propyl]-4-methyl-benzamide
[0287] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-methyl-benzoic
acid was coupled with (.+-.)-2-(4-chloro-phenyl)-propylamine as in
EXAMPLE 1, Part C. HPLC: R.sub.T=10.22 min. MS (ESI-): mass calcd.
for C.sub.23H.sub.21ClN.sub.4O.sub.3S.sub.2, 500.07; m/z found, 499
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.48 (s, 1H), 8.31
(dd, J=7.0, 1.0, 1H), 8.18 (dd, J=8.8, 1.0, 1H), 7.67 (dd, J=8.8,
7.0, 1H), 7.47 (s, 1H), 7.33-7.27 (m, 2H), 7.16-7.10 (m, 2H), 6.90
(d, J=8.0, 1H), 6.71 (d, J=8.0, 1H), 5.75-5.70 (m, 1H), 3.73-3.64
(m, 1H), 3.30-3.21 (m, 1H), 3.05-2.94 (m, 1H), 2.26 (s, 3H), 1.30
(d, J=7.0, 3H).
Example 55
##STR00065##
[0288]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[(1R,2S)-2-(-
4-chloro-phenyl)-2-hydroxy-1-methyl-ethyl]-benzamide
[0289] A. (R)-4-Benzyl-3-propionyl-oxazolidin-2-one. To a solution
of (R)-4-benzyl-oxazolidin-2-one (3.0 g, 16.9 mmol) in THF (100 mL)
at -78.degree. C. was added n-BuLi (2.5 M hexanes, 7.1 mL, 17.8
mmol) in rapid drops via syringe. The solution was stirred for 20
min at -78.degree. C. Propionyl chloride (1.6 mL, 18.4 mmol) was
added rapidly via syringe. The reaction solution was allowed to
warm slowly to rt overnight then was quenched by the addition of
satd. aq. NH.sub.4Cl. The mixture was concentrated, diluted with
water, and extracted with DCM (3.times.). The combined organic
layers were dried (Na.sub.2SO.sub.4) and concentrated to give the
crude product, which was purified by flash chromatography
(EtOAc/hexanes) to afford the title compound as a white solid (3.70
g, 94%). .sup.1H NMR (500 MHz, CDCl.sub.3): 7.36-7.31 (m, 2H),
7.30-7.25 (m, 1H), 7.23-7.19 (m, 2H), 4.71-4.64 (m, 1H), 4.20 (dd,
J=9.1, 7.5, 1H), 4.17 (dd, J=9.1, 3.1, 1H), 3.31 (dd, J=13.4, 3.3,
1H), 2.99 (dq, J=17.9, 7.4, 1H), 2.93 (dq, J=17.9, 7.3, 1H), 2.77
(dd, J=13.4, 9.6, 1H), 1.21 (t, J=7.3, 3H).
[0290] B.
(4R)-4-Benzyl-3-[(2R,3R)-3-(4-chloro-phenyl)-3-hydroxy-2-methyl--
propionyl]-oxazolidin-2-one. To a solution of
(R)-4-benzyl-3-propionyl-oxazolidin-2-one (1.0 g, 4.3 mmol) in dry
DCM (10 mL) at 0.degree. C. under an inert atmosphere was added
n-Bu.sub.2BOTf (1.32 mL, 5.2 mmol) followed by Et.sub.3N (0.78 mL,
5.6 mmol) both in a dropwise manner via syringe while keeping the
internal temperature below 4.degree. C. After 30 min at 0.degree.
C., the mixture was cooled to -65.degree. C., and a solution of
p-chlorobenzaldehyde (661 mg, 4.7 mmol) in DCM (2 mL) was added
dropwise via syringe. The resulting mixture was stirred for 1 h at
-65.degree. C., then was allowed to warm to 0.degree. C. slowly and
was held at 0.degree. C. for 1 h. The reaction was quenched by the
addition of 3:1 MeOH/pH 7 phosphate buffer (20 mL). A 2:1 solution
of MeOH/30% H.sub.2O.sub.2 (15 mL) was carefully added by pipet
while keeping the internal temperature below 10.degree. C. After
addition was complete, the mixture was concentrated, and the
residue was poured into water and extracted with DCM (3.times.).
The combined organic layers were dried (Na.sub.2SO.sub.4) and
concentrated to give the crude product, which was purified by flash
chromatography (0 to 30% Et.sub.2O in 1:1 hexanes/DCM) to afford
the aldol adduct as a white foam (1.32 g, 82%). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.37-7.26 (m, 7H), 7.23-7.17 (m, 2H), 5.12-5.08
(m, 1H), 4.69-4.62 (m, 1H), 4.22-4.13 (m, 2H), 4.03 (dq, J=7.0,
3.6, 1H), 3.25 (dd, J=13.4, 3.3, 1H), 3.20 (d, J=2.5, 1H), 2.79
(dd, J=13.4, 9.4, 1H), 1.18 (d, J=7.0, 3H).
[0291] C. (2R,3R)-3-(4-Chloro-phenyl)-3-hydroxy-2-methyl-propionic
acid. A solution of
(4R)-4-benzyl-3-[(2R,3R)-3-(4-chloro-phenyl)-3-hydroxy-2-methyl-propionyl-
]-oxazolidin-2-one (1.32 g, 3.53 mmol) in 4:1 THF/water (20 mL) was
cooled to 0.degree. C. and treated with 30% aq. H.sub.2O.sub.2 (1.5
mL, 13.2 mmol) and LiOH (1 M in water, 5.6 mL, 5.6 mmol). The
reaction mixture was stirred for 1 h at 0.degree. C., and then a
solution of Na.sub.2SO.sub.3 (1.76 g, 14 mmol) in water (10 mL) was
added. The mixture was concentrated at a temperature<30.degree.
C. The aqueous layer was extracted with DCM (3.times.), then was
acidified with conc. HCl and extracted with EtOAc (4.times.). The
combined EtOAc layers were dried (Na.sub.2SO.sub.4) and
concentrated to give the crude acid, which was used without further
purification (0.76 g, quant.). .sup.1H NMR (500 MHz, CDCl.sub.3):
7.36-7.32 (m, 2H), 7.32-7.28 (m, 2H), 5.16 (d, J=3.9, 1H), 2.81
(dq, J=7.2, 3.9, 1H), 1.15 (d, J=7.2, 3H).
[0292] D.
(2R,3R)-3-(tert-Butyl-dimethyl-silyloxy)-3-(4-chloro-phenyl)-2-m-
ethyl-propionic acid. A solution of
(2R,3R)-3-(4-chloro-phenyl)-3-hydroxy-2-methyl-propionic acid (0.76
g, 3.5 mmol) in DCM (20 mL) was cooled to 0.degree. C. and treated
with 2,6-lutidine (1.24 mL, 10.6 mmol) and tert-butyldimethylsilyl
trifluoromethanesulfonate (1.9 mL, 8.27 mmol). The reaction
solution was stirred at 0.degree. C. for 30 min then allowed to
warm to rt and stir 1 h. The reaction was quenched with 1 M HCl and
the mixture was extracted with DCM (3.times.). The combined organic
layers were dried (Na.sub.2SO.sub.4) and concentrated to give the
crude bis-silylated ester. The silyl ester was stirred in MeOH (10
mL) at rt and treated with 5% aq. K.sub.2CO.sub.3 (5 mL). The
mixture was stirred 3 h, then was concentrated, diluted with 1 N
HCl, and extracted with DCM (4.times.). The combined organic layers
were dried (Na.sub.2SO.sub.4) and concentrated to give the crude
acid, which was used without further purification (1.06 g, 91%).
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.32-7.27 (m, 2H), 7.27-7.22 (m,
2H), 5.01 (d, J=5.3, 1H), 2.70 (dq, J=7.2, 5.6, 1H), 1.11 (d,
J=6.8, 3H), 0.88 (s, 9H), 0.03 (s, 3H), -0.18 (s, 3H).
[0293] E.
(1R,2S)-[2-(tert-Butyl-dimethyl-silyloxy)-2-(4-chloro-phenyl)-1--
methyl-ethyl]-carbamic acid tert-butyl ester. To a solution of
(2R,3R)-3-(tert-butyl-dimethyl-silyloxy)-3-(4-chloro-phenyl)-2-methyl-pro-
pionic acid (0.93 g, 2.8 mmol) in THF (30 mL) at 0.degree. C. was
added Et.sub.3N (0.438 mL, 3.1 mmol) followed by ethyl
chloroformate (0.30 mL, 3.1 mmol). The solution was stirred for 1 h
at 0.degree. C., and a solution of NaN.sub.3 (552 mg, 8.5 mmol) in
water (10 mL) was added. The reaction solution was stirred for 4 h
with warming to rt. The mixture was poured into water and extracted
with Et.sub.2O (3.times.). The combined organic extracts were dried
(MgSO.sub.4) and concentrated to afford the crude acyl azide. A
mixture of the acyl azide, tert-butanol (10 mL), and toluene (20
mL) was heated at reflux for 12 h. The reaction mixture was cooled
and concentrated, and the residue was purified by flash
chromatography (EtOAc/hexanes) to provide the desired product as a
colorless oil (354 mg, 31%). .sup.1H NMR (400 MHz, CDCl.sub.3):
7.28 (s, 4H), 4.90 (br s, 1H), 4.60 (br d, J=8.0, 1H), 3.77-3.65
(m, 1H), 1.46 (s, 9H), 0.94 (s, 9H), 0.88 (d, J=6.8, 3H), 0.06 (s,
3H), -0.13 (s, 3H).
[0294] F. (1S,2R)-2-Amino-1-(4-chloro-phenyl)-propan-1-ol
hydrochloride. A solution of
(1R,2S)-[2-(tert-butyl-dimethyl-silyloxy)-2-(4-chloro-phenyl)-1-methyl-et-
hyl]-carbamic acid tert-butyl ester (354 mg, 0.88 mmol) in MeOH (10
mL) at rt was treated with HCl (4 M in dioxane, 3 mL). After 1 h,
the mixture was concentrated to provide the desired amine as the
hydrochloride salt (200 mg, quant.). .sup.1H NMR (400 MHz,
CD.sub.3OD): 7.43-7.37 (m, 4H), 4.91 (d, J=3.4, 1H), 3.50 (dq,
J=6.8, 3.5, 1H), 1.07 (d, J=6.8, 3H).
[0295] G.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[(1R,2S)--
2-(4-chloro-phenyl)-2-hydroxy-1-methyl-ethyl]-benzamide.
2-(Benzo[1,2,5]-thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
was coupled with (1S,2R)-2-amino-1-(4-chloro-phenyl)-propan-1-ol
hydrochloride as in EXAMPLE 1, Part C. HPLC: R.sub.T=10.17 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.18Cl.sub.2N.sub.4O.sub.4S.sub.2, 536.01; m/z found,
535/537 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.64 (s,
1H), 8.39 (dd, J=7.0, 1.0, 1H), 8.23 (dd, J=8.8, 1.0, 1H), 7.73
(dd, J=8.8, 7.0, 1H), 7.72 (d, J=2.0, 1H), 7.38-7.33 (m, 2H),
7.33-7.28 (m, 2H), 7.24 (d, J=8.5, 1H), 6.95 (dd, J=8.4, 2.0, 1H),
6.22 (br d, J=8.1, 1H), 4.97 (d, J=2.9, 1H), 4.42 (ddq, J=8.3, 7.0,
2.9, 1H), 1.04 (d, J=6.9, 3H).
Example 56
##STR00066##
[0296]
(2S,3R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-ben-
zoylamino]-3-(3,4-dichloro-phenyl)-butyric acid
[0297] A. 3,4-Dichlorocinnamyl alcohol. To a stirred suspension of
3,4-dichlorocinnamic acid (25.39 g, 117 mmol) in THF (117 mL) at rt
was added Et.sub.3N (16.7 mL, 120 mmol). The resulting mixture was
cooled in an ice bath and treated with ethyl chloroformate (11.5
mL, 120 mmol) while keeping the internal temperature below
10.degree. C. The resulting thick suspension was stirred rapidly
for 1 h in an ice bath. The mixture was filtered through a sintered
glass funnel, washing with THF. The filtrate was concentrated to
afford the mixed carbonate. The crude carbonate was stirred in MeOH
(71 mL) at rt as NaBH.sub.4 (16.82 g, 445 mmol) was added in
portions while maintaining the internal temperature below
45.degree. C. The mixture was stirred overnight. The mixture was
concentrated, diluted with DCM, and washed with 1 N NaOH
(2.times.). The organic layer was dried (Na.sub.2SO.sub.4) and
concentrated to afford a white solid, which was recrystallized
(EtOAc/hexanes) to afford 3 crops of the desired cinnamyl alcohol
totaling 15.9 g (67%, 96% purity by .sup.1H NMR). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.46 (d, J=2.1, 1H), 7.38 (d, J=8.3, 1H), 7.20
(dd, J=8.4, 2.1, 1H), 6.54 (dt, J=15.9, 1.5, 1H), 6.36 (dt, J=15.9,
5.3, 1H), 4.34 (ddd, J=5.8, 5.3, 1.5, 2H), 1.51 (t, J=5.8, 1H).
[0298] B. (2S-trans)-[3-(3,4-Dichloro-phenyl)-oxiranyl]-methanol.
To a suspension of powdered 4 .ANG. molecular sieves (3.2 g) in DCM
(144 mL) was added Ti(O-iPr).sub.4 (0.864 mL, 2.93 mmol),
(+)-L-diisopropyl tartrate (0.924 mL, 4.39 mmol), and t-BuOOH (5.5
M in decane, 10.8 mL, 59.4 mmol). The mixture was cooled to
-20.degree. C. stirred for 1 h. A solution of 3,4-dichlorocinnamyl
alcohol (6.0 g, 29.5 mmol) in DCM (30 mL) was added via cannula.
After 18 h at -20.degree. C., the reaction was quenched by addition
of 10% aq. NaOH and brine (10%, 4 mL). The cooling bath was
removed, and after stirring for 20 min, Et.sub.2O (30 mL) was added
followed by MgSO.sub.4 (8 g) and diatomaceous earth (8 g). The
mixture was stirred rapidly for 15 min then was filtered through a
pad of diatomaceous earth, washing with excess Et.sub.2O. The
filtrate was concentrated, and the desired epoxide was crystallized
from the yellow residue with a warm DCM/hexanes mixture to afford
4.22 g (65%) of pale yellow crystals. The epoxide was determined to
be >95% ee by .sup.1H NMR analysis of both the R- and S-Mosher
ester derivatives. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.42 (d,
J=8.3, 1H), 7.37 (d, J=2.0, 1H), 7.13 (dd, J=8.3, 2.0, 1H), 4.04
(dd, J=12.9, 2.2, 1H), 3.91 (d, J=2.0, 1H), 3.82 (dd, J=12.9, 3.4,
1H), 3.18-3.11 (m, 1H), 1.80 (br s, 1H).
[0299] C. (2R,3R)-3-(3,4-Dichloro-phenyl)-butane-1,2-diol. To a
slurry of CuCN (5.20 g, 58.1 mmol) in dry Et.sub.2O (300 mL) under
an inert atmosphere at -78.degree. C. was added MeLi (1.6 M in
Et.sub.2O, 73 mL, 117 mmol). A yellow precipitate formed, and the
mixture was allowed to stir until homogeneous (1 h). A solution of
(2S-trans)-[3-(3,4-dichloro-phenyl)-oxiranyl]-methanol (4.22 g,
19.3 mmol) in Et.sub.2O (80 mL) was added dropwise via cannula over
40 min. The mixture was stirred for 1 h at -78.degree. C., then was
allowed to warm to 0.degree. C. over 2 h. The reaction was quenched
by careful addition of satd. aq. NH.sub.4Cl (160 mL) causing
vigorous gas evolution and precipitation of a white and yellow
solid. Concentrated NH.sub.4OH (33% NH.sub.3, 20 mL) was added, and
the mixture was stirred vigorously for 10 min. The biphasic mixture
was separated, and the aqueous layer was extracted with Et.sub.2O
(3.times.). The combined organic layers were dried (MgSO.sub.4) and
concentrated. The residue was purified by flash chromatography
(EtOAc/hexanes) to afford the diol as a colorless viscous liquid
(3.40 g, 75%). .sup.1H NMR (400 MHz, CDCl.sub.3): 7.40 (d, J=8.3,
1H), 7.36 (d, J=2.1, 1H), 7.10 (dd, J=8.4, 2.2, 1H), 3.81-3.71 (m,
2H), 3.57-3.47 (m, 1H), 2.84 (quint, J=7.2, 1H), 3.18-3.11 (m, 1H),
1.96 (br s, 1H), 1.89 (br s, 1H), 1.26 (d, J=7.1, 3H).
[0300] D.
(2R,3R)-1-(tert-Butyl-dimethyl-silyloxy)-3-(3,4-dichloro-phenyl)-
-butan-2-ol. To a stirred solution of
(2R,3R)-3-(3,4-dichloro-phenyl)-butane-1,2-diol (3.20 g, 13.6 mmol)
and imidazole (1.39 g, 20.4 mmol) in DCM (28 mL) at rt was added
tert-butyldimethylsilyl chloride (TBSCl; 2.15 g, 14.3 mmol). The
solution was stirred for 1 h then quenched by addition of satd. aq.
NH.sub.4Cl (100 mL). The mixture was stirred for 5 min, the layers
were separated, and the aqueous layer was extracted with DCM
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated to yield a viscous yellow
liquid. The product was purified by flash chromatography
(EtOAc/hexanes) to afford 4.52 g (95%) of the desired product as a
colorless viscous liquid. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.37
(d, J=8.3, 1H), 7.36 (d, J=2.1, 1H), 7.10 (dd, J=8.2, 2.1, 1H),
3.75-3.68 (m, 1H), 3.65 (dd, J=9.9, 3.8, 1H), 3.45 (dd, J=9.9, 7.1,
1H), 2.81 (quint, J=7.0, 1H), 2.37 (d, J=4.0, 1H), 1.25 (d, J=7.2,
3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H).
[0301] E.
(2R,3R)-1-(tert-Butyl-dimethyl-silyloxy)-3-(3,4-dichloro-phenyl)-
-2-methanesulfonyloxy-butane. To a solution of
(2R,3R)-1-(tert-butyl-dimethyl-silyloxy)-3-(3,4-dichloro-phenyl)-butan-2--
ol (4.63 g, 13.2 mmol) in DCM (44 mL) at 0.degree. C. were added
Et.sub.3N (4.6 mL, 33.0 mmol), DMAP (81.0 mg, 0.7 mmol), and MsCl
(2.2 ml, 28.4 mmol). The mixture was stirred overnight at rt. The
reaction was quenched with water (100 mL) and extracted with DCM
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated to yield an orange oil. The
product was purified by flash chromatography (Et.sub.2O/hexanes) to
afford 4.99 g (88%) of the desired product as a colorless liquid.
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.39 (d, J=8.3, 1H), 7.35 (d,
J=2.1, 1H), 7.12 (dd, J=8.3, 2.1, 1H), 4.72-4.69 (m, 1H), 3.71 (dd,
J=11.4, 5.7, 1H), 3.64 (dd, J=11.4, 4.3, 1H), 3.24-3.18 (m, 1H),
2.81 (s, 3H), 1.36 (d, J=7.2, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.06
(s, 3H).
[0302] F.
(2R,3R)-3-(3,4-Dichloro-phenyl)-2-methanesulfonyloxy-butan-1-ol. To
a solution of
(2R,3R)-1-(tert-butyl-dimethyl-silyloxy)-3-(3,4-dichloro-phenyl)-2-methan-
esulfonyloxy-butane (4.99 g, 11.7 mmol) in THF (117 mL) at
0.degree. C. was added tetrabutylammonium fluoride (TBAF; 1.0 M in
THF, 23.4 mL). The solution was stirred at 0.degree. C. for 15 min,
then was diluted with 1 N HCl (100 ml) and extracted with DCM
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated to yield a yellow oil. The
product was purified by flash chromatography (EtOAc/hexanes) to
give 3.45 g (94%) of the desired product. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.41 (d, J=8.0, 1H), 7.35 (d, J=2.0, 1H), 7.12 (dd,
J=8.2, 2.4, 1H), 4.82-4.78 (m, 1H), 3.88-3.84 (m, 1H), 3.74-3.69
(m, 1H), 3.17 (q, J=7.1, 1H), 2.78 (s, 3H), 1.98 (br s, 1H), 1.36
(d, J=7.2, 3H).
[0303] G.
(2R,3R)-3-(3,4-Dichloro-phenyl)-2-methanesulfonyloxy-butyric acid
methyl ester. Jones reagent was prepared by mixing chromium (VI)
oxide (2.87 g, 28.7 mmol), sulfuric acid (2.44 mL), and water (9.5
mL) for 10 min. The solution was used directly, and was added
dropwise to a solution of
(2R,3R)-3-(3,4-dichloro-phenyl)-2-methanesulfonyloxy-butan-1-ol
(1.50 g, 4.79 mmol) in acetone (100 mL). After 4 h, isopropanol (9
mL) was added and the mixture was concentrated. Water was added,
and the aqueous layer was extracted with DCM (3.times.). The
combined organic layers were washed with brine, dried (MgSO.sub.4),
and concentrated to give the crude acid. To a solution of
(2R,3R)-3-(3,4-dichloro-phenyl)-2-methanesulfonyloxy-butyric acid
(1.57 g, 4.80 mmol) in DMF (20 mL) were added KHCO.sub.3 (1.44 g,
14.4 mmol) and MeI (0.90 mL, 14.4 mmol). After 12 h, the mixture
was diluted with water and extracted with EtOAc (2.times.), and the
combined organic phases were washed with brine, dried (MgSO.sub.4)
and concentrated. The product was purified by flash chromatography
to give 1.13 g (69% over 2 steps) of the desired product. .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.38 (d, J=8.3, 1H), 7.31 (d, J=2.1,
1H), 7.08 (dd, J=8.3, 2.1, 1H), 5.14 (d, J=4.7, 1H), 3.73 (s, 3H),
3.47-3.43 (m, 1H), 3.07 (s, 3H), 1.43 (d, J=7.2, 3H).
[0304] H. (2S,3R)-2-Azido-3-(3,4-dichloro-phenyl)-butyric acid
methyl ester. To a solution of
(2R,3R)-3-(3,4-dichloro-phenyl)-2-methanesulfonyloxy-butyric acid
methyl ester (0.70 g, 2.05 mmol) in DMF (10 mL) was added NaN.sub.3
(0.27 g, 4.10 mmol). The reaction was heated at 55.degree. C.
overnight. The mixture was quenched with water and extracted with
EtOAc. The organic phase was washed with water (2.times.), dried
(MgSO.sub.4), and concentrated. The product was purified by flash
chromatography to give 0.42 g (71%) of product. .sup.1H NMR (500
MHz, CDCl.sub.3): 7.39 (d, J=8.3, 1H), 7.35 (d, J=2.1, 1H), 7.10
(dd, J=8.3, 2.1, 1H), 3.96 (d, J=6.4, 1H), 3.71 (s, 3H), 3.29 (m,
1H), 1.33 (d, J=7.0, 3H).
[0305] I. (2S,3R)-2-Amino-3-(3,4-dichloro-phenyl)-butyric acid
methyl ester. To a solution of
(2S,3R)-2-azido-3-(3,4-dichloro-phenyl)-butyric acid methyl ester
(0.42 g, 1.46 mmol) in EtOAc (30 mL) was added Lindlar's catalyst.
The mixture was hydrogenated at 50 psi. After 16 h, the reaction
mixture was filtered through SiO.sub.2 and concentrated to afford
0.28 g (74%) of the desired product. .sup.1H NMR (500 MHz,
CDCl.sub.3): 7.39 (d, J=8.3, 1H), 7.35 (d, J=2.1, 1H), 7.10 (dd,
J=8.3, 2.1, 1H), 3.96 (d, J=6.4, 1H), 3.71 (s, 3H), 3.31-3.27 (m,
1H), 1.33 (d, J=7.0, 3H).
[0306] J.
(2S,3R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro--
benzoylamino]-3-(3,4-dichloro-phenyl)-butyric acid.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
was coupled to (2S,3R)-2-amino-3-(3,4-dichloro-phenyl)-butyric acid
methyl ester as in EXAMPLE 1, Part C. The resulting methyl ester
was hydrolyzed as in EXAMPLE 2, Part E, to afford the title
compound. HPLC: R.sub.T=10.22 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17Cl.sub.3N.sub.4O.sub.5S.sub.2, 597.97; m/z found,
597/599 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.26 (s,
1H), 8.36 (d, J=7.0, 1H), 8.21 (d, J=8.8, 1H), 7.73-7.70 (m, 2H),
7.37 (d, J=8.3, 1H), 7.27 (m, 1H), 7.23 (d, J=6.4, 1H), 7.04 (dd,
J=8.2, 2.0, 1H), 6.96 (dd, J=8.4, 2.0, 1H), 6.44 (d, J=8.6, 1H),
4.97-4.94 (m, 1H), 3.38-3.36 (m, 1H), 1.46 (d, J=7.2, 3H).
Example 57
##STR00067##
[0307]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3-
,4-dichloro-phenyl)-propyl]-benzamide
[0308] The title compound was prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
and (.+-.)-2-(3,4-dichloro-phenyl)-propylamine hydrochloride as in
EXAMPLE 1, Part C. HPLC: R.sub.T=11.97 min. MS (ESI-): mass calcd.
for C.sub.22H.sub.17Cl.sub.3N.sub.4O.sub.3S.sub.2, 553.98; m/z
found, 553/555/557 [M-H]. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.51
(s, 1H), 8.36 (dd, J=7.0, 1.1, 1H), 8.22 (dd, J=8.8, 1.0, 1H),
7.74-7.70 (m, 2H), 7.40 (d, J=8.2, 1H), 7.29 (d, J=2.1, 1H), 7.04
(dd, J=8.3, 2.1, 1H), 7.01-6.99 (m, 1H), 6.89 (dd, J=8.4, 2.0, 1H),
5.81 (s, 1H), 3.74-3.67 (m, 1H), 3.34-3.28 (m, 1H), 3.06-2.98 (m,
1H), 1.30 (d, J=7.0, 3H).
Example 58
##STR00068##
[0309]
(.+-.)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-N-[-
2-(3,4-dichloro-phenyl)-propyl]-benzamide
[0310] The title compound was prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid and (.+-.)-2-(3,4-dichloro-phenyl)-propylamine hydrochloride
as in EXAMPLE 1, Part C. HPLC: R.sub.T=12.51 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.16Cl.sub.4N.sub.4O.sub.3S.sub.2, 587.94;
m/z found, 587/589/591 [M-H]. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.22 (s, 1H), 8.35 (d, J=7.0, 1H), 8.24 (d, J=8.8, 1H), 7.89 (s,
1H), 7.74-7.71 (m, 1H), 7.41 (d, J=8.2, 1H), 7.29 (d, J=2.0, 1H),
7.14 (s, 1H), 7.05 (dd, J=8.2, 2.0, 1H), 5.79 (s, 1H), 3.69-3.63
(m, 1H), 3.34-3.29 (m, 1H), 3.03-2.99 (m, 1H), 1.31 (d, J=7.0,
3H).
Example 59
##STR00069##
[0311]
(.+-.)-4-Chloro-N-[2-(3,4-dichloro-phenyl)-propyl]-2-(quinoxaline-5-
-sulfonylamino)-benzamide
[0312] The title compound was prepared from
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid and
(.+-.)-2-(3,4-dichloro-phenyl)-propylamine hydrochloride as in
EXAMPLE 1, Part C. HPLC: R.sub.T=10.78 min. MS (ESI+): mass calcd.
for C.sub.24H.sub.19Cl.sub.3N.sub.4O.sub.3S, 548.02; m/z found,
551/553 [M+H].sup.+, m/z found, 571/575 [M+Na].sup.+. .sup.1H NMR
(400 MHz, CDCl.sub.3): 11.21 (s, 1H), 9.04 (d, J=1.7, 1H), 8.96 (d,
J=1.7, 1H), 8.57 (dd, J=7.3, 1.3, 1H), 8.33 (dd, J=8.5, 1.2, 1H),
7.91-7.87 (m, 1H), 7.71 (d, J=1.9, 1H), 7.39 (d, J=8.2, 1H), 7.29
(d, J=2.0, 1H), 7.04 (dd, J=8.2, 2.0, 1H), 6.99 (d, J=8.4, 1H),
6.88 (dd, J=8.4, 2.0, 1H), 5.82 (s, 1H), 3.70-3.63 (m, 1H),
3.33-3.26 (m, 1H), 3.02-2.98 (m, 1H), 1.30 (d, J=7.0, 3H).
Example 60
##STR00070##
[0313]
(R)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid
[0314]
(R)-2-(tert-Butoxycarbonylamino)-3-(3,4-dichloro-phenyl)-propionic
acid was treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-(3,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled to
4-iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in EXAMPLE
1, Part C. The resulting methyl ester was hydrolyzed as in EXAMPLE
2, Part E, to afford the title compound. HPLC: R.sub.T=10.06 min.
MS (ESI-): mass calcd. for
C.sub.24H.sub.17Cl.sub.2IN.sub.4O.sub.5S, 669.93; m/z found,
669/671 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.85 (s,
1H), 9.00 (d, J=1.8, 1H), 8.92 (d, J=1.7, 1H), 8.54 (dd, J=7.4,
1.2, 1H), 8.33-8.31 (m, 1H), 8.07 (d, J=1.5, 1H), 7.91-7.87 (m,
1H), 7.47-7.22 (m, 3H), 6.98 (dd, J=8.2, 2.0, 1H), 6.87 (d, J=8.3,
1H), 6.37 (d, J=7.7, 1H), 4.92-4.88 (m, 1H), 3.23 (dd, J=14.2, 5.9,
1H), 3.14 (dd, J=14.1, 6.1, 1H).
Example 61
##STR00071##
[0315]
(.+-.)-N-[2-(3,4-Dichloro-phenyl)-propyl]-4-iodo-2-(quinoxaline-5-s-
ulfonylamino)-benzamide
[0316] The title compound was prepared from
4-iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid and
(.+-.)-2-(3,4-dichloro-phenyl)-propylamine hydrochloride as in
EXAMPLE 1, Part C. HPLC: R.sub.T=10.97 min. MS (ESI+): mass calcd.
for C.sub.24H.sub.19Cl.sub.2IN.sub.4O.sub.3S, 639.96; m/z found,
641/643 [M+H].sup.+, m/z found, 663/665 [M+Na].sup.+. .sup.1H NMR
(400 MHz, CDCl.sub.3): 11.07 (s, 1H), 9.03 (d, J=1.8, 1H), 8.95 (d,
J=1.8, 1H), 8.56 (dd, J=7.4, 1.4, 1H), 8.33 (dd, J=8.5, 1.4, 1H),
8.05 (d, J=1.6, 1H), 7.91-7.87 (m, 1H), 7.39 (d, J=8.2, 1H),
7.28-7.24 (m, 2H), 7.02 (dd, J=8.3, 2.1, 1H), 6.75 (d, J=8.2, 1H),
5.81 (s, 1H), 3.68-3.61 (m, 1H), 3.31-3.24 (m, 1H), 3.00-2.95 (m,
1H), 1.29 (d, J=7.0, 3H).
Example 62
##STR00072##
[0317]
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoyl-
amino]-3-(4-chloro-phenyl)-propionic acid
[0318]
(R)-2-(tert-Butoxycarbonylamino)-3-(4-chloro-phenyl)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(R)-2-amino-3-(4-chloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled with
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoic acid
as in EXAMPLE 1, Part C. The resulting methyl ester was hydrolyzed
as in EXAMPLE 2, Part E, to afford the title compound. HPLC:
R.sub.T=10.28 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16Cl.sub.2N.sub.4O.sub.5S.sub.2, 549.99; m/z found,
549/551 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.92 (s,
1H), 8.30 (d, J=7.0, 1H), 8.19 (d, J=8.8, 1H), 7.70-7.66 (m, 1H),
7.64 (d, J=9.0, 1H), 7.31-7.26 (m, 3H), 7.14 (d, J=2.3, 1H), 7.08
(d, J=8.3, 2H), 6.38 (d, J=7.3, 1H), 5.00-4.96 (m, 1H), 3.29 (dd,
J=14.3, 5.7, 1H), 3.20 (dd, J=14.2, 5.8, 1H).
Example 63
##STR00073##
[0319]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3--
cyano-phenyl)-propionic acid
[0320]
(S)-2-(tert-Butoxycarbonylamino)-3-(3-cyano-phenyl)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(S)-2-amino-3-(3-cyano-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled to
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in EXAMPLE
1, Part C. The resulting methyl ester was hydrolyzed as in EXAMPLE
2, Part E, to afford the title compound. HPLC: R.sub.T=8.94 min. MS
(ESI-): mass calcd. for C.sub.25H.sub.18ClN.sub.5O.sub.5S, 535.07;
m/z found, 534/536 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.01 (s, 1H), 9.03 (d, J=1.7, 1H), 8.94 (d, J=1.7, 1H), 8.57 (d,
J=7.4, 1H), 8.33 (d, J=8.5, 1H), 7.90 (t, 7.5, 1H), 7.74 (d, J=1.9,
1H), 7.57-7.55 (m, 1H), 7.47-7.41 (m, 3H), 7.12 (d, J=8.4, 1H),
6.93 (dd, J=5.6, 1.9, 1H), 6.40 (d, J=7.3, 1H), 5.02-4.98 (m, 1H),
3.36 (dd, J=14.1, 6.0, 1H), 3.25 (dd, J=14.2, 5.6, 1H).
Example 64
##STR00074##
[0321]
(S)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,-
4-dichloro-phenyl)-butyric acid
[0322]
(S)-3-(tert-Butoxycarbonylamino)-4-(3,4-dichloro-phenyl)-butyric
acid was treated as in EXAMPLE 2, Part A, to produce
(S)-3-amino-4-(3,4-dichloro-phenyl)-butyric acid methyl ester
hydrochloride as a white solid. This ester was coupled to
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in EXAMPLE
1, Part C. The resulting methyl ester was hydrolyzed as in EXAMPLE
2, Part E. HPLC: R.sub.T=9.78 min. MS (ESI-): mass calcd. for
C.sub.25H.sub.19Cl.sub.3N.sub.4O.sub.5S, 592.01; m/z found, 593/595
[M-H].sup.-. .sup.1H NMR (500 MHz, CD.sub.3OD): 8.97 (d, J=1.8,
1H), 8.93 (d, J=1.8, 1H), 8.55 (dd, J=7.4, 1.3, 1H), 8.33 (dd,
J=8.5, 1.3, 1H), 7.97-7.94 (m, 1H), 7.69 (d, J=2.0, 1H), 7.42 (d,
J=8.2, 1H), 7.38-7.36 (m, 2H), 7.16 (dd, J=8.2, 2.0, 1H), 6.97 (dd,
J=8.6, 2.0, 1H), 4.56-4.50 (m, 1H), 2.90 (dd, J=13.7, 6.1, 1H),
2.81 (dd, J=13.7, 7.7, 1H), 2.54 (dd, J=15.9, 6.2, 1H), 2.45 (dd,
J=15.9, 7.4, 1H).
Example 65
##STR00075##
[0323]
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylam-
ino)-benzoylamino]-propionic acid methyl ester
[0324]
3-Benzo[b]thiophen-3-yl-2-(tert-butoxycarbonylamino)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(S)-2-amino-3-benzo[b]thiophen-3-yl-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled to
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in EXAMPLE
1, Part C, to afford the title compound. HPLC: R.sub.T=10.33 min.
MS (ESI-): mass calcd. for C.sub.27H.sub.21ClN.sub.4O.sub.5S.sub.2,
580.06; m/z found, 579/581 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.35 (s, 1H), 8.94 (d, J=1.8, 1H), 8.85 (d, J=1.8,
1H), 8.58 (dd, J=7.3, 1.4, 1H), 8.31 (dd, J=8.5, 1.3, 1H),
7.90-7.86 (m, 2H), 7.77 (d, J=2.0, 1H), 7.72-7.70 (m, 1H),
7.37-7.26 (m, 2H), 7.09 (s, 1H), 7.00 (d, J=8.4, 1H), 6.83 (dd,
J=8.4, 2.0, 1H), 6.45 (d, J=7.1, 1H), 5.09-5.05 (m, 1H), 3.77 (s,
3H), 3.53 (dd, J=14.7, 5.8, 1H), 3.45 (dd, J=14.8, 5.2, 1H).
Example 66
##STR00076##
[0325]
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylam-
ino)-benzoylamino]-propionic acid
[0326]
(S)-3-Benzo[b]thiophen-3-yl-2-[4-chloro-2-(quinoxaline-5-sulfonylam-
ino)-benzoylamino]-propionic acid methyl ester was hydrolyzed as in
EXAMPLE 2, Part E. HPLC: R.sub.T=9.67 min. MS (ESI-): mass calcd.
for C.sub.26H.sub.19ClN.sub.4O.sub.5S.sub.2, 566.05; m/z found,
565/567 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.09 (s,
1H), 8.96 (d, J=1.8, 1H), 8.84 (d, J=1.8, 1H), 8.54 (dd, J=7.4,
1.3, 1H), 8.28 (dd, J=8.5, 1.3, 1H), 7.87-7.84 (m, 2H), 7.75-7.74
(m, 2H), 7.36-7.33 (m, 2H), 7.21 (s, 1H), 6.89 (d, J=8.4, 1H), 6.80
(dd, J=8.4, 2.0, 1H), 6.35 (d, J=7.2, 1H), 5.06 (m, 1H), 3.58 (dd,
J=15.0, 5.5, 1H), 3.47 (dd, J=15.0, 6.0, 1H).
Example 67
##STR00077##
[0327]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(4-chloro-phenyl)-propionic acid methyl ester
[0328]
(S)-2-(tert-Butoxycarbonylamino)-3-(4-chloro-phenyl)-propionic acid
was treated as in EXAMPLE 2, Part A, to produce
(S)-2-amino-3-(4-chloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled to
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid as in EXAMPLE 1, Part C, to afford the title compound. HPLC:
R.sub.T=11.61 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17Cl.sub.3N.sub.4O.sub.5S.sub.2, 597.97; m/z found,
597/599 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.20 (s,
1H), 8.36 (d, J=6.3, 1H), 8.23 (d, J=8.7, 1H), 7.87 (s, 1H),
7.74-7.71 (m, 1H), 7.27-7.25 (m, 3H), 6.98 (d, J=8.3, 2H), 6.38 (d,
J=7.3, 1H), 4.96-4.92 (m, 1H), 3.82 (s, 3H), 3.23-3.14 (m, 2H).
Example 68
##STR00078##
[0329]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(4-chloro-phenyl)-propionic acid
[0330]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(4-chloro-phenyl)-propionic acid methyl ester was
hydrolyzed as in EXAMPLE 2, Part E, to afford the title compound.
HPLC: R.sub.T=10.34 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 583.95; m/z found,
583/585 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.07 (s,
1H), 8.34 (d, J=7.9, 1H), 8.22 (d, J=8.8, 1H), 7.83 (s, 1H),
7.74-7.71 (m, 1H), 7.28-7.24 (m, 3H), 7.07 (d, J=8.3, 2H), 6.38 (d,
J=7.2, 1H), 5.01-4.97 (m, 1H), 3.30 (dd, J=14.2, 5.7, 1H), 3.21
(dd, J=14.2, 5.8, 1H).
[0331] Examples 69-93 were prepared as described in the preceding
examples. Satisfactory analytical data was obtained for each
compound.
Example 69
##STR00079##
[0332]
(R)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-
-3-(4-chloro-phenyl)-propionic acid methyl ester
[0333] MS (ESI-): mass calcd. for
C.sub.23H.sub.18Cl.sub.2F.sub.2N.sub.2O.sub.5S, 542.03; m/z found,
541/543 [M-H].sup.-.
Example 70
##STR00080##
[0334]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(2,4-dich-
loro-phenyl)-ethyl]-benzamide
[0335] MS (ESI-): mass calcd. for
C.sub.21H.sub.15Cl.sub.3N.sub.4O.sub.3S.sub.2, 539.97; m/z found,
539/541 [M-H].sup.-.
Example 71
##STR00081##
[0336]
(S)-2-[4-Chloro-2-(2,4-difluoro-benzenesulfonylamino)-benzoylamino]-
-3-(4-chloro-phenyl)-propionic acid methyl ester
[0337] MS (ESI-): mass calcd. for
C.sub.23H.sub.18Cl.sub.2F.sub.2N.sub.2O.sub.5S, 542.03; m/z found,
541/543 [M-H].sup.-.
Example 72
##STR00082##
[0338]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)--
propyl]-4-iodo-benzamide
[0339] MS (ESI-): mass calcd. for
C.sub.22H.sub.18ClIN.sub.4O.sub.3S.sub.2, 611.96; m/z found,
611/613 [M-H].sup.-.
Example 73
##STR00083##
[0340]
(R)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydro-
xy-1-methyl-2,2-diphenyl-ethyl)-benzamide
[0341] MS (ESI-): mass calcd. for
C.sub.28H.sub.23ClN.sub.4O.sub.4S.sub.2, 578.08; m/z found, 577/579
[M-H].sup.-.
Example 74
##STR00084##
[0342]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-(2-hydro-
xy-1-methyl-2,2-diphenyl-ethyl)-benzamide
[0343] MS (ESI-): mass calcd. for
C.sub.28H.sub.23ClN.sub.4O.sub.4S.sub.2, 578.08; m/z found, 577/579
[M-H].sup.-.
Example 75
##STR00085##
[0344]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(2,4-dichloro-phen-
yl)-ethyl]-benzamide
[0345] MS (ESI-): mass calcd. for
C.sub.21H.sub.16Cl.sub.2N.sub.4O.sub.3S.sub.2, 506.00; m/z found,
505/507 [M-H].sup.-.
Example 76
##STR00086##
[0346]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(4-fluoro-phenyl)-propionic acid
[0347] MS (ESI-): mass calcd. for
C.sub.22H.sub.16ClFN.sub.4O.sub.5S.sub.2, 534.02; m/z found,
533/535 [M-H].sup.-.
Example 77
##STR00087##
[0348]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-thiophen-3-yl-propionic acid
[0349] MS (ESI-): mass calcd. for
C.sub.20H.sub.15ClN.sub.4O.sub.5S.sub.3, 521.99; m/z found, 521/523
[M-H].sup.-.
Example 78
##STR00088##
[0350]
(S)-3-(3-Chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-propionic acid
[0351] MS (ESI-): mass calcd. for
C.sub.24H.sub.18Cl.sub.2N.sub.4O.sub.5S, 544.04; m/z found, 543/545
[M-H].sup.-.
Example 79
##STR00089##
[0352]
(S)-2-[4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-p-tol-
yl-propionic acid
[0353] MS (ESI-): mass calcd. for C.sub.25H.sub.21IN.sub.4O.sub.5S,
616.03; m/z found, 615 [M-H].sup.-.
Example 80
##STR00090##
[0354]
N-[2-(4-Bromo-phenyl)-ethyl]-4-chloro-2-(2,6-difluoro-benzenesulfon-
ylamino)-benzamide
[0355] MS (ESI-): mass calcd. for
C.sub.21H.sub.16BrClF.sub.2N.sub.2O.sub.3S, 527.97; m/z found,
527/529 [M-H].sup.-.
Example 81
##STR00091##
[0356]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-6-chloro-N-[2-(3,4-dich-
loro-phenyl)-propyl]-benzamide
[0357] MS (ESI-): mass calcd. for
C.sub.22H.sub.17Cl.sub.3N.sub.4O.sub.3S.sub.2, 553.98; m/z found,
553/555 [M-H].sup.-.
Example 82
##STR00092##
[0358]
(R)-3-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-4-(3,-
4-dichloro-phenyl)-butyric acid
[0359] MS (ESI-): mass calcd. for
C.sub.25H.sub.19Cl.sub.3N.sub.4O.sub.5S, 592.01; m/z found, 591/593
[M-H].sup.-.
Example 83
##STR00093##
[0360]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-5-chloro-benzoyl-
amino]-3-(4-chloro-phenyl)-propionic acid
[0361] MS (ESI-): mass calcd. for
C.sub.22H.sub.16Cl.sub.2N.sub.4O.sub.5S.sub.2, 549.99; m/z found,
549/551 [M-H].sup.-.
Example 84
##STR00094##
[0362]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3--
nitro-phenyl)-propionic acid
[0363] MS (ESI-): mass calcd. for
C.sub.24H.sub.18ClN.sub.5O.sub.7S, 555.06; m/z found, 554/556
[M-H].sup.-.
Example 85
##STR00095##
[0364]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(3,-
4-difluoro-phenyl)-propionic acid
[0365] MS (ESI-): mass calcd. for
C.sub.24H.sub.17ClF.sub.2N.sub.4O.sub.5S, 546.06; m/z found,
545/547 [M-H].sup.-.
Example 86
##STR00096##
[0366]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-(4--
cyano-phenyl)-propionic acid
[0367] MS (ESI-): mass calcd. for
C.sub.25H.sub.18ClN.sub.5O.sub.5S, 535.07; m/z found, 534/536
[M-H].sup.-.
Example 87
##STR00097##
[0368]
(S)-2-[4-Chloro-2-(quinoxaline-5-sulfonylamino)-benzoylamino]-3-thi-
ophen-3-yl-propionic acid
[0369] MS (ESI-): mass calcd. for
C.sub.22H.sub.17ClN.sub.4O.sub.5S.sub.2, 516.03; m/z found, 515/517
[M-H].sup.-.
Example 88
##STR00098##
[0370]
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-butyric acid methyl ester
[0371] MS (ESI+): mass calcd. for
C.sub.26H.sub.22Cl.sub.2N.sub.4O.sub.5S, 572.07; m/z found, 573/575
[M+H].sup.+, 595/597 [M+Na].sup.+.
Example 89
##STR00099##
[0372]
(S)-4-(4-Chloro-phenyl)-3-[4-chloro-2-(quinoxaline-5-sulfonylamino)-
-benzoylamino]-butyric acid
[0373] MS (ESI-): mass calcd. for
C.sub.25H.sub.20Cl.sub.2N.sub.4O.sub.5S, 558.05; m/z found, 557/559
[M-H].sup.-.
Example 90
##STR00100##
[0374]
(S)-3-(4-Chloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamino)-b-
enzoylamino]-propionic acid
[0375] MS (ESI-): mass calcd. for
C.sub.24H.sub.18ClIN.sub.4O.sub.5S, 635.97; m/z found, 635/637
[M-H].sup.-.
Example 91
##STR00101##
[0376]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-4-chloro-phenyl)-propionic acid
[0377] HPLC: R.sub.T=10.22 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrClIN.sub.4O.sub.5S.sub.2, 721.77; m/z found,
719/721 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.09 (s,
1H), 8.31 (d, J=7.0, 1H), 8.19 (d, J=8.8, 1H), 8.02 (s, 1H), 7.71
(dd, J=8.7, 7.1, 1H), 7.39 (d, J=1.7, 1H), 7.34 (d, J=8.2, 1H),
7.31-7.25 (m, 1H), 7.02 (dd, J=8.2, 1.5, 1H), 6.89 (d, J=8.3, 1H),
6.50 (br s, 1H), 4.95 (q, J=5.8, 1H), 3.32-3.13 (m, 2H).
Example 92
##STR00102##
[0378]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(4-chloro-3-iodo-phenyl)-propionic acid
[0379] HPLC: R.sub.T=10.24 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cll.sub.2N.sub.4O.sub.5S.sub.2, 768.77; m/z found,
767/769 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.16 (s,
1H), 8.35 (d, J=6.9, 1H), 8.22 (d, J=8.8, 1H), 8.10-8.06 (m, 1H),
7.73 (dd, J=8.6, 7.3, 1H), 7.65-7.63 (m, 1H), 7.38-7.30 (m, 2H),
7.10-7.05 (m, 1H), 6.92 (d, J=8.3, 1H), 6.43 (d, J=7.2, 1H), 4.95
(q, J=5.5, 1H), 3.30-3.12 (m, 2H).
Example 93
##STR00103##
[0380]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
[0381] HPLC: R.sub.T=10.92 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrFIN.sub.4O.sub.5S.sub.2, 705.32; m/z found,
703/705 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.16 (s,
1H), 8.34 (dd, J=7.0, 0.9, 1H), 8.20 (dd, J=8.8, 0.9, 1H), 8.04 (d,
J=1.5, 1H), 7.72 (dd, J=8.8, 7.1, 1H), 7.32 (dd, J=6.5, 1.8, 1H),
7.29 (dd, J=8.2, 1.6, 1H), 7.09-6.99 (m, 2H), 6.89 (d, J=8.3, 1H),
6.45 (d, J=7.1, 1H), 4.96 (q, J=5.7, 1H), 3.31-3.14 (m, 2H).
Example 94
##STR00104##
[0382]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3,3-bis-(4-chloro-phenyl)-propionic acid
[0383] A.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3,3-bis-(4-chloro-phenyl)-propionic acid methyl ester. The
title compound (49 mg, 84%) was prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid
(EXAMPLE 101, Part D) and
(S)-2-amino-3,3-bis-(4-chloro-phenyl)-propionic acid methyl ester
(EXAMPLE 106, Part H) as in Example 1, Part C. .sup.1H NMR (500
MHz, CDCl.sub.3): 11.16 (s, 1H), 8.36 (dd, J=7.0, 1.0, 1H), 8.23
(dd, J=8.8, 1.0, 1H), 8.03 (d, J=1.6, 1H), 7.72 (dd, J=8.8, 7.1,
1H), 7.32-7.27 (m, 4H), 7.24 (dd, J=8.2, 1.6, 1H), 7.21-7.15 (m,
4H), 6.71 (d, J=8.3, 1H), 6.22 (br d, J=8.8, 1H), 5.48 (t, J=8.5,
1H), 4.48 (d, J=8.3, 1H), 3.62 (s, 3H).
[0384] B.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3,3-bis-(4-chloro-phenyl)-propionic acid. A mixture of
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-
,3-bis-(4-chloro-phenyl)-propionic acid methyl ester (49 mg, 0.064
mmol), THF (2 mL), and LiOH (1 M in water, 1 mL) was stirred
vigorously overnight at rt. The mixture was acidified with conc.
HCl (4 drops), diluted with THF to 3.5 mL, and purified by
preparative reverse phase HPLC to provide 37 mg (77%) of the acid
as a white solid. HPLC: R.sub.T=10.62 min. MS (ESI-): mass calcd.
for C.sub.28H.sub.19Cl.sub.2IN.sub.4O.sub.5S.sub.2, 753.42; m/z
found, 751/753 [M-H].sup.-. .sup.1H NMR (500 MHz, MeOD): 8.32 (dd,
J=7.1, 0.9, 1H), 8.24 (dd, J=8.8, 0.8, 1H), 7.95 (d, J=1.5, 1H),
7.76 (dd, J=8.8, 7.1, 1H), 7.38-7.21 (m, 9H), 6.72 (d, J=8.3, 1H),
5.37 (d, J=11.5, 1H), 4.50 (d, J=11.5, 1H).
Example 95
##STR00105##
[0385]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(4-chloro-phenyl)-3-methyl-butyric acid
[0386] A.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3-(4-chloro-phenyl)-3-methyl-butyric acid methyl ester. The
title compound (61 mg, 90%) was prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid
(EXAMPLE 101, Part D) and
(S)-2-amino-3-(4-chloro-phenyl)-3-methyl-butyric acid methyl ester
(EXAMPLE 107, Part F) as in Example 94, Part A. .sup.1H NMR (500
MHz, CDCl.sub.3): 11.26 (s, 1H), 8.36 (dd, J=7.0, 1.0, 1H), 8.21
(dd, J=8.8, 1.0, 1H), 8.07 (d, J=1.6, 1H), 7.72 (dd, J=8.8, 7.0,
1H), 7.35-7.25 (m, 5H), 6.89 (d, J=8.3, 1H), 6.32 (br d, J=9.2,
1H), 4.97 (d, J=9.0, 1H), 3.64 (s, 3H), 1.45 (s, 3H), 1.40 (s,
3H).
[0387] B.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoy-
lamino]-3-(4-chloro-phenyl)-3-methyl-butyric acid. The title
compound (22 mg, 37%) was prepared as in Example 94, Part B, along
with 27 mg (44%) of the starting methyl ester. HPLC: R.sub.T=10.30
min. MS (ESI-): mass calcd. for
C.sub.24H.sub.20ClIN.sub.4O.sub.5S.sub.2, 670.93; m/z found,
669/671 [M-H].sup.-. .sup.1H NMR (500 MHz, MeOD): 8.27 (dd, J=7.1,
0.7, 1H), 8.23 (dd, J=8.8, 0.7, 1H), 7.96 (d, J=1.5, 1H), 7.75 (dd,
J=8.8, 7.1, 1H), 7.41-7.37 (m, 2H), 7.31 (dd, J=8.2, 1.6, 1H),
7.29-7.27 (m, 2H), 6.89 (d, J=8.2, 1H), 4.94 (s, 1H), 1.48 (s, 3H),
1.41 (s, 3H).
[0388] The compounds in Examples 96-98 may be prepared using
methods analogous to those described in the preceding and
subsequent examples.
Example 96
##STR00106##
[0389]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(4-chloro-phenyl)-2-methyl-propionic acid
Example 97
##STR00107##
[0390]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(3-bromo-phenyl)-propionic acid
Example 98
##STR00108##
[0391]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(4-chloro-phenyl)-3-hydroxy-propionic acid
Example 99
##STR00109##
[0392]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(4-chloro--
phenyl)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide
[0393] A.
4-(S)-Benzyl-3-[(2R,3R)-3-(4-chloro-phenyl)-3-hydroxy-2-methyl-p-
ropionyl]-oxazolidin-2-one. The title compound (1.32 g, 80%) was
prepared from 4-(S)-benzyl-3-propionyl-oxazolidin-2-one and
4-chlorobenzaldehyde as in Example 55, Part B. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.37-7.26 (m, 7H), 7.23-7.17 (m, 2H), 5.12-5.08
(m, 1H), 4.69-4.62 (m, 1H), 4.22-4.13 (m, 2H), 4.03 (dq, J=7.0,
3.6, 1H), 3.25 (dd, J=13.4, 3.3, 1H), 3.20 (d, J=2.5, 1H), 2.79
(dd, J=13.4, 9.4, 1H), 1.18 (d, J=7.0, 3H).
[0394] B. (2R,3R)-3-(4-Chloro-phenyl)-3-hydroxy-2-methyl-propionic
acid. The title compound (0.76 g, 100%) was prepared as in Example
55, Part C. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.36-7.32 (m, 2H),
7.32-7.28 (m, 2H), 5.16 (d, J=3.9, 1H), 2.81 (dq, J=7.2, 3.9, 1H),
1.15 (d, J=7.2, 3H).
[0395] C.
(2R,3R)-3-(4-Chloro-phenyl)-3-(tert-butyl-dimethyl-silanyloxy)-2-
-methyl-propionic acid. The title compound was prepared as in
Example 55, Part D. Purification by flash chromatography
(EtOAc/hexanes) provided 1.06 g (91%) of the desired silylated acid
as a colorless oil. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.32-7.27
(m, 2H), 7.27-7.22 (m, 2H), 5.01 (d, J=5.3, 1H), 2.70 (dq, J=7.2,
5.6, 1H), 1.11 (d, J=7.2, 3H), 0.88 (s, 9H), 0.03 (s, 3H), -0.18
(s, 3H).
[0396] D.
(1R,2S)-[2-(4-Chloro-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)--
1-methyl-ethyl]-carbamic acid tert-butyl ester. The title compound
(354 mg, 31%) was prepared as in Example 55, Part E. .sup.1H NMR
(400 MHz, CDCl.sub.3; rotameric broadening): 7.28 (s, 4H), 4.90 (br
s, 1H), 4.60 (br d, J=8.0, 1H), 3.77-3.65 (m, 1H), 1.46 (s, 9H),
0.94 (s, 9H), 0.88 (d, J=6.8, 3H), 0.06 (s, 3H), -0.13 (s, 3H).
[0397] E. (1S,2R)-2-Amino-1-(4-chloro-phenyl)-propan-1-ol
hydrochloride salt. The title compound (195 mg, 100%) was prepared
as in Example 55, Part F. MS (ESI+): mass calcd. for
C.sub.9H.sub.12BrNO, 229.01; m/z found, 230, 232 [M+H].sup.+.
.sup.1H NMR (400 MHz, CD.sub.3OD): 7.43-7.37 (m, 4H), 4.91 (d,
J=3.4, 1H), 3.50 (dq, J=6.8, 3.5, 1H), 1.07 (d, J=6.8, 3H).
[0398] F.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(4-chlo-
ro-phenyl)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide. The title
compound (42 mg, 67%) was obtained from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid
(EXAMPLE 101, Part D) and
(1S,2R)-2-amino-1-(4-chloro-phenyl)-propan-1-ol hydrochloride salt
as in Example 1, Part C. HPLC: R.sub.T=10.13 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.18ClIN.sub.4O.sub.4S.sub.2, 628.89; m/z
found, 627/629 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.49 (s, 1H), 8.37 (dd, J=7.0, 0.8, 1H), 8.23 (dd, J=8.8, 0.8,
1H), 8.07 (d, J=1.5, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.37-7.27 (m,
5H), 6.98 (d, J=8.3, 1H), 6.20 (d, J=8.1, 1H), 4.95 (d, J=2.7, 1H),
4.42-4.38 (m, 1H), 2.65 (s, 1H), 1.03 (d, J=6.9, 1H).
Example 100
##STR00110##
[0399]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3,4-dichloro-phen-
yl)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide
[0400] The title compound may be prepared using methods described
in the preceding and subsequent examples.
Example 101
##STR00111##
[0401]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-p-
henyl)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide
[0402] A. 4-Iodo-2-nitrobenzoic acid. 4-Iodo-2-nitrotoluene (9.0 g,
34.2 mmol), KMnO.sub.4 (22.0 g, 139 mmol) and water (340 mL) were
heated at reflux for 5 h. The resulting brown suspension was
filtered through a pad of diatomaceous earth, washing with water.
The basic filtrate was acidified with conc. HCl. The resulting
solids were collected by suction filtration and dried to afford
1.86 g of the acid. The mother liquor was extracted with DCM
(3.times.), and the combined extracts were dried (Na.sub.2SO.sub.4)
and concentrated to afford an additional 0.16 g of the benzoic
acid. Total yield=2.02 g (20%). .sup.1H NMR (400 MHz, CD.sub.3OD):
8.13 (d, J=1.6, 1H), 8.01 (dd, J=8.1, 1.6, 1H), 7.50 (d, J=8.1,
1H).
[0403] B. Methyl 2-amino-4-iodobenzoate. The title compound (1.87
g, 91%) was prepared as in Example 20, Part B. .sup.1H NMR (500
MHz, CDCl.sub.3): 7.52 (d, J=8.5, 1H), 7.07 (d, J=1.6, 1H), 6.96
(dd, J=8.5, 1.6, 1H), 5.72 (br s, 2H), 3.86 (s, 3H).
[0404] C.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic acid
methyl ester. The title compound (1.87 g, 68%) was prepared as in
Example 20, Part C (without DMAP). MS (ESI-): mass calcd. for
C.sub.14H.sub.10IN.sub.3O.sub.4S.sub.2, 474.92; m/z found, 474
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.26 (br s, 1H),
8.40 (dd, J=7.0, 1.0, 1H), 8.24 (dd, J=8.8, 1.0, 1H), 8.12 (d,
J=1.5, 1H), 7.74 (dd, J=8.8, 7.0, 1H), 7.53 (d, J=8.5, 1H), 7.32
(dd, J=8.5, 1.5, 1H), 3.91 (s, 3H).
[0405] D. 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic
acid. The title compound (1.24 g, 69%) was prepared as in Example
20, Part D. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.03 (br s, 1H),
8.34 (dd, J=7.2, 1.1, 1H), 8.19 (dd, J=8.8, 1.1, 1H), 8.09 (d,
J=1.6, 1H), 7.69 (dd, J=8.8, 7.2, 1H), 7.56 (d, J=8.5, 1H), 7.30
(dd, J=8.5, 1.6, 1H).
[0406] E.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-brom-
o-phenyl)-2-hydroxy-1-methyl-ethyl]-4-iodo-benzamide.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodobenzoic acid was
coupled with (1S,2R)-2-amino-1-(3-bromo-phenyl)-propan-1-ol
hydrochloride salt (EXAMPLE 108, Part E) as in Example 1, Part C
(11 mg, 16%). HPLC: R.sub.T=10.19 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.18BrIN.sub.4O.sub.4S.sub.2, 673.34; m/z found,
671/673 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.45 (s,
1H), 8.37 (d, J=7.0, 1H), 8.23 (d, J=8.8, 1H), 8.08 (d, J=1.5, 1H),
7.73 (dd, J=8.8, 7.1, 1H), 7.55-7.53 (m, 1H), 7.47-7.43 (m, 1H),
7.33 (dd, J=8.2, 1.5, 1H), 7.31-7.21 (m, 3H), 6.99 (d, J=8.3, 1H),
6.19 (d, J=8.6, 1H), 4.95-4.94 (m, 1H), 4.44-4.40 (m, 1H), 2.60 (s,
1H), 1.03 (d, J=6.9, 3H).
[0407] The compounds in Examples 102-105 may be prepared using
methods analogous to those described in the preceding and
subsequent examples.
Example 102
##STR00112##
[0408]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(3,4-dichloro-phenyl)-3-hydroxy-propionic acid
Example 103
##STR00113##
[0409]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(3-bromo-phenyl)-butyric acid
Example 104
##STR00114##
[0410]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-p-
ropyl]-4-iodo-benzamide
Example 105
##STR00115##
[0411]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-
-3-(3,4-dichloro-phenyl)-acrylic acid
Example 106
##STR00116##
[0412]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3,3-bis-(4-chloro-phenyl)-propionic acid
[0413] A. 3,3-Bis-(4-chloro-phenyl)-propionic acid. To a suspension
of 4-chlorocinnamic acid (10.0 g, 54.8 mmol) in chlorobenzene (75
mL) at 0.degree. C. was added AlCl.sub.3 (12.0 g, 90 mmol) in 4
portions. The mixture was stirred for 10 min at 0.degree. C. then
was warmed to 40.degree. C. and stirred for 1 h. Crushed ice (75 g)
was added carefully, followed by water (75 mL). The aqueous layer
was extracted with DCM (3.times.). The combined organic extracts
were dried (Na.sub.2SO.sub.4) and concentrated to provide the crude
acid as a tan solid. Recrystallization from EtOH provided 7.81 g
(48%) of the desired acid as a pale yellow solid. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.31-7.22 (m, 4H), 7.14-7.07 (m, 4H), 4.47 (t,
J=8.0, 1H), 3.03 (d, J=7.9, 2H).
[0414] B.
4-(S)-Benzyl-3-[3,3-bis-(4-chloro-phenyl)-propionyl]-oxazolidin--
2-one. A suspension of 3,3-bis-(4-chloro-phenyl)-propionic acid
(3.0 g, 10.2 mmol) in SOCl.sub.2 (10 mL) was heated at reflux for
30 min. The mixture was cooled and concentrated, and the residue
was azeotroped with toluene (3.times.) to give the acid chloride as
a yellow liquid. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.32-7.26 (m,
4H), 7.15-7.10 (m, 4H), 4.55 (t, J=7.8, 1H), 3.57 (d, J=7.8, 2H).
To a stirred solution of 4-(S)-benzyl-oxazolidin-2-one (1.65 g, 9.3
mmol) in THF (46 mL) at -78.degree. C. was added n-BuLi (1.6 M in
hexanes, 6.1 mL, 9.8 mmol). After stirring 20 min at -78.degree.
C., a solution of the acid chloride (10.2 mmol) in THF (7 mL) was
added rapidly via cannula. The mixture was stirred overnight with
slow warming to rt and was quenched by addition of satd. aq.
NH.sub.4Cl. The mixture was concentrated, and the residue was
diluted with water and extracted with DCM (3.times.). The combined
organic extracts were dried (Na.sub.2SO.sub.4) and concentrated.
The residue was purified by flash chromatography (EtOAc/hexanes) to
give 3.83 g (91%) of the title acyl imide as a white solid. .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.33-7.25 (m, 7H), 7.25-7.19 (m, 4H),
7.10-7.05 (m, 2H), 4.66 (t, J=7.7, 1H), 4.62-4.54 (m, 1H),
4.18-4.10 (m, 2H), 3.76 (dd, J=17.0, 7.4, 1H), 3.65 (dd, J=17.0,
8.0, 1H), 3.10 (dd, J=13.5, 3.3, 1H), 2.64 (dd, J=13.4, 9.4,
1H).
[0415] C. 2,4,6-Triisoprorylbenzenesulfonyl azide. To a solution of
triisopropylbenzenesulfonyl chloride (6.94 g, 22.9 mmol) in acetone
(115 mL) at 0.degree. C. was added a solution of NaN.sub.3 (1.64 g,
25.2 mmol) in water (10 mL). The mixture was stirred for 30 min at
0.degree. C. and then was warmed to rt and stirred for 1 h. The
mixture was concentrated, diluted with water, and extracted with
DCM (3.times.). The combined organic extracts were dried
(Na.sub.2SO.sub.4) and concentrated. The residue was purified by
flash chromatography (EtOAc/hexanes) to provide 6.71 g (95%) of the
desired sulfonyl azide as a white solid. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.22 (s, 2H), 4.05 (sept, J=6.7, 2H), 2.93 (sept,
J=6.9, 1H), 1.29 (d, J=6.8, 12H), 1.27 (d, J=6.9, 6H).
[0416] D.
3-[2-(S)-Azido-3,3-bis-(4-chloro-phenyl)-propionyl]-4-(S)-benzyl-
-oxazolidin-2-one.
[0417] A solution of
4-(S)-benzyl-3-[3,3-bis-(4-chloro-phenyl)-propionyl]-oxazolidin-2-one
(2.0 g, 4.4 mmol) in THF (25 mL) was cooled to -78.degree. C. and
added via cannula to a solution of potassium
bis(trimethylsilyl)amide (0.5 M in toluene, 9.7 mL, 4.8 mmol) in
THF (15 mL) at -78.degree. C. After 30 min at -78.degree. C., a
solution of 2,4,6-triisopropylbenzenesulfonyl azide (1.77 g, 5.7
mmol) in THF (15 mL) was cooled to -78.degree. C. and added via
cannula. After 1 min, the reaction was quenched by addition of AcOH
(1.2 mL, 21 mmol). The cooling bath was removed, and the mixture
was allowed to warm to rt and stir overnight. The reaction mixture
was diluted with water and extracted with DCM (3.times.). The
combined organic extracts were dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by flash chromatography
(EtOAc/hexanes) to provide 1.58 g (72%) of the desired azide as a
white foam. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.38-7.15 (m, 13H),
5.94 (d, J=11.0, 1H), 4.50 (d, J=11.0, 1H), 4.34-4.25 (m, 1H), 4.08
(dd, J=9.2, 2.4, 1H), 3.76 (dd, J=8.8, 8.1, 1H), 3.22 (dd, J=13.5,
3.3, 1H), 2.77 (dd, J=13.5, 9.5, 1H).
[0418] E. (S)-2-Azido-3,3-bis-(4-chloro-phenyl)-propionic acid. To
a solution of
3-[2-(S)-azido-3,3-bis-(4-chloro-phenyl)-propionyl]-4-(S)-benzyl-oxazolid-
in-2-one (1.53 g, 3.1 mmol) in 3:1 THF/water (60 mL) at 0.degree.
C. was added 30% aq. H.sub.2O.sub.2 (1.4 mL, 12.3 mmol) and
LiOH.H.sub.2O (259 mg, 6.2 mmol). The mixture was stirred for 1 h
at 0.degree. C. Na.sub.2SO.sub.3 (2.52 g, 20 mmol) was added, and
the mixture was stirred for 30 min at 0.degree. C., then warmed to
rt, and stirred for 1 h. The mixture was concentrated without
external heating, and the residue was diluted with water and
extracted with DCM (3.times.). The aqueous layer was acidified with
conc. HCl and extracted with EtOAc (4.times.). The combined EtOAc
extracts were dried (Na.sub.2SO.sub.4) and concentrated to provide
the desired azidoacid as a colorless solid (0.98 g, 94%). .sup.1H
NMR (500 MHz, CDCl.sub.3): 7.33-7.24 (m, 6H), 7.21-7.18 (m, 2H),
4.52 (d, J=8.3, 1H), 4.49 (d, J=8.3, 1H).
[0419] F. (S)-2-Amino-3,3-bis-(4-chloro-phenyl)-propionic acid.
(S)-2-Azido-3,3-bis-(4-chloro-phenyl)-propionic acid (0.98 g, 2.9
mmol), Lindlar's catalyst (307 mg, 5 mol % Pd), and EtOAc (29 mL)
was placed in a 500 mL Parr bottle. The bottle was pressurized with
50 psi of H.sub.2 and shaken overnight in a Parr shaker apparatus.
The mixture was diluted with MeOH, and the catalyst was removed by
filtration through diatomaceous earth, rinsing with MeOH. The
filtrate was concentrated to provide 0.90 g (100%) of the desired
amino acid as a white solid. MS (ESI-): mass calcd. for
C.sub.15H.sub.13Cl.sub.2NO.sub.2, 309; m/z found, 308 [M-H].sup.-.
.sup.1H NMR (400 MHz, CD.sub.3OD): 7.41-7.22 (m, 8H), 4.46 (d,
J=9.1, 1H), 4.26 (d, J=9.1, 1H).
[0420] G.
(S)-2-tert-Butoxycarbonylamino-3,3-bis-(4-chloro-phenyl)-propion-
ic acid methyl ester. To a solution of
(S)-2-amino-3,3-bis-(4-chloro-phenyl)-propionic acid (0.90 g, 2.9
mmol) in MeOH (20 mL) at rt was added SOCl.sub.2 (2 mL) carefully
via pipette. The mixture was allowed to stand for 1 h at rt and was
then concentrated. .sup.1H NMR indicated only partial conversion to
the methyl ester. A mixture of the crude methyl ester, Boc.sub.2O
(0.77 g, 3.52 mmol), and 1 M NaOH (10 mL) was stirred rapidly for 2
h. The reaction mixture was extracted with DCM (3.times.), and the
combined organic extracts were dried (Na.sub.2SO.sub.4) and
concentrated. The residue was purified by flash chromatography
(EtOAc/hexanes) to provide 0.24 g (19%) of the desired N-Boc methyl
ester. MS (ESI+): mass calcd. for C.sub.21H.sub.23Cl.sub.2NO.sub.4,
423.10; m/z found, 446 [M+Na].sup.+. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.38-7.10 (m, 8H), 5.10-5.00 (br m, 1H), 4.81 (br d,
J=9.3, 1H), 4.34 (br d, J=8.4, 1H), 3.54 (s, 3H), 1.37 (s, 9H).
[0421] H. (S)-2-Amino-3,3-bis-(4-chloro-phenyl)-propionic acid
methyl ester. To a solution of
(S)-2-tert-butoxycarbonylamino-3,3-bis-(4-chloro-phenyl)-propionic
acid methyl ester (0.23 g, 0.54 mmol) in DCM (3 mL) at rt was added
TFA (1 mL). After 2 h, the mixture was concentrated, diluted with
water, and extracted with DCM (3.times.). The combined organic
extracts were dried (Na.sub.2SO.sub.4) and concentrated to provide
100 mg (57%) of the amine as a tan viscous oil. MS (ESI+): mass
calcd. for C.sub.16H.sub.15Cl.sub.2NO.sub.2, 323.05; m/z found, 324
[M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 7.32-7.19 (m, 8H),
4.26 (d, J=8.0, 1H), 4.15 (app q, J=7.4, 1H), 3.57 (s, 3H), 1.46
(br d, J=6.6, 2H).
[0422] I.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3,3-bis-(4-chloro-phenyl)-propionic acid methyl ester.
The title compound (48 mg, 94%) was obtained from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
and (S)-2-amino-3,3-bis-(4-chloro-phenyl)-propionic acid methyl
ester as in Example 1, Part C. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.28 (s, 1H), 8.37 (dd, J=7.0, 1.0, 1H), 8.22 (dd, J=8.8, 1.0,
1H), 7.72 (dd, J=8.8, 7.1, 1H), 7.68 (d, J=1.9, 1H), 7.32-7.28 (m,
4H), 7.20-7.15 (m, 4H), 6.96 (d, J=8.5, 1H), 6.87 (dd, J=8.4, 2.0,
1H), 6.21 (br d, J=8.8, 1H), 5.50 (t, J=8.5, 1H), 4.48 (d, J=8.3,
1H), 3.63 (s, 3H).
[0423] J.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3,3-bis-(4-chloro-phenyl)-propionic acid. The title
compound (35 mg, 74%) was prepared as in Example 94, Part B. HPLC:
R.sub.T=10.54 min. MS (ESI-): mass calcd. for
C.sub.28H.sub.19Cl.sub.3N.sub.4O.sub.5S.sub.2, 661.96; m/z found,
659/661 [M-H].sup.-. .sup.1H NMR (500 MHz, MeOD): 8.36-8.34 (m,
1H), 8.26-8.23 (m, 1H), 7.79-7.75 (m, 1H), 7.62-7.61 (m, 1H),
7.39-7.26 (m, 8H), 7.00-6.98 (m, 1H), 6.88-6.86 (m, 1H), 5.41-5.38
(m, 1H), 4.53-4.50 (m, 1H).
Example 107
##STR00117##
[0424]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(4-chloro-phenyl)-3-methyl-butyric acid
[0425] A. 3-(4-Chloro-phenyl)-3-methyl-butyric acid. The title
compound was prepared from 3-methyl-2-butenoic acid as in Example
106, Part A. Recrystallization from EtOAc/hexanes provided 9.80 g
(84%) of the desired acid as a white solid. .sup.1H NMR (500 MHz,
CDCl.sub.3): 7.30-7.25 (m, 4H), 2.63 (s, 2H), 1.43 (s, 6H).
[0426] B.
(S)-4-Benzyl-3-[3-(4-chloro-phenyl)-3-methyl-butyryl]-oxazolidin-
-2-one. The title compound (3.72 g, 78%) was prepared as in Example
106, Part B. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.38-7.22 (m, 7H),
7.15-7.09 (m, 2H), 4.52-4.45 (m, 1H), 4.09-3.97 (m, 2H), 3.38 (d,
J=16.0, 1H), 3.33 (d, J=16.0, 1H), 3.12 (dd, J=13.4, 3.3, 1H), 2.55
(dd, J=13.4, 9.8, 1H), 1.50 (s, 3H), 1.49 (s, 3H).
[0427] C.
3-[2-(S)-Azido-3-(4-chloro-phenyl)-3-methyl-butyryl]-4-(S)-benzy-
l-oxazolidin-2-one.
[0428] The title compound (1.60 g, 72%) was prepared as in Example
106, Part D. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.38-7.25 (m, 7H),
7.19-7.14 (m, 2H), 5.64 (s, 1H), 4.27-4.19 (m, 1H), 4.03 (dd,
J=9.0, 2.0, 1H), 3.66 (ddd, J=8.9, 7.6, 0.6, 1H), 3.22 (dd, J=13.4,
3.2, 1H), 2.73 (dd, J=13.4, 9.6, 1H), 1.55 (s, 3H), 1.53 (s,
3H).
[0429] D. (S)-2-Azido-3-(4-chloro-phenyl)-3-methyl-butyric acid.
The title compound (0.89 g, 99%) was prepared as in Example 106,
Part E. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.35-7.29 (m, 4H), 4.18
(s, 1H), 1.48 (s, 6H).
[0430] E. (S)-2-Azido-3-(4-chloro-phenyl)-3-methyl-butyric acid
methyl ester. A mixture of
(S)-2-azido-3-(4-chloro-phenyl)-3-methyl-butyric acid (0.89 g, 3.5
mmol), powdered KHCO.sub.3 (780 mg, 7.8 mmol), MeI (0.44 mL, 7.1
mmol), and DMF (7 mL) was stirred rapidly at rt overnight. The
mixture was poured into water and extracted with Et.sub.2O
(3.times.). The combined organic layers were washed with water
(4.times.), dried (MgSO.sub.4), and concentrated to provide 0.90 g
(96%) of the desired methyl ester as a colorless liquid. .sup.1H
NMR (400 MHz, CDCl.sub.3): 7.34-7.28 (m, 4H), 4.10 (s, 1H), 3.64
(s, 3H), 1.46 (s, 3H), 1.43 (s, 3H).
[0431] F. (S)-2-Amino-3-(4-chloro-phenyl)-3-methyl-butyric acid
methyl ester. The title compound was prepared as in Example 106,
Part F. The crude residue was purified by flash chromatography
(EtOAc/hexanes) to give the starting azide (0.39 g, 43%) and the
desired amine as a colorless oil (0.39 g, 48%). MS (ESI+): mass
calcd. for C.sub.12H.sub.16ClNO.sub.2, 241.09; m/z found, 242
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.29 (br s, 4H),
3.60 (s, 3H), 3.59 (s, 1H), 1.38 (s, 3H), 1.37 (s, 3H).
[0432] G.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3-(4-chloro-phenyl)-3-methyl-butyric acid methyl ester.
The title compound (57 mg, 97%) was obtained from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
(37 mg, 0.1 mmol) and
(S)-2-amino-3-(4-chloro-phenyl)-3-methyl-butyric acid methyl ester
(0.048 g, 0.20 mmol) as in Example 1, Part C. .sup.1H NMR (500 MHz,
CDCl.sub.3): 11.39 (s, 1H), 8.36 (dd, J=7.1, 1.0, 1H), 8.21 (dd,
J=8.8, 1.0, 1H), 7.72 (d, J=2.0, 1H), 7.71 (dd, J=8.8, 7.1, 1H),
7.34-7.26 (m, 4H), 7.14 (d, J=8.4, 1H), 6.94 (dd, J=8.4, 2.0, 1H),
6.32 (br d, J=9.0, 1H), 4.99 (d, J=9.0, 1H), 3.64 (s, 3H), 1.46 (s,
3H), 1.41 (s, 3H).
[0433] H.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3-(4-chloro-phenyl)-3-methyl-butyric acid. The title
compound (21 mg, 38%) was prepared as in Example 94, Part B. HPLC:
R.sub.T=10.19 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.20Cl.sub.2N.sub.4O.sub.5S.sub.2, 579.48; m/z found,
577/579 [M-H].sup.-. .sup.1H NMR (500 MHz, MeOD): 8.29 (dd, J=7.0,
0.9, 1H), 8.23 (dd, J=8.8, 0.9, 1H), 7.74 (dd, J=8.8, 7.1, 1H),
7.62 (d, J=2.0, 1H), 7.45-7.40 (m, 2H), 7.32-7.24 (m, 2H), 7.15 (d,
J=8.4, 1H), 6.95 (dd, J=8.4, 2.0, 1H), 4.96 (s, 1H), 1.49 (s, 3H),
1.42 (s, 3H).
Example 108
##STR00118##
[0434]
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-bromo-p-
henyl)-2-hydroxy-1-methyl-ethyl]-4-chloro-benzamide
[0435] A.
4-(S)-Benzyl-3-[(2R,3R)-3-(3-bromo-phenyl)-3-hydroxy-2-methyl-pr-
opionyl]-oxazolidin-2-one. The title compound (2.73 g, 76%) was
prepared from 4-(S)-benzyl-3-propionyl-oxazolidin-2-one and
3-bromobenzaldehyde as in Example 55, Part B. .sup.1H NMR (400 MHz,
CDCl.sub.3): 7.59-7.56 (m, 1H), 7.42-7.38 (m, 1H), 7.37-7.28 (m,
4H), 7.25-7.18 (m, 3H), 5.11 (app t, J=2.8, 1H), 4.73-4.64 (m, 1H),
4.22-4.16 (m, 2H), 4.02 (dq, J=7.0, 3.3, 1H), 3.27 (d, J=2.6, 1H),
3.25 (dd, J=13.4, 3.4, 1H), 2.80 (dd, J=13.4, 9.4, 1H), 1.18 (d,
J=7.0, 3H).
[0436] B. (2R,3R)-3-(3-Bromo-phenyl)-3-hydroxy-2-methyl-propionic
acid. The title compound (1.54 g, 91%) was prepared as in Example
55, Part C. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.56-7.52 (m, 1H),
7.45-7.39 (m, 1H), 7.31-7.26 (m, 1H), 7.23 (dd, J=7.7, 7.7, 1H),
5.17 (d, J=3.6, 1H), 2.83 (dq, J=7.2, 3.6, 1H), 1.15 (d, J=7.2,
3H).
[0437] C.
(2R,3R)-3-(3-Bromo-phenyl)-3-(tert-butyl-dimethyl-silanyloxy)-2--
methyl-propionic acid. The title compound (1.88 g, 85%) was
prepared as in Example 55, Part D. MS (ESI-): mass calcd. for
C.sub.16H.sub.25BrO.sub.3Si, 372.08; m/z found, 371, 373
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.48-7.45 (m, 1H),
7.42-7.37 (m, 1H), 7.27-7.23 (m, 1H), 7.19 (dd, J=7.8, 7.8, 1H),
5.03 (d, J=5.0, 1H), 2.73 (dq, J=7.2, 4.8, 1H), 1.11 (d, J=7.2,
3H), 0.89 (s, 9H), 0.05 (s, 3H), -0.16 (s, 3H).
[0438] D.
(1R,2S)-[2-(3-Bromo-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-1-
-methyl-ethyl]-carbamic acid tert-butyl ester. The title compound
(0.71 g, 32%) was prepared as in Example 55, Part E. MS (ESI+):
mass calcd. for C.sub.20H.sub.34BrNO.sub.3Si, 443.15; m/z found,
466, 468 [M+Na].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3; rotameric
broadening): 7.53-7.49 (m, 1H), 7.38-7.34 (m, 1H), 7.31-7.26 (m,
1H), 7.18 (dd, J=7.8, 7.7, 1H), 4.90 (br s, 1H), 4.61 (br d, J=8.4,
1H), 3.80-3.69 (m, 1H), 1.46 (s, 9H), 0.95 (s, 9H), 0.89 (d, J=6.0,
3H), 0.06 (s, 3H), -0.11 (s, 3H).
[0439] E. (1S,2R)-2-Amino-1-(3-bromo-phenyl)-propan-1-ol
hydrochloride salt. To a solution of
(1R,2S)-[2-(3-bromo-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-1-methyl-e-
thyl]-carbamic acid tert-butyl ester (0.71 g, 1.6 mmol) in MeOH (10
mL) was added 4 M HCl in dioxane (3 mL). After 1 h, the mixture was
diluted with basic brine (prepared by dissolving a quantity of NaOH
in brine), and extracted with DCM (4.times.). The combined organic
layers were dried (Na.sub.2SO.sub.4) and concentrated. The residue
was purified by preparative reverse phase HPLC. The TFA salt thus
obtained was diluted with basic brine and extracted with DCM
(4.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated. The residue was diluted with
MeOH and treated with 4 M HCl in dioxane. The mixture was
concentrated to provide the desired HCl salt. MS (ESI+): mass
calcd. for C.sub.9H.sub.12BrNO, 229.01; m/z found, 230, 232
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3; free base):
7.53-7.50 (m, 1H), 7.43-7.38 (m, 1H), 7.27-7.24 (m, 1H), 7.21 (dd,
J=7.7, 7.6, 1H), 4.53 (d, J=4.0, 1H), 3.30-3.18 (m, 1H), 0.93 (d,
J=6.5, 3H).
[0440] F.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[(2S,1R)-2-(3-brom-
o-phenyl)-2-hydroxy-1-methyl-ethyl]-4-chloro-benzamide. The title
compound (7 mg, 12%) was obtained from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
and (1S,2R)-2-amino-1-(3-bromo-phenyl)-propan-1-ol hydrochloride
salt as in Example 1, Part C. HPLC: R.sub.T=10.08 min. MS (ESI-):
mass calcd. for C.sub.22H.sub.18BrClN.sub.4O.sub.4S.sub.2, 581.89;
m/z found, 579/581 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.58 (s, 1H), 8.38 (dd, J=7.0, 0.9, 1H), 8.22 (dd, J=8.8, 0.9,
1H), 7.74-7.71 (m, 2H), 7.55-7.53 (m, 1H), 7.47-7.43 (m, 1H),
7.31-7.22 (m, 2H), 6.95 (dd, J=8.4, 2.0, 1H), 6.19 (d, J=8.5, 1H),
4.95 (d, J=2.7, 1H), 4.48-4.39 (m, 1H), 2.61 (s, 1H), 1.04 (d,
J=6.9, 3H).
[0441] The compounds in Examples 109-114 may be prepared using
methods analogous to those described in the preceding and
subsequent examples.
Example 109
##STR00119##
[0442]
2-[2-(Benzooxazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-3-(4-
-chloro-phenyl)-propionic acid
Example 110
##STR00120##
[0443]
2-[2-(Benzooxazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,4-dic-
hloro-phenyl)-propionic acid
Example 111
##STR00121##
[0444]
2-[2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3,-
4-dichloro-phenyl)-propionic acid
Example 112
##STR00122##
[0445]
2-(Benzo[1,3]dioxole-4-sulfonylamino)-4-chloro-N-[2-(4-chloro-pheny-
l)-2-hydroxy-1-methyl-ethyl]-benzamide
Example 113
##STR00123##
[0446]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoyl-
amino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester
Example 114
##STR00124##
[0447]
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoyl-
amino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
pyridin-3-ylmethyl ester
Example 115
##STR00125##
[0448]
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-phenyl)-propionic acid
[0449]
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-phenyl)-propionic acid was prepared as in EXAMPLE
4, substituting (1S,2S)-pseudoephedrine glycinamide hydrate in Part
A. HPLC: R.sub.T=9.93 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16BrIN.sub.4O.sub.5S.sub.2, 687.33; m/z found,
685/687 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.23 (s,
1H), 8.33 (dd, J=7.1, 0.8, 1H), 8.15 (dd, J=8.8, 0.8, 1H), 8.01 (d,
J=1.5, 1H), 7.70 (dd, J=8.8, 7.1, 1H), 7.37-7.35 (m, 1H), 7.30 (s,
1H), 7.23 (dd, J=8.3, 1.5, 1H), 7.16-7.06 (m, 2H), 6.92 (d, J=8.3,
1H), 6.66 (d, J=7.4, 1H), 4.99 (q, J=6.1, 1H), 3.36-3.17 (m,
2H).
Example 116
##STR00126##
[0450]
(2S,3R)-3-(3,4-Dichloro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzoylamino]-butyric acid methyl ester
[0451] 2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoic acid
was coupled to (2S,3R)-2-amino-3-(3,4-dichloro-phenyl)-butyric acid
methyl ester as in EXAMPLE 1, Part C, to afford the title compound.
HPLC: R.sub.T=12.39 min. MS (ESI+): mass calcd. for
C.sub.24H.sub.19Cl.sub.2F.sub.2IN.sub.2O.sub.5S, 683.29; m/z found,
683/685 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.29 (s,
1H), 8.11 (d, J=1.6, 1H), 7.52-7.47 (m, 1H), 7.42 (dd, J=8.3, 1.6,
1H), 7.37 (d, J=13.9, 1H), 7.24 (d, J=2.1, 2H), 7.11 (d, J=8.3,
1H), 7.02-6.98 (m, 3H), 6.65 (d, J=8.3, 1H), 4.95-4.91 (m, 1H),
3.26 (s, 3H), 3.31 (quin, J=7.2, 1H), 1.43 (d, J=7.2, 3H).
Example 117
##STR00127##
[0452]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3,4-dichloro-phenyl)-propionic acid
[0453] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic
acid was coupled to (S)-2-amino-3-(3,4-dichloro-phenyl)-propionic
acid methyl ester hydrochloride as in EXAMPLE 1, Part C. The
resulting methyl ester was hydrolyzed as in EXAMPLE 2, Part E, to
afford the title compound. HPLC: R.sub.T=10.98 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 585.87;
m/z found, 583/585 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.35 (s, 1H), 8.36 (dd, J=7.0, 0.8, 1H), 8.21 (dd, J=8.8, 0.8,
1H), 7.74-7.69 (m, 1H), 7.34 (d, J=8.2, 1H), 7.21 (d, J=2.0, 1H),
7.15 (d, J=8.4, 1H), 6.97 (dd, J=8.2, 2.0, 1H), 6.93 (dd, J=8.4,
2.0, 1H), 6.44 (d, J=7.0, 1H), 4.95-5.00 (m, 1H), 3.32-3.16 (m,
2H).
Example 118
##STR00128##
[0454]
(R)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3,4-dichloro-phenyl)-propionic acid
[0455] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic
acid was coupled to (R)-2-amino-3-(3,4-dichloro-phenyl)-propionic
acid methyl ester hydrochloride as in EXAMPLE 1, Part C. The
resulting methyl ester was hydrolyzed as in EXAMPLE 2, Part E, to
afford the title compound. HPLC: R.sub.T=10.97 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 585.87;
m/z found, 583/585 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.36 (s, 1H), 8.36 (dd, J=7.0, 0.8, 1H), 8.21 (dd, J=8.8, 0.6,
1H), 7.74-7.70 (m, 2H), 7.34 (d, J=8.2, 1H), 7.21 (d, J=1.9, 1H),
7.15 (d, J=8.4, 1H), 6.97 (dd, J=8.2, 2.0, 1H), 6.93 (dd, J=8.4,
2.0, 1H), 6.44 (d, J=7.0, 1H), 4.98 (q, J=5.7, 1H), 3.32-3.15 (m,
2H).
Example 119
##STR00129##
[0456]
(S)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid
[0457] 2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoic acid
was coupled to (S)-2-amino-3-(3,4-dichloro-phenyl)-propionic acid
methyl ester hydrochloride as in EXAMPLE 1, Part C. The resulting
methyl ester was hydrolyzed as in EXAMPLE 2, Part E, to afford the
title compound. HPLC: R.sub.T=11.00 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3F.sub.2N.sub.2O.sub.5S.sub.2, 563.79; m/z
found, 561/563 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.45 (s, 1H), 7.75 (d, 1.9, 1H), 7.56-7.45 (m, 1H), 7.36 (d,
J=8.2, 1H), 7.29-7.25 (m, 2H), 7.05-6.97 (m, 4H), 6.62 (d, J=7.0,
1H), 5.03 (q, J=5.5, 1H), 3.39-3.17 (m, 2H).
Example 120
##STR00130##
[0458]
(R)-2-[4-Chloro-2-(2,6-difluoro-benzenesulfonylamino)-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid
[0459] 2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoic acid
was coupled to (R)-2-amino-3-(3,4-dichloro-phenyl)-propionic acid
methyl ester hydrochloride as in EXAMPLE 1, Part C. The resulting
methyl ester was hydrolyzed as in EXAMPLE 2, Part E, to afford the
title compound. HPLC: R.sub.T=11.00 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3F.sub.2N.sub.2O.sub.5S, 563.79; m/z found,
561/563 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.45 (s,
1H), 7.75 (d, J=1.9, 1H), 7.53-7.44 (m, 1H), 7.36 (d, J=8.2, 1H),
7.31-7.25 (m, 2H), 7.06-6.96 (m, 4H), 6.61 (d, J=6.9, 1H), 5.03 (d,
J=5.6, 1H), 3.38-3.17 (m, 2H).
Example 121
##STR00131##
[0460]
anti-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoy-
lamino]-3-(3,4-dichloro-phenyl)-3-hydroxy-propionic acid
[0461] A solution of
2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(-
3,4-dichloro-phenyl)-3-oxo-propionic acid methyl ester (35 mg,
0.057 mmol) in THF (2 mL) was cooled to -78.degree. C. and lithium
tri-sec-butylborohydride (L-Selectride; 1 M in THF, 86 .mu.L, 0.086
mmol) was added. The mixture was stirred at -78.degree. C. for 1 h
and water (0.1 mL), EtOH (0.1 mL), 15% NaOH (0.1 mL), and 30%
H.sub.2O.sub.2 (0.1 mL) were added and the solution was warmed to
rt. The mixture was diluted with satd. aq. Na.sub.2S.sub.2O.sub.3
and water and extracted with EtOAc (3.times.). The combined organic
layers were washed with brine, dried (MgSO.sub.4), and
concentrated. The crude product was purified by reverse phase HPLC
to provide
2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(-
3,4-dichloro-phenyl)-3-hydroxy-propionic acid methyl ester as a
single diastereomer (20 mg, 57%). The methyl ester was hydrolyzed
as in EXAMPLE 2, Part E, to provide the title compound (73%). HPLC:
R.sub.T=9.51 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 601.87; m/z found,
599/601 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.31 (s,
1H), 8.34 (dd, J=7.0, 0.6, 1H), 8.19 (dd, J=8.8, 0.6, 1H), 7.71
(dd, J=8.8, 7.1, 1H), 7.64 (d, J=1.9, 1H), 7.43 (d, J=1.7, 1H),
7.36 (d, J=8.3, 1H), 7.23 (d, J=8.5, 1H), 7.18 (dd, J=8.3, 1.8,
1H), 7.01 (d, J=7.3, 1H), 6.86 (dd, J=8.4, 1.9, 1H), 5.37 (d,
J=3.7, 1H), 5.10 (dd, J=7.3, 3.9, 1H).
Example 122
##STR00132##
[0462]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-4-chloro-phenyl)-propionic acid methyl ester
[0463] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic
acid was coupled to
(S)-2-amino-3-(3-bromo-4-chloro-phenyl)-propionic acid methyl ester
hydrochloride as in EXAMPLE 1, Part C, to afford the title
compound. HPLC: R.sub.T=10.85 min. MS (ESI+): mass calcd. for
C.sub.23H.sub.17BrClIN.sub.4O.sub.5S.sub.2, 735.80; m/z found,
735/737 [M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.31 (s,
1H), 8.36 (d, J=7.1, 1H), 8.22 (d, J=8.7, 1H), 8.08 (d, J=1.4, 1H),
7.72 (dd, J=8.8, 7.1, 1H), 7.36-7.28 (m, 3H), 6.96-6.90 (m, 2H),
6.46 (d, J=7.1, 1H), 4.93 (q, J=5.5, 1H), 3.82 (s, 3H), 3.23-3.10
(m, 2H).
Example 123
##STR00133##
[0464]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester
[0465] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic
acid was coupled to
(S)-2-amino-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester
hydrochloride as in EXAMPLE 1, Part C, to afford the title
compound. HPLC: R.sub.T=10.57 min. MS (ESI+): mass calcd. for
C.sub.23H.sub.17BrFIN.sub.4O.sub.5S.sub.2, 719.34; m/z found,
719/721 [M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.31 (s,
1H), 8.36 (dd, J=7.0, 0.7, 1H), 8.22 (dd, J=8.8, 0.7, 1H), 8.08 (d,
J=1.5, 1H), 7.72 (dd, J=8.8, 7.1, 1H), 7.32 (dd, J=8.2, 1.5, 1H),
7.23 (dd, J=6.5, 2.1, 1H), 7.06-6.99 (m, 1H), 6.98-6.89 (m, 2H),
6.46 (d, J=6.9, 1H), 4.93 (q, J=5.5, 1H), 3.82 (s, 3H), 3.25-3.08
(m, 2H).
Example 124
##STR00134##
[0466]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid methyl ester
[0467] 4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid was
coupled to (S)-2-amino-3-(3-bromo-4-fluoro-phenyl)-propionic acid
methyl ester hydrochloride as in EXAMPLE 1, Part C, to afford the
title compound. HPLC: R.sub.T=10.30 min. MS (ESI+): mass calcd. for
C.sub.25H.sub.19BrFIN.sub.4O.sub.5S, 713.32; m/z found, 713/715
[M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.09 (s, 1H), 8.99
(d, J=1.7, 1H), 8.92 (d, J=1.7, 1H), 8.58 (dd, J=7.3, 1.3, 1H),
8.33 (dd, J=8.5, 1.3, 1H), 8.09 (d, J=1.5, 1H), 7.90 (dd, J=8.3,
7.5, 1H), 7.30 (dd, J=8.2, 1.5, 1H), 7.25-7.23 (m, 1H), 7.05-6.98
(m, 1H), 6.98-6.90 (m, 2H), 6.43 (d, J=7.1, 1H), 4.90 (q, J=5.5,
1H), 3.81 (s, 3H), 3.20-3.08 (m, 2H).
Example 125
##STR00135##
[0468]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzoylamino]-propionic acid methyl ester
[0469] 2-(2,6-Difluoro-benzenesulfonylamino)-4-iodo-benzoic acid
was coupled to (S)-2-amino-3-(3-bromo-4-fluoro-phenyl)-propionic
acid methyl ester hydrochloride as in EXAMPLE 1, Part C, to afford
the title compound. HPLC: R.sub.T=10.54 min. MS (ESI+): mass calcd.
for C.sub.23H.sub.17BrF.sub.3IN.sub.2O.sub.5S, 697.26; m/z found,
697/699 [M+H].sup.+. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.37 (s,
1H), 8.11 (d, J=1.4, 1H), 7.55-7.44 (m, 1H), 7.40 (dd, J=8.3, 1.4,
1H), 7.27-7.26 (m, 1H), 7.09-7.04 (m, 2H), 7.02-6.96 (m, 3H), 6.63
(d, J=6.8, 1H), 4.98 (q, J=5.6, 1H), 3.81 (s, 3H), 3.27-3.13 (m,
2H).
Example 126
##STR00136##
[0470]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid
[0471]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyl-
amino)-benzoylamino]-propionic acid methyl ester was hydrolyzed as
in EXAMPLE 2, Part E, to afford the title compound. HPLC:
R.sub.T=9.68 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.17BrFIN.sub.4O.sub.5S, 699.29; m/z found, 697/699
[M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.86 (s, 1H), 9.00
(d, J=1.7, 1H), 8.91 (d, J=1.7, 1H), 8.53 (dd, J=7.4, 1.2, 1H),
8.31 (dd, J=8.5, 1.1, 1H), 8.08 (d, J=1.4, 1H), 7.88 (dd, J=8.3,
7.6, 1H), 7.33 (dd, J=6.3, 1.8, 1H), 7.28 (dd, J=8.3, 1.5, 1H),
7.08-6.98 (m, 2H), 6.86 (d, J=8.2, 1H), 6.35 (d, J=7.5, 1H), 4.89
(d, J=5.9, 1H), 3.30-3.07 (m, 2H).
Example 127
##STR00137##
[0472]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzoylamino]-propionic acid
[0473]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[2-(2,6-difluoro-benzenesulfonyla-
mino)-4-iodo-benzoylamino]-propionic acid methyl ester was
hydrolyzed as in EXAMPLE 2, Part E, to afford the title compound.
HPLC: R.sub.T=9.93 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrF.sub.3IN.sub.2O.sub.5S, 683.23; m/z found,
681/683 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.27 (s,
1H), 8.07 (d, J=1.4, 1H), 7.54-7.44 (m, 1H), 7.38 (dd, J=8.3, 1.4,
1H), 7.35 (dd, J=6.4, 1.9, 1H), 6.96-7.13 (m, 5H), 6.63 (d, J=6.9,
1H), 5.00 (q, J=5.7, 1H), 3.39-3.14 (m, 2H).
Example 128
##STR00138##
[0474]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3-ch-
loro-benzylcarbamoyl)-2-(3,4-dichloro-phenyl)-ethyl]-benzamide
[0475] A.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3-(3,4-dichloro-phenyl)-propionic acid methyl ester. To a
solution of
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chlorobenzoic acid
(300 mg, 0.81 mmol) in 1:4 THF/DMF (5 mL) at rt was added pyridine
(0.196 mL, 2.4 mmol) followed by HATU (616 mg, 1.6 mmol). The
mixture was stirred for 1 h, and (S)-3,4-dichlorophenylalanine
methyl ester hydrochloride (461 mg, 1.6 mmol) and Hunig's base
(0.282 mL, 1.6 mmol) were added. After 18 h, the mixture was poured
into 1 N HCl and extracted with EtOAc (4.times.). The combined
organic extracts were washed with water (3.times.), dried
(Na.sub.2SO.sub.4), and concentrated to provide the crude methyl
ester, which was used without further purification. .sup.1H NMR
(400 MHz, CDCl.sub.3): 11.48 (br s, 1H), 8.38 (dd, J=7.0, 1.0, 1H),
8.23 (dd, J=8.8, 1.0, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.73 (d,
J=1.8, 1H), 7.34 (d, J=8.2, 1H), 7.19 (d, J=8.4, 1H), 7.14 (d,
J=2.0, 1H), 6.96 (dd, J=8.4, 2.0, 1H), 6.90 (dd, J=8.2, 2.0, 1H),
6.48 (br d, J=7.1, 1H), 5.00-4.93 (m, 1H), 3.82 (s, 3H), 3.22 (dd,
J=14.1, 5.9, 1H), 3.16 (dd, J=14.0, 5.1, 1H).
[0476] B.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benz-
oylamino]-3-(3,4-dichloro-phenyl)-propionic acid. A mixture of
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid methyl ester (0.81 mmol),
THF (10 mL), and LiOH (2 M in water, 5 mL) was stirred vigorously
overnight at rt. The mixture was poured into water, acidified to pH
1 with conc. HCl, and extracted with EtOAc (4.times.). The combined
organic layers were dried (Na.sub.2SO.sub.4) and concentrated to
provide the desired acid as a tan solid. The acid was purified by
preparative reverse phase HPLC to provide 0.44 g (94%, 2 steps) of
the acid as a white solid. HPLC: R.sub.T=10.08 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.15Cl.sub.3N.sub.4S.sub.5O.sub.2, 583.95;
m/z found, 583 [M-H].sup.-. .sup.1H NMR (400 MHz, CD.sub.3OD): 8.34
(dd, J=7.0, 1.0, 1H), 8.25 (dd, J=8.8, 1.0, 1H), 7.77 (dd, J=8.8,
7.0, 1H), 7.66 (d, J=2.0, 1H), 7.45-7.37 (m, 3H), 7.18 (dd, J=8.2,
2.0, 1H), 6.99 (dd, J=8.5, 2.1, 1H), 4.75 (dd, J=9.3, 5.2, 1H),
3.28 (dd, J=14.0, 5.1, 1H), 3.03 (dd, J=14.0, 9.4, 1H).
[0477] C.
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3-
-chloro-benzylcarbamoyl)-2-(3,4-dichloro-phenyl)-ethyl]-benzamide.
The title compound (29 mg, 48%) was obtained from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid and 3-chlorobenzylamine as
in Example 1, Part C. HPLC: R.sub.T=10.95 min. MS (ESI-): mass
calcd. for C.sub.29H.sub.21Cl.sub.4N.sub.5O.sub.4S.sub.2, 709.45;
m/z found, 706/708 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.55 (s, 1H), 8.39 (dd, J=7.0, 0.9, 1H), 8.22 (dd, J=8.8, 0.8,
1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.70 (d, J=2.0, 1H), 7.38-7.30 (m,
3H), 7.16 (d, J=0.5, 1H), 7.05-6.99 (m, 2H), 6.96 (dd, J=8.5, 2.0,
1H), 6.88-6.81 (m, 1H), 5.87-5.80 (m, 1H), 4.70-4.61 (m, 1H),
4.49-4.41 (m, 1H), 4.34-4.26 (m, 1H), 3.17-3.09 (m, 1H), 3.06-2.96
(m, 1H).
Example 129
##STR00139##
[0478]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[1-benzylcarbamoy-
l-2-(3,4-dichloro-phenyl)-ethyl]-4-chloro-benzamide
[0479] The title compound (19 mg, 33%) was obtained from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid and benzyl amine as in
Example 1, Part C. HPLC: R.sub.T=10.73 min. MS (ESI-): mass calcd.
for C.sub.29H.sub.22Cl.sub.3N.sub.5O.sub.4S.sub.2, 675.01; m/z
found, 672/674 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.59 (s, 1H), 8.38 (dd, J=7.1, 0.7, 1H), 8.20 (d, J=8.8, 1H),
7.74-7.71 (m, 2H), 7.37-7.25 (m, 5H), 7.13-7.11 (m, 2H), 7.03-6.98
(m, 1H), 6.96-6.87 (m, 2H), 5.79-5.71 (m, 1H), 4.66-4.61 (m, 1H),
4.50-4.45 (m, 1H), 4.33-4.29 (m, 1H), 3.14-3.10 (m, 1H), 3.00-2.96
(m, 1H),
Example 130
##STR00140##
[0480]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4--
dichloro-phenyl)-(4-fluoro-benzylcarbamoyl)-ethyl]-benzamide
[0481] The title compound (27 mg, 46%) was obtained from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid and 4-fluorobenzyl amine as
in Example 1, Part C. HPLC: R.sub.T=10.66 min. MS (ESI-): mass
calcd. for C.sub.29H.sub.21Cl.sub.3FN.sub.5O.sub.4S.sub.2, 693.00;
m/z found, 690/692 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.55 (s, 1H), 8.38 (dd, J=7.0, 0.8, 1H), 8.21 (dd, J=8.8, 0.6,
1H), 7.72 (dd, J=8.8, 7.1, 1H), 7.68 (d, J=1.9, 1H), 7.35-7.32 (m,
1H), 7.30-7.25 (m, 2H), 7.12-7.07 (m, 2H), 7.05-6.99 (m, 5H), 6.94
(dd, J=8.4, 1.9, 1H), 6.88-6.81 (m, 1H), 5.79-5.72 (m, 1H),
4.67-4.59 (m, 1H), 4.47-4.40 (m, 1H), 4.29-4.25 (m, 1H), 3.15-3.11
(m, 1H), 3.00-2.96 (m, 1H).
Example 131
##STR00141##
[0482]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoyla-
mino]-3-(3,4-dichloro-phenyl)-propionic acid
[0483] A. 4-Bromo-2-nitrobenzoic acid. The title compound (1.22 g,
22%) was prepared as in Example 20, Part A. MS (ESI-): mass calcd.
for C.sub.7H.sub.4BrNO.sub.4, 244.93; m/z found, 244 [M-H].sup.-.
.sup.1H NMR (400 MHz, CD.sub.3OD): 8.07 (d, J=1.9, 1H), 7.85 (dd,
J=8.2, 1.9, 1H), 7.65 (d, J=8.2, 1H).
[0484] B. Methyl 2-amino-4-bromobenzoate. The title compound (2.89
g, 93%) was prepared as in Example 20, Part B. .sup.1H NMR (400
MHz, CDCl.sub.3): 7.70 (d, J=8.6, 1H), 6.84 (d, J=1.9, 1H), 6.75
(dd, J=8.6, 1.9, 1H), 5.78 (br s, 2H), 3.86 (s, 3H).
[0485] C.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid
methyl ester. The title compound (3.95 g, 75%) was prepared as in
Example 20, Part C (without DMAP). MS (ESI-): mass calcd. for
C.sub.14H.sub.10BrN.sub.3O.sub.4S.sub.2, 429.93; m/z found, 426
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.34 (br s, 1H),
8.40 (dd, J=7.0, 0.9, 1H), 8.24 (dd, J=8.8, 0.9, 1H), 7.92 (d,
J=1.8, 1H), 7.74 (dd, J=8.8, 7.0, 1H), 7.72 (d, J=8.5, 1H), 7.10
(dd, J=8.5, 1.8, 1H), 3.92 (s, 3H).
[0486] D.
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid.
The title compound (2.76 g, 97%) was prepared as in Example 20,
Part D. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.14 (br s, 1H), 8.42
(dd, J=7.2, 1.1, 1H), 8.26 (dd, J=8.8, 1.1, 1H), 7.98 (d, J=1.6,
1H), 7.82 (d, J=8.5, 1H), 7.75 (dd, J=8.8, 7.2, 1H), 7.16 (dd,
J=8.5, 1.6, 1H).
[0487] E.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzo-
ylamino]-3-(3,4-dichloro-phenyl)-propionic acid methyl ester. The
title compound (61 mg, 95%) was prepared from
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromobenzoic acid and
(S)-3,4-dichlorophenylalanine methyl ester hydrochloride as in
Example 1, Part C. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.43 (br s,
1H), 8.38 (dd, J=7.0, 1.0, 1H), 8.23 (dd, J=8.8, 1.0, 1H), 7.90 (t,
J=1.0, 1H), 7.73 (dd, J=8.8, 7.0, 1H), 7.35 (d, J=8.2, 1H), 7.14
(d, J=2.0, 1H), 7.11 (d, J=1.0, 2H), 6.89 (dd, J=8.2, 2.1, 1H),
6.48 (br d, J=7.1, 1H), 5.00-4.92 (m, 1H), 3.82 (s, 3H), 3.22 (dd,
J=14.0, 5.8, 1H), 3.16 (dd, J=14.0, 5.1, 1H).
[0488] F.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzo-
ylamino]-3-(3,4-dichloro-phenyl)-propionic acid. The title compound
(43 mg, 72%) was prepared as in Example 94, Part B. HPLC:
R.sub.T=10.14 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrCl.sub.2N.sub.4O.sub.5S.sub.2, 630.32; m/z found,
627/629 [M-H].sup.-. .sup.1H NMR (500 MHz, MeOD): 8.32 (dd, J=7.0,
0.8, 1H), 8.24 (dd, J=8.8, 0.9, 1H), 7.81 (d, J=1.8, 1H), 7.76 (dd,
J=8.8, 7.1, 1H), 7.44-7.38 (m, 2H), 7.31 (d, J=8.4, 1H), 7.19-7.13
(m, 2H), 4.76-4.70 (m, 1H), 3.29-3.24 (m, 1H), 3.02 (dd, J=14.0,
9.4, 1H).
Example 132
##STR00142##
[0489]
(S)-3-(3,4-Dichloro-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonylamin-
o)-benzoylamino]-propionic acid
[0490] 4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid was
coupled with (S)-2-amino-3-(3,4-dichloro-phenyl)-propionic acid
methyl ester hydrochloride as in Example 1, Part C. The resulting
methyl ester was hydrolyzed as in EXAMPLE 2, Part E, to afford the
title compound. HPLC: R.sub.T=10.05 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.17Cl.sub.2IN.sub.4O.sub.5S, 671.29; m/z found,
669/671 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.86 (s,
1H), 9.01 (d, J=1.6, 1H), 8.92 (d, J=1.6, 1H), 8.55 (dd, J=7.3,
1.0, 1H), 8.32 (dd, J=8.5, 1.0, 1H), 8.08 (d, J=1.3, 1H), 7.91-7.88
(m, 1H), 7.34 (d, J=8.2, 1H), 7.30-7.24 (m, 2H), 6.98 (dd, J=8.2,
1.9, 1H), 6.88 (d, J=8.2, 1H), 6.38 (d, J=7.3, 1H), 4.90 (q, J=5.9,
1H), 3.28-3.12 (m, 2H).
Example 133
##STR00143##
[0491]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(2,4-dichloro-phenyl)-propionic acid
[0492]
(S)-2-tert-Butoxycarbonylamino-3-(2,4-dichloro-phenyl)-propionic
acid was treated as in EXAMPLE 2, Part A, to produce
(S)-2-amino-3-(2,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride as a white solid. This ester was coupled to
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic acid as
in EXAMPLE 1, Part C. The resulting methyl ester was hydrolyzed as
in EXAMPLE 2, Part E, to afford the title compound. HPLC:
R.sub.T=10.19 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.2IN.sub.4O.sub.5S.sub.2, 677.32; m/z found,
675/677 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 11.16 (s,
1H), 8.34 (d, J=7.1, 1H), 8.21 (d, J=8.8, 1H), 8.07-8.05 (m, 1H),
7.71 (dd, J=8.8, 7.1, 1H), 7.40-7.39 (m, 1H), 7.32-7.26 (m, 1H),
7.24-7.22 (m, 2H), 6.94 (d, J=8.3, 1H), 6.53 (d, J=7.5, 1H),
5.02-4.95 (m, 1H), 3.53-3.44 (m, 1H), 3.34-3.24 (m, 1H).
Example 134
##STR00144##
[0493]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(2,4-dichloro-5-fluoro-phenyl)-propionic acid
[0494] The title compound was prepared as in EXAMPLE 4,
substituting 2,4-dichloro-5-fluorobenzyl bromide in Part B. HPLC:
R.sub.T=10.21 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.14Cl.sub.2FIN.sub.4O.sub.5S.sub.2, 695.31; m/z found,
693/695 [M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 11.75 (s,
1H), 9.07 (d, J=7.9, 1H), 8.42-8.40 (m, 2H), 7.88 (t, J=7.9, 1H),
7.83-7.81 (m, 2H), 7.46-7.44 (m, 2H), 7.38-7.36 (m, 1H), 4.68-4.65
(m, 1H), 3.40-3.20 (m, 1H), 3.14-3.08 (m, 1H).
Example 135
##STR00145##
[0495]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3-iodo-phenyl)-propionic acid
[0496] The title compound was prepared as in EXAMPLE 4,
substituting 3-iodobenzyl bromide in Part B. HPLC: R.sub.T=10.03
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.16I.sub.2N.sub.4O.sub.5S.sub.2, 734.33; m/z found,
733 [M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 11.76 (s,
1H), 9.01 (d, J=7.9, 1H), 8.42-8.40 (m, 2H), 7.88 (t, J=7.9, 1H),
7.82 (d, J=1.5, 1H), 7.68 (s, 1H), 7.57 (d, J=7.9, 1H), 7.43 (d,
J=8.2, 1H), 7.36 (d, J=8.3, 1H), 7.29 (d, J=7.6, 1H), 7.08 (t,
J=7.7, 1H), 4.59-4.54 (m, 1H), 3.18-3.13 (m, 1H), 2.99-2.93 (m,
1H).
Example 136
##STR00146##
[0497]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(4-chloro-3-iodo-phenyl)-propionic acid methyl ester
[0498] 2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic
acid was coupled to
(S)-2-amino-3-(4-chloro-3-iodo-phenyl)-propionic acid methyl ester
hydrochloride as in EXAMPLE 1, Part C, to afford title compound.
HPLC: R.sub.T=10.87 min. MS (ESI+): mass calcd. for
C.sub.23H.sub.17ClI.sub.2N.sub.4O.sub.5S.sub.2, 782.80; m/z found,
783/785 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.31 (s,
1H), 8.37 (dd, J=7.0, 0.9, 1H), 8.23 (dd, J=8.8, 0.9, 1H), 8.09 (d,
J=1.5, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.55 (d, J=2.0, 1H),
7.35-7.33 (m, 2H), 7.00-6.94 (m, 2H), 6.46 (d, J=7.1, 1H),
4.97-4.91 (m, 1H), 3.82 (s, 3H), 3.21-3.10 (m, 2H).
Example 137
##STR00147##
[0499]
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyla-
mino)-benzoylamino]-propionic acid methyl ester
[0500] 4-Iodo-2-(quinoxaline-5-sulfonylamino)-benzoic acid was
coupled to (S)-2-amino-3-(4-chloro-3-iodo-phenyl)-propionic acid
methyl ester hydrochloride as in EXAMPLE 1, Part C, to afford title
compound. HPLC: R.sub.T=10.61 min. MS (ESI+): mass calcd. for
C.sub.25H.sub.19ClI.sub.2N.sub.4O.sub.5S, 776.77; m/z found,
777/779 [M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.09 (s,
1H), 9.01-8.98 (m, 1H), 8.95-8.92 (m, 1H), 8.58 (d, J=7.3, 1H),
8.34 (d, J=8.5, 1H), 8.11 (d, J=1.5, 1H), 7.94-7.88 (m, 1H), 7.57
(d, J=1.9, 1H), 7.36-7.26 (m, 2H), 7.00-6.94 (m, 2H), 6.42 (d,
J=6.3, 1H), 4.95-4.88 (m, 1H), 3.81 (s, 3H), 3.20-3.07 (m, 2H).
Example 138
##STR00148##
[0501]
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyla-
mino)-benzoylamino]-propionic acid
[0502]
(S)-3-(4-Chloro-3-iodo-phenyl)-2-[4-iodo-2-(quinoxaline-5-sulfonyla-
mino)-benzoylamino]-propionic acid methyl ester was hydrolyzed as
in EXAMPLE 2, Part E, to afford the title compound. HPLC:
R.sub.T=10.01 min. MS (ESI-): mass calcd. for
C.sub.24H.sub.17ClI.sub.2N.sub.4O.sub.5S.sub.2, 762.74; m/z found,
761/763 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3): 10.92 (s,
1H), 8.99 (d, J=1.7, 1H), 8.92 (d, J=1.6, 1H), 8.56-8.52 (m, 1H),
8.33-8.29 (m, 1H), 8.10 (d, J=1.3, 1H), 7.88 (m, 1H), 7.62 (d,
J=1.8, 1H), 7.35-7.25 (m, 2H), 7.08-7.02 (m, 1H), 6.89 (d, J=8.2,
1H), 6.31 (d, J=7.3, 1H), 4.92-4.86 (m, 1H), 3.24-3.08 (m, 2H).
Example 139
##STR00149##
[0503]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[2-(3,4--
dichloro-phenyl)-phenylcarbamoyl-ethyl]-benzamide
[0504] The title compound (25 mg, 45%) was prepared from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid and aniline as in Example
1, Part C. HPLC: R.sub.T=10.81 min. MS (ESI-): mass calcd. for
C.sub.28H.sub.20Cl.sub.3N.sub.5O.sub.4S.sub.2, 660.98; m/z found,
658/660 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.54 (s,
1H), 8.39 (dd, J=7.1, 1.0, 1H), 8.19 (dd, J=8.8, 0.8, 1H),
7.75-7.67 (m, 2H), 7.67-7.62 (m, 1H), 7.47-7.42 (m, 2H), 7.42-7.33
(m, 4H), 7.26-7.23 (m, 1H), 7.11-7.09 (m, 1H), 6.96-6.90 (m, 2H),
4.84-4.77 (m, 1H), 3.23-3.10 (m, 2H).
Example 140
##STR00150##
[0505]
(S)-2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-N-[1-(3,4--
dichloro-benzyl)-2-oxo-2-piperidin-1-yl-ethyl]-benzamide
[0506] The title compound (37 mg, 66%) was prepared from
(S)-2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-propionic acid and piperidine as in
Example 1, Part C. HPLC: R.sub.T=11.00 min. MS (ESI-): mass calcd.
for C.sub.27H.sub.24Cl.sub.3N.sub.5O.sub.4S.sub.2, 653.00; m/z
found, 650/652 [M-H].sup.-. .sup.1H NMR (500 MHz, CDCl.sub.3):
11.70 (m, 1H), 8.38 (d, J=7.0, 1H), 8.21 (d, J=8.8, 1H), 7.72 (dd,
J=8.8, 7.1, 1H), 7.69 (d, J=1.9, 1H), 7.35 (d, J=8.2, 1H),
7.28-7.25 (m, 1H), 7.22 (d, J=1.9, 1H), 7.13 (d, J=7.4, 1H), 6.99
(dd, J=8.2, 1.9, 1H), 6.92 (dd, J=8.4, 1.9, 1H), 5.26-5.21 (m, 1H),
3.62-3.49 (m, 2H), 3.43-3.35 (m, 1H), 3.26-3.19 (m, 1H), 3.08-2.95
(m, 2H), 1.70-1.46 (m, 5H), 1.33-1.23 (m, 1H).
Example 141
##STR00151##
[0507]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3,4-dichloro-phenyl)-propionic acid
[0508] The title compound was prepared as in EXAMPLE 1,
substituting 2-amino-3-(3,4-dichloro-phenyl)-propionic acid methyl
ester hydrochloride (prepared as in Example 2, Part A) and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid in Part C. HPLC: R.sub.T=10.48 min. MS (ESI-): mass calcd. for
C.sub.22H.sub.14Cl.sub.4N.sub.4O.sub.5S.sub.2, 620.31; m/z found,
617/619/621 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6):
11.64 (s, 1H), 8.53 (s, 2H), 8.46 (d, J=7.0, 1H), 8.29 (d, J=8.7,
1H), 7.89 (dd, J=8.8, 7.1, 1H), 7.83 (s, 1H), 7.75 (s, 1H), 7.56
(d, J=1.8, 1H), 7.49 (d, J=8.2, 1H), 7.34 (dd, J=8.2, 1.8, 1H),
5.00-4.94 (m, 1H), 3.40-3.36 (m, 1H), 3.25-3.17 (m, 1H).
Example 142
##STR00152##
[0509]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoyla-
mino]-3-(3-bromo-4-chloro-phenyl)-propionic acid methyl ester
[0510] The title compound was prepared as in EXAMPLE 4,
substituting 3-bromo-4-chlorobenzyl bromide in Part B, substituting
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid in
Part E, and eliminating the LiOH hydrolysis step in Part E. HPLC:
R.sub.T=10.67 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17Br.sub.2ClN.sub.4O.sub.5S.sub.2, 688.80; m/z found,
687/689 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.42 (s,
1H), 8.36 (dd, J=7.0, 0.9, 1H), 8.22 (dd, J=8.8, 0.9, 1H), 7.88 (d,
J=1.7, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.35-7.32 (m, 1H), 7.18-7.05
(m, 2H), 6.96 (dd, J=8.2, 2.0, 1H), 6.57 (d, J=7.0, 1H), 4.97-4.92
(m, 1H), 3.82 (s, 3H), 3.25-3.09 (m, 2H).
Example 143
##STR00153##
[0511]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoyla-
mino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester
[0512] A. 2-Acetylamino-3-(3-bromo-4-fluoro-phenyl)-acrylic acid. A
mixture of 3-bromo-4-fluorobenzaldehyde (50.0 g, 0.25 mol),
N-acetylglycine (26.2 g, 0.22 mol), NaOAc (13.8 g, 0.56 mol), and
Ac.sub.2O (52 mL) was heated at 130.degree. C. for 10 h in a flask
fitted with a reflux condenser. The resulting precipitate was
collected by filtration, washed with water, and suspended in AcOH
(250 mL). This mixture was heated at 100.degree. C. for 1 h in a
flask fitted with a reflux condenser, and then was cooled to
0.degree. C. The solids were collected by filtration, washing with
water, to give the product as a yellow solid (53.5 g, 76%). MS
(ESI-): mass calcd. for C.sub.11H.sub.9BrFNO.sub.3, 301.0; m/z
found, 299.9 [M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6):
12.80 (br s, 1H), 9.52 (br s, 1H), 7.93 (dd, J=6.9, 1.9, 1H), 7.66
(ddd, J=8.4, 4.8, 1.9, 1H), 7.42 (t, J=8.7, 1H), 7.19 (s, 1H), 1.98
(s, 3H).
[0513] B. (S)-2-Acetylamino-3-(3-bromo-4-fluoro-phenyl)-propionic
acid. A mixture of bis(1,5-cyclooctadiene)rhodium(I)
trifluoromethanesulfonate (0.11 g, 0.18 mmol) and
(R)--N-diphenylphosphino-N-methyl-1-[(S)-2-diphenylphosphino)ferrocenyl]e-
thylamine [(R)-methyl BoPhoz; 70 mg, 0.15 mmol] in MeOH (150 mL)
under N.sub.2 was stirred for 30 min.
2-Acetylamino-3-(3-bromo-4-fluoro-phenyl)-acrylic acid (4.5 g, 15
mmol) was added, and the mixture was stirred under H.sub.2 (40 psi)
on a Parr apparatus for 18 h. The mixture was concentrated to give
the title compound as an orange oil (4.5 g, 100%). MS (ESI-): mass
calcd. for C.sub.11H.sub.11BrFNO.sub.3, 303.0; m/z found, 301.8
[M-H].sup.-. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 7.50 (dd, J=6.7,
2.1, 1H), 7.24 (ddd, J=8.4, 4.7, 2.2, 1H), 7.13 (t, J=8.6, 1H),
4.65 (dd, J=9.0, 5.2, 1H), 3.19 (dd, J=14.0, 5.2, 1H), 2.93 (dd,
J=14.0, 9.0, 1H), 1.93 (s, 3H).
[0514] C. 3-Bromo-4-fluoro-L-phenylalanine hydrochloride. A
suspension of
(S)-2-acetylamino-3-(3-bromo-4-fluoro-phenyl)-propionic acid (2.5
g, 8.2 mmol) in HCl (6.0 M in water, 5.0 mL) was heated at
100.degree. C. for 2 h and then cooled to 0.degree. C. The
resulting solid was collected by filtration to give the title
phenylalanine as a light tan solid (2.1 g, 86%). MS (ESI+): mass
calcd. for C.sub.9H.sub.9BrFNO.sub.2, 261.0; m/z found, 261.8
[M+H].sup.+. .sup.1H NMR (400 MHz, D.sub.2O): 7.50 (dd, J=6.6, 2.1,
1H), 7.21 (ddd, J=8.4, 4.7, 2.2, 1H), 7.14 (t, J=8.7, 1H), 3.90
(dd, J=7.7, 5.5, 1H), 3.16 (dd, J=14.7, 5.4, 1H), 3.04 (dd, J=14.7,
7.7, 1H).
[0515] D. 3-Bromo-4-fluoro-L-phenylalanine methyl ester
hydrochloride. 3-Bromo-4-fluoro-L-phenylalanine hydrochloride was
converted to the methyl ester as described in EXAMPLE 2, Part
A.
[0516] E.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzo-
ylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester.
The title compound was prepared as in EXAMPLE 1, substituting
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid in
Part C. HPLC: R.sub.T=10.39 min. MS (ESI-): mass calcd. for
C.sub.23H.sub.17Br.sub.2FN.sub.4O.sub.5S.sub.2, 672.34; m/z found,
671 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.42 (s, 1H),
8.37 (d, J=7.1, 1H), 8.22 (d, J=8.8, 1H), 7.88 (s, 1H), 7.75-7.71
(m, 1H), 7.27-7.25 (m, 1H), 7.11 (q, J=8.4, 2H), 7.09-6.94 (m, 2H),
6.56 (d, J=7.0, 1H), 4.94 (q, J=5.8, 1H), 3.82 (s, 3H), 3.25-3.11
(m, 2H).
Example 144
##STR00154##
[0517]
(Z)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3,4-dichloro-phenyl)-acrylic acid
[0518] To a solution of
2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(-
3,4-dichloro-phenyl)-3-hydroxy-propionic acid methyl ester (42 mg,
0.068 mmol) in DCM (1.5 mL) was added Et.sub.3N (38 .mu.L, 0.273
mmol) and the mixture was cooled to 0.degree. C. MsCl (8 .mu.L,
0.102 mmol) was added and the mixture was warmed to rt and stirred
for 1.5 h. The mixture was heated to 50.degree. C., treated with
catalytic DMAP, and stirred overnight. The mixture was diluted with
satd. aq. NaHCO.sub.3 and extracted with DCM (3.times.). The
combined organic layers were dried (MgSO.sub.4) and concentrated to
provide
2-[2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoylamino]-
-3-(3,4-dichloro-phenyl)-acrylic acid methyl ester. The crude
product was hydrolyzed as in EXAMPLE 2, Part E, to provide the
title compound (25% for two steps). HPLC: R.sub.T=9.97 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 618.30; m/z found,
581/583 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6): 11.82
(s, 1H), 9.37 (d, J=5.1, 1H), 8.48 (d, J=7.1, 1H), 8.34 (dd, J=8.8,
0.9, 1H), 7.96-7.86 (m, 2H), 7.82-7.75 (m, 2H), 7.64-7.55 (m, 3H),
7.11 (dd, J=8.5, 2.0, 1H).
Example 145
##STR00155##
[0519]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3-bromo-4-chloro-phenyl)-propionic acid
[0520]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3-bromo-4-chloro-phenyl)-propionic acid was prepared from
3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
as in EXAMPLE 1, Part C. Hydrolysis of the methyl ester as in
EXAMPLE 2, Part E, provided the title compound. HPLC: R.sub.T=10.07
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15BrCl.sub.2N.sub.4O.sub.5S.sub.2, 630.32; m/z found,
629/631 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.35 (s,
1H), 8.36 (d, J=7.0, 1H), 8.20 (d, J=8.8, 1H), 7.76-7.69 (m, 2H),
7.41 (d, J=1.7, 1H), 7.36 (d, J=8.2, 1H), 7.17 (d, J=8.5, 1H), 7.05
(dd, J=8.2, 1.8, 1H), 6.91 (dd, J=8.4, 1.8, 1H), 6.53 (d, J=7.1,
1H), 5.04-4.95 (m, 1H), 3.36-3.15 (m, 2H).
Example 146
##STR00156##
[0521]
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfon-
ylamino)-benzoylamino]-propionic acid
[0522]
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfon-
ylamino)-benzoylamino]-propionic acid was prepared from
3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in Example
1, Part C. Hydrolysis of the methyl ester as in EXAMPLE 2, Part E,
provided the title compound. HPLC: R.sub.T=9.80 min. MS (ESI-):
mass calcd. for C.sub.24H.sub.17BrCl.sub.2N.sub.4O.sub.5S, 624.29;
m/z found, 621/623/625 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.04 (s, 1H), 8.98 (d, J=1.6, 1H), 8.90 (d, J=1.6,
1H), 8.54 (dd, J=7.3, 1.0, 1H), 8.28 (dd, J=8.4, 0.9, 1H),
7.91-7.86 (m, 1H), 7.71 (d, J=1.9, 1H), 7.43 (d, J=1.8, 1H), 7.33
(d, J=8.2, 1H), 7.13 (d, J=8.4, 1H), 7.05 (dd, J=8.2, 1.9, 1H),
6.86 (dd, J=8.4, 1.9, 1H), 6.53 (d, J=7.5, 1H), 4.91 (q, J=6.2,
1H), 3.34-3.09 (m, 2H).
Example 147
##STR00157##
[0523]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-chloro-phenyl)-propionic acid
[0524]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-chloro-phenyl)-propionic acid was prepared
from 3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride
and 4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in
Example 1, Part C. Hydrolysis of the methyl ester as in EXAMPLE 2,
Part E, provided the title compound. HPLC: R.sub.T=10.43 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.14BrCl.sub.3N.sub.4O.sub.5S.sub.2, 664.76; m/z found,
661/663/665 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.12
(s, 1H), 8.34 (d, J=7.0, 1H), 8.19 (d, J=8.8, 1H), 7.77 (s, 1H),
7.71 (dd, J=8.6, 7.2, 1H), 7.43 (d, J=1.7, 1H), 7.36-7.31 (m, 2H),
7.07 (dd, J=8.2, 1.6, 1H), 6.78 (d, J=7.3, 1H), 4.97 (q, J=6.3,
1H), 3.32-3.14 (m, 2H).
Example 148
##STR00158##
[0525]
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-su-
lfonylamino)-benzoylamino]-propionic acid
[0526]
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-su-
lfonylamino)-benzoylamino]-propionic acid was prepared from
3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and
4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid (prepared
from quinoxaline-5-sulfonyl chloride as in EXAMPLE 14, Part A) as
in Example 1, Part C. Hydrolysis of the methyl ester as in EXAMPLE
2, Part E, provided the title compound. HPLC: R.sub.T=10.21 min. MS
(ESI-): mass calcd. for C.sub.24H.sub.16BrCl.sub.3N.sub.4O.sub.5S,
658.74; m/z found, 655/657/659 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 10.83 (s, 1H), 8.98 (d, J=1.8, 1H), 8.92 (d, J=1.7,
1H), 8.52 (dd, J=7.3, 1.2, 1H), 8.30 (dd, J=8.5, 1.3, 1H), 7.88 (d,
J=7.5, 1H), 7.85 (s, 1H), 7.43-7.42 (m, 1H), 7.37-7.34 (m, 1H),
7.07-7.02 (m, 1H), 6.47 (d, J=7.6, 1H), 4.91-4.85 (m, 1H),
3.24-3.09 (m, 2H).
Example 149
##STR00159##
[0527]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl ester
[0528] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
as in Example 1, Part C. HPLC: R.sub.T=10.36 min. MS (ESI-): mass
calcd. for C.sub.23H.sub.17BrClFN.sub.4O.sub.5S.sub.2, 627.89; m/z
found, 625/627 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.46 (s, 1H), 8.37 (dd, J=7.0, 0.8, 1H), 8.22 (dd, J=8.8, 0.9,
1H), 7.75-7.68 (m, 2H), 7.32-7.14 (m, 2H), 7.09-6.88 (m, 3H), 6.53
(d, J=6.8, 1H), 4.98-4.90 (m, 1H), 3.82 (s, 3H), 3.24-3.10 (m,
2H).
Example 150
##STR00160##
[0529]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid methyl
ester
[0530] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid as in Example 1, Part C. HPLC: R.sub.T=10.74 min. MS (ESI-):
mass calcd. for C.sub.23H.sub.16BrCl.sub.2FN.sub.4O.sub.5S.sub.2,
662.34; m/z found, 659/661 [M-H].sup.-. .sup.1H NMR (500 MHz,
CDCl.sub.3): 11.16 (s, 1H), 8.36 (dd, J=7.1, 0.8, 1H), 8.24 (dd,
J=8.8, 0.8, 1H), 7.86 (s, 1H), 7.74 (dd, J=8.8, 7.1, 1H), 7.33 (s,
1H), 7.30-7.27 (m, 1H), 7.06 (t, J=8.3, 1H), 7.03-6.98 (m, 1H),
6.53 (d, J=7.1, 1H), 4.93 (q, J=5.8, 1H), 3.22 (s, 3H), 3.24-3.11
(m, 2H).
Example 151
##STR00161##
[0531]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfony-
lamino)-benzoylamino]-propionic acid methyl ester
[0532] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4-bromo-2-(quinoxaline-5-sulfonylamino)-benzoic acid (EXAMPLE 8,
Parts A-E, substituting 2-amino-4-bromo-benzoic acid methyl ester
in Part D) as in Example 1, Part C. HPLC: R.sub.T=10.11 min. MS
(ESI-): mass calcd. for C.sub.25H.sub.19Br.sub.2FN.sub.4O.sub.5S,
666.31; m/z found, 665/667 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.19 (s, 1H), 8.98 (d, J=1.5, 1H), 8.92 (d, J=1.4,
1H), 8.58 (d, J=7.3, 1H), 8.33 (d, J=8.5, 1H), 7.94-7.86 (m, 2H),
7.25 (d, J=1.9, 1H), 7.12-6.92 (m, 4H), 6.45 (d, J=7.1, 1H), 4.92
(q, J=5.7, 1H), 3.81 (s, 3H), 3.22-3.09 (m, 2H).
Example 152
##STR00162##
[0533]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfon-
ylamino)-benzoylamino]-propionic acid methyl ester
[0534] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in Example
1, Part C. HPLC: R.sub.T=10.09 min. MS (ESI-): mass calcd. for
C.sub.25H.sub.19BrClFN.sub.4O.sub.5S, 621.86; m/z found, 619/621
[M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.24 (s, 1H), 8.98
(d, J=1.6, 1H), 8.92 (d, J=1.6, 1H), 8.58 (dd, J=7.3, 1.1, 1H),
8.33 (dd, J=8.5, 1.1, 1H), 7.92-7.86 (m, 1H), 7.76 (d, J=1.9, 1H),
7.28-7.25 (m, 1H), 7.19 (d, J=8.4, 1H), 7.06-6.94 (m, 2H), 6.92
(dd, J=8.4, 1.9, 1H), 6.48 (d, J=7.2, 1H), 4.92 (q, J=5.7, 1H),
3.81 (s, 3H), 3.22-3.09 (m, 2H).
Example 153
##STR00163##
[0535]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-su-
lfonylamino)-benzoylamino]-propionic acid methyl ester
[0536] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid (prepared
from quinoxaline-5-sulfonyl chloride as in EXAMPLE 14, Part A) as
in Example 1, Part C. HPLC: R.sub.T=10.50 min. MS (ESI-): mass
calcd. for C.sub.25H.sub.18BrCl.sub.2FN.sub.4O.sub.5S, 656.31; m/z
found, 653/655/657 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
10.99 (s, 1H), 8.96 (d, J=1.7, 1H), 8.93 (d, J=1.7, 1H), 8.55 (dd,
J=7.3, 1.1, 1H), 8.33 (dd, J=8.5, 1.1, 1H), 7.91-7.85 (m, 2H),
7.31-7.22 (m, 2H), 7.07-6.94 (m, 2H), 6.52 (d, J=7.3, 1H), 4.89 (q,
J=5.8, 1H), 3.81 (s, 3H), 3.21-3.08 (m, 2H).
Example 154
##STR00164##
[0537]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylam-
ino]-3-(3,4-dichloro-phenyl)-propionic acid methyl ester
[0538] The title compound was prepared from
2-amino-3-(3,4-dichloro-phenyl)-propionic acid methyl ester
hydrochloride (prepared as in Example 2, Part A) and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoic acid as
in Example 1, Part C. HPLC: R.sub.T=10.50 min. MS (ESI-): mass
calcd. for C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 691.35;
m/z found, 689/691 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3):
11.34 (s, 1H), 8.36 (dd, J=7.1, 0.9, 1H), 8.23 (dd, J=8.8, 0.9,
1H), 8.08 (d, J=1.5, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.36-7.30 (m,
2H), 7.14 (d, J=2.0, 1H), 6.95 (d, J=8.3, 1H), 6.90 (dd, J=8.2,
2.0, 1H), 6.53 (d, J=7.0, 1H), 4.94 (q, J=5.6, 1H), 3.82 (s, 3H),
3.25-3.10 (m, 2H).
Example 155
##STR00165##
[0539]
(S)-3-(3-Bromo-4-chloro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfony-
lamino)-benzoylamino]-propionic acid
[0540] The title compound was prepared from
3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and
4-bromo-2-(quinoxaline-5-sulfonylamino)-benzoic acid (EXAMPLE 8,
Parts A-E, substituting 2-amino-4-bromo-benzoic acid methyl ester
in Part D) as in Example 1, Part C, followed by hydrolysis of the
resulting methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=9.86
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2, 668.74; m/z found,
665/667/669 [M-H].sup.-. .sup.1H NMR (400 MHz, CDCl.sub.3): 11.01
(s, 1H), 9.00 (s, 1H), 8.92 (s, 1H), 8.55 (d, J=7.2, 1H), 8.30 (d,
J=8.4, 1H), 7.94-7.85 (m, 2H), 7.42 (s, 1H), 7.34 (d, J=8.1, 1H),
7.10-6.99 (m, 3H), 6.43 (d, J=7.0, 1H), 4.95-4.87 (m, 1H),
3.29-3.10 (m, 2H).
Example 156
##STR00166##
[0541]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoyl-
amino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
[0542] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoic acid
as in EXAMPLE 1, Part C, followed by hydrolysis of the resulting
methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=9.72 min. MS
(ESI-): mass calcd. for C.sub.22H.sub.15BrClFN.sub.4O.sub.5S.sub.2,
613.87; m/z found, 611/613 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.36 (s, 1H), 8.34 (d, J=6.9, 1H), 8.16 (d, J=8.7,
1H), 7.74-7.67 (m, 1H), 7.66-7.63 (m, 1H), 7.38-7.32 (m, 1H),
7.20-7.15 (m, 1H), 7.12-7.05 (m, 1H), 7.05-6.98 (m, 1H), 6.91-6.84
(m, 1H), 6.68 (d, J=6.7, 1H), 6.09 (s, 2H), 5.04-4.94 (m, 1H),
3.35-3.15 (m, 2H).
Example 157
##STR00167##
[0543]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
[0544] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid as in Example 1, Part C, followed by hydrolysis of the
resulting methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=10.10
min. MS (ESI-): mass calcd. for
C.sub.22H.sub.14BrCl.sub.2FN.sub.4O.sub.5S.sub.2, 648.31; m/z
found, 645/647/649 [M-H].sup.-. .sup.1H NMR (400 MHz,
acetone-d.sub.6): 11.58 (s, 1H), 8.47-8.42 (m, 1H), 8.34-8.20 (m,
2H), 7.92-7.85 (m, 1H), 7.85-7.80 (m, 1H), 7.75-7.70 (m, 1H),
7.67-7.60 (m, 1H), 7.42-7.35 (m, 1H), 7.25-7.18 (m, 1H), 4.96-4.87
(m, 1H), 3.40-3.32 (m, 1H), 3.20-3.10 (m, 1H).
Example 158
##STR00168##
[0545]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-bromo-2-(quinoxaline-5-sulfony-
lamino)-benzoylamino]-propionic acid
[0546] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4-bromo-2-(quinoxaline-5-sulfonylamino)-benzoic acid (EXAMPLE 8,
Parts A-E, substituting 2-amino-4-bromo-benzoic acid methyl ester
in Part D) as in Example 1, Part C, followed by hydrolysis of the
resulting methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=9.52
min. MS (ESI-): mass calcd. for
C.sub.24H.sub.17Br.sub.2FN.sub.4O.sub.5S, 652.29; m/z found,
649/651/653 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6):
11.64 (s, 1H), 8.99-8.93 (m, 2H), 8.62-8.57 (m, 1H), 8.37-8.31 (m,
1H), 8.07-7.98 (m, 2H), 7.94-7.90 (m, 1H), 7.65-7.59 (m, 1H),
7.51-7.45 (m, 1H), 7.41-7.34 (m, 1H), 7.23-7.16 (m, 1H), 7.14-7.08
(m, 1H), 5.00-4.90 (m, 1H), 3.37-3.29 (m, 1H), 3.18-3.09 (m,
1H).
Example 159
##STR00169##
[0547]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4-chloro-2-(quinoxaline-5-sulfon-
ylamino)-benzoylamino]-propionic acid
[0548] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4-chloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid as in Example
1, Part C, followed by hydrolysis of the resulting methyl ester as
in EXAMPLE 2, Part E. HPLC: R.sub.T=9.46 min. MS (ESI-): mass
calcd. for C.sub.24H.sub.17BrClFN.sub.4O.sub.5S, 607.84; m/z found,
605/607 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6): 11.66
(s, 1H), 8.99-8.93 (m, 2H), 8.63-8.57 (m, 1H), 8.37-8.31 (m, 1H),
8.02-7.97 (m, 2H), 7.78-7.75 (m, 1H), 7.65-7.60 (m, 1H), 7.58-7.53
(m, 1H), 7.41-7.34 (m, 1H), 7.24-7.17 (m, 1H), 6.97 (dd, J=8.3,
1.6, 1H), 5.00-4.92 (m, 1H), 3.37-3.28 (m, 1H), 3.18-3.10 (m,
1H).
Example 160
##STR00170##
[0549]
(S)-3-(3-Bromo-4-fluoro-phenyl)-2-[4,5-dichloro-2-(quinoxaline-5-su-
lfonylamino)-benzoylamino]-propionic acid
[0550] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
4,5-dichloro-2-(quinoxaline-5-sulfonylamino)-benzoic acid (prepared
from quinoxaline-5-sulfonyl chloride as in EXAMPLE 14, Part A) as
in Example 1, Part C, followed by hydrolysis of the resulting
methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=9.91 min. MS
(ESI-): mass calcd. for C.sub.24H.sub.16BrCl.sub.2FN.sub.4O.sub.5S,
642.28; m/z found, 639/641/643 [M-H].sup.-. .sup.1H NMR (400 MHz,
acetone-d.sub.6): 11.49 (s, 1H), 9.00-8.93 (m, 2H), 8.62-8.57 (m,
1H), 8.37-8.32 (m, 1H), 8.20-8.12 (m, 1H), 8.05-7.97 (m, 1H),
7.93-7.88 (m, 1H), 7.73-7.67 (m, 1H), 7.65-7.61 (m, 1H), 7.41-7.33
(m, 1H), 7.25-7.15 (m, 1H), 5.00-4.90 (m, 1H), 3.38-3.28 (m, 1H),
3.18-3.10 (m, 1H).
Example 161
##STR00171##
[0551]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoyla-
mino]-3-(3-bromo-4-chloro-phenyl)-propionic acid
[0552] The title compound was prepared from
3-bromo-4-chloro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid as
in Example 1, Part C, followed by hydrolysis of the resulting
methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=10.05 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.15Br.sub.2ClN.sub.4O.sub.5S.sub.2, 674.77; m/z found,
673/675 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6): 11.77
(s, 1H), 8.46-8.42 (m, 1H), 8.34-8.29 (m, 1H), 8.19-8.13 (m, 1H),
7.93-7.87 (m, 1H), 7.87-7.82 (m, 1H), 7.73-7.69 (m, 1H), 7.54-7.46
(m, 2H), 7.40-7.35 (m, 1H), 7.17-7.12 (m, 1H), 4.97-4.88 (m, 1H),
3.40-3.32 (m, 1H), 3.22-3.14 (m, 1H).
Example 162
##STR00172##
[0553]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoyla-
mino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
[0554] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine methyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-bromo-benzoic acid as
in Example 1, Part C, followed by hydrolysis of the resulting
methyl ester as in EXAMPLE 2, Part E. HPLC: R.sub.T=9.75 min. MS
(ESI-): mass calcd. for
C.sub.22H.sub.15Br.sub.2FN.sub.4O.sub.5S.sub.2, 658.32; m/z found,
655/657/659 [M-H].sup.-. .sup.1H NMR (400 MHz, acetone-d.sub.6):
11.76 (s, 1H), 8.46-8.41 (m, 1H), 8.32-8.27 (m, 1H), 8.16-8.09 (m,
1H), 7.93-7.82 (m, 2H), 7.66-7.60 (m, 1H), 7.53-7.47 (m, 1H),
7.41-7.34 (m, 1H), 7.24-7.11 (m, 2H), 4.95-4.86 (m, 1H), 3.39-3.31
(m, 1H), 3.21-3.12 (m, 1H).
Example 163
##STR00173##
[0555]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid ethyl
ester
[0556] The title compound was prepared from
3-bromo-4-fluoro-L-phenylalanine ethyl ester hydrochloride and
2-(benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-benzoic
acid as in Example 1, Part C. HPLC: R.sub.T=10.96 min. MS (ESI-):
mass calcd. for C.sub.22H.sub.15Cl.sub.3N.sub.4O.sub.5S.sub.2,
676.36; m/z found, 673/675 [M-H].sup.-. .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.20 (s, 1H), 8.36 (dd, J=7.0, 0.8, 1H), 8.23 (dd,
J=8.8, 0.9, 1H), 7.86 (s, 1H), 7.73 (dd, J=8.8, 7.1, 1H), 7.34 (s,
1H), 7.29 (dd, J=6.5, 1.9, 1H), 7.07-6.99 (m, 2H), 6.59 (d, J=7.0,
1H), 4.89 (q, J=5.8, 1H), 4.27 (q, J=7.1, 2H), 3.17 (d, J=5.8, 1H),
1.33 (t, J=7.2, 3H).
[0557] The racemic compounds in Examples 164-173 may be prepared
according to the methods described above.
Example 164
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3-b-
romo-4-chloro-phenyl)-propionic acid
Example 165
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4-c-
hloro-3-iodo-phenyl)-propionic acid
Example 166
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(3-b-
romo-4-fluoro-phenyl)-propionic acid
Example 167
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3,3-bi-
s-(4-chloro-phenyl)-propionic acid
Example 168
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-iodo-benzoylamino]-3-(4-c-
hloro-phenyl)-3-methyl-butyric acid
Example 169
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(4-chloro-phenyl)-2-hydro-
xy-1-methyl-ethyl]-4-iodo-benzamide
Example 170
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-hydrox-
y-1-methyl-ethyl]-4-iodo-benzamide
Example 171
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3,3--
bis-(4-chloro-phenyl)-propionic acid
Example 172
2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4-chloro-benzoylamino]-3-(4-
-chloro-phenyl)-3-methyl-butyric acid
Example 173
2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-N-[2-(3-bromo-phenyl)-2-hydrox-
y-1-methyl-ethyl]-4-chloro-benzamide
Example 174
##STR00174##
[0558]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid tert-butyl
ester
[0559] A.
(S)-2-(Benzhydrylidene-amino)-3-(3-bromo-4-fluoro-phenyl)-propio-
nic acid tert-butyl ester. To a flame-dried flask was added
(benzhydrylidene-amino)-acetic acid tert-butyl ester (250 mg, 0.846
mmol), O-allyl-N-(9-anthracenylmethyl)-cinchonidinium bromide (51
mg, 0.085 mmol), and DCM (5 mL). The flask was cooled to
-55.degree. C. and CsOH.H.sub.2O (1.4 g, 8.46 mmol) was added. The
mixture was stirred for 30 min, treated with 3-bromo-4-fluorobenzyl
bromide (1.1 g, 4.23 mmol), and stirred at -55.degree. C.
overnight. The mixture was diluted with Et.sub.2O (5 mL) and water
(10 mL), warmed to rt, and washed with water and brine. The organic
layer was dried (MgSO.sub.4) and concentrated. The residue was
purified by column chromatography to provide the title compound
(300 mg, 74%, er=97:3). MS (ESI+): mass calcd. for
C.sub.26H.sub.25BrFNO.sub.2, 482.4; m/z found, 483.4 [M+H].sup.+.
.sup.1H NMR (400 MHz, CDCl.sub.3): 7.59-7.54 (m, 2H), 7.41-7.20 (m,
7H), 7.02-6.91 (m, 2H), 6.72 (d, J=6.5 Hz, 2H), 4.11-4.07 (m, 1H),
3.19-3.08 (m, 2H), 1.45 (s, 9H).
[0560] B. (S)-2-Amino-3-(3-bromo-4-fluoro-phenyl)-propionic acid
tert-butyl ester. A solution of
(S)-2-(benzhydrylidene-amino)-3-(3-bromo-4-fluoro-phenyl)-propionic
acid tert-butyl ester (300 mg, 0.622 mmol) in THF (3 mL) was
treated with 10% citric acid (3 mL). The mixture was stirred
overnight, diluted with water, and extracted with Et.sub.2O
(2.times.). The aqueous layer was basified to pH=10 with satd. aq.
K.sub.2CO.sub.3 and extracted with EtOAc (3.times.). The combined
organic layers were dried (MgSO.sub.4) and concentrated to give the
title compound (247 mg, 64%). MS (ESI+): mass calcd. for
C.sub.13H.sub.17BrFNO.sub.2, 318.18; m/z found, 262.2
[M-t-Bu].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3): 7.42 (dd, J=6.6,
2.1 Hz, 1H), 7.16-7.11 (m, 1H), 7.08-7.02 (m, 1H), 3.56 (dd, J=7.3,
5.9 Hz, 1H), 2.85-2.78 (m, 1H), 2.99-2.92 (m, 1H), 1.43 (m,
9H).
[0561] C.
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro--
benzoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid tert-butyl
ester. The title compound may be prepared as described in Example
1, Part C.
[0562] The compounds in Examples 175-176 may be prepared according
to the methods described above.
Example 175
##STR00175##
[0563]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
2-morpholin-4-yl-ethyl ester
Example 176
##STR00176##
[0564]
(S)-2-[2-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-4,5-dichloro-ben-
zoylamino]-3-(3-bromo-4-fluoro-phenyl)-propionic acid
dimethylcarbamoylmethyl ester
##STR00177##
[0565] Preparation of 3-bromo-4-chloro-L-phenylalanine
[0566] A. 3-Bromo-4-chlorobenzyl chloride. To a solution of
3-bromo-4-chlorobenzyl alcohol (9.6 g, 43 mmol) in CH.sub.2Cl.sub.2
(100 mL) was added Ph.sub.3P (17.1 g, 1.5 mmol) and CCl.sub.4 (6.3
mL, 65 mmol). After 18 h, the solution was washed with brine
(3.times.100 mL) and passed through a short silica gel column to
afford the product as colorless oil (9.14 g, 88%). .sup.1H NMR (400
MHz, CDCl.sub.3): 7.65 (d, J=2.1 Hz, 1H), 7.43 (d, J=8.2 Hz, 1H),
7.27 (dd, J=8.3, 2.1 Hz, 1H), 4.51 (s, 3H).
[0567] B. 3-Bromo-4-chloro-L-phenylalanine. To a solution of
2-acetylamino-malonic acid diethyl ester (15.1 g, 70 mmol) and
3-bromo-4-chlorobenzyl chloride (16.7 g, 70 mmol) in EtOH (110 mL)
was added a solution of NaOEt (20% in EtOH, 28.7 mL, 73 mmol). The
mixture was heated at reflux for 3 h in a flask fitted with a
reflux condenser, then was treated with additional
2-acetylamino-malonic acid diethyl ester (3.0 g, 14 mmol) and NaOEt
(20% in EtOH, 2.0 mL, 5.1 mmol). The mixture was heated at reflux
for an additional 3 h. The mixture was cooled to rt and treated
with water (200 mL). The resulting white precipitate was collected
by filtration, washed with water, and suspended in a mixture of
water (60 mL) and EtOH (60 mL). This mixture was heated to reflux
temperature in a flask fitted with a reflux condenser. A solution
of KOH (3.3 g, 59 mmol) in water (10 mL) was added dropwise. After
2 h at reflux, more KOH (5.9 g, 105 mmol) in water (20 mL) was
added dropwise, and the mixture was heated at reflux for 3 h. The
mixture was cooled to 0.degree. C., diluted with water (120 mL),
and treated with 50% aq. HCl until pH .about.1. The resulting white
precipitate was collected by filtration and washed with 0.1 M HCl.
The solid was suspended in water (80 mL) and treated with 2 M aq.
KOH until pH .about.8.0. The solution was filtered. The filtrate
was warmed to 40.degree. C., treated with Acylase "Amano" (0.19 g,
Amano Enzyme Inc., Japan) and CoCl.sub.2 (10 mg), and 2 M aq. KOH
was added to keep the pH of solution at 8.0. After 4 d at
40.degree. C., 2 M HCl was added until pH=1. The suspension was
filtered and the filtrate was concentrated to 20 mL. The pH was
adjusted to 6.0 with 2.0 M KOH. The mixture was kept at 0.degree.
C. overnight and the solid was collected by filtration to obtain
the title compound as a light tan solid (7.67 g, 40% overall).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): 7.66 (br s, 1H), 7.51 (d,
J=8.2 Hz, 1H), 7.29 (d, J=8.2 Hz, 1H), 3.39 (dd, J=7.1, 5.3 Hz,
1H), 3.08 (dd, J=14.2, 4.6 Hz, 1H), 2.86 (dd, J=14.0, 7.7 Hz, 1H).
To determine the enantiomeric ratio, the product was transformed to
the corresponding methyl ester (SOCl.sub.2, MeOH, rt) and then to
the Mosher's amide (Mosher's acid chloride, iPr.sub.2NEt,
CH.sub.2Cl.sub.2). The analysis of .sup.1H-NMR data of the amide
showed that the product was a single enantiomer (e.e.
>99.5%).
[0568] C. The product from Step B may be used to prepare compounds
of the invention according to the methods described in the
preceding examples.
Assay Methods
A. Binding Assays
1. CCK1 Assay Development and Data Generation
Cell Culture
[0569] CHO-K1 cells that had undergone stable transfection with the
CCK-1 receptor were grown in DMEM supplemented with L-glutamine (2
mM), penicillin (50 units/mL) and streptomycin (50 .mu.g/mL). Cells
were cultured under continuous G418 selection (2 mM) and were
harvested using a rubber cell scraper. CHO-K1 cells were
sub-cultured a maximum of ten times before being reseeded from the
original stocks.
Membrane Preparation
[0570] Membranes were prepared from the stably transfected CHO-K1
cells. Frozen cell pellets (-40.degree. C.) were thawed in 14 mL of
buffer A (10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl, 1 mM
EGTA and 15.4 mg/100 mL bacitracin at pH 7.2), adapted from Harper
et al. (Br. J. Pharmacol. 1996, 118:1717-1726). The thawed pellets
were homogenized using a Polytron PT-10 (7.times.1 s). The
homogenates were centrifuged for 5 min at 1500 rpm (600.times.g),
and the resulting pellets were discarded. The supernatants were
re-centrifuged in order to collect the receptor-membrane pellets
(25 min 15,000 rpm; 39,800.times.g), which were re-suspended in
buffer A.
Incubation Conditions
[0571] All assays were conducted in 96-well plates (GF/B millipore
filter plates) using buffer A, with 0.3 .mu.M PD-134,308, for the
dilutions. The CCK-2 receptor ligand was included to eliminate the
contribution of this receptor subtype to the binding. For the
optimal cell number determination experiments 20 pM
[.sup.125I]-BH-CCK-8S (50 .mu.L 60 .mu.M solution) was incubated
with a range of cell concentrations (2.5.times.105 to
12.5.times.105 cells/well) in a total volume of 150 .mu.L. Total
binding of [.sup.125I]-BH-CCK-8S was determined in the presence of
15 .mu.L of buffer A. Non-specific binding of [.sup.125I]-BH-CCK-8S
was determined in the presence of 15 .mu.L of 100 .mu.M
2-naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP: see R.
A. Hull et al. Br. J. Pharmacol. 1993, 108:734-740), a CCK-1
receptor selective antagonist that is structurally unrelated to the
radioligand [.sup.125I]-BH-CCK-8S. The assay preparation was
incubated for 1 h at 21.+-.3.degree. C., and then the assay was
terminated upon rapid filtration of the preparation under reduced
pressure. The loaded filters were washed three times using
undiluted PBS (100 EL), and then the residues were transferred to 5
mL scintillation tubes. Bound radioactivity was determined using a
gamma counter (count time=1 min). From these experiments a cell
concentration of 1 pellet in 40 mL of buffer (2.5.times.106
cells/mL) was chosen for use in other assays (below). To validate
the radioligand concentration and incubation time for the assay,
saturation and kinetic binding studies were also conducted (see M.
F. Morton, The Pharmacological Characterization of Cholecystokinin
Receptors in the Human Gastrointestinal Tract. PhD Thesis,
University of London, 2000). The affinity of novel compounds was
estimated by incubating membrane preparations with 15 .mu.L of
competing ligand (0.1 pM-1 mM) for 60 min at 21.+-.3.degree. C. The
assay was then terminated according to the procedure outlined
above.
2. CCK2 Assay Development and Data Generation
[0572] Zinc Finger Proteins (ZFP) specific for the CCK2R gene were
identified by Sangamo Biosciences. The ZFP domain was fused with
the herpes simplex virus VP16 activation domain, and the fusion
protein was subsequently cloned into the pcDNA3 mammalian
expression vector (Invitrogen, San Diego, Calif.). Tet-inducible
cell lines expressing the coding region from the ZFP vector were
created using the T-REx-293.TM. cell line (Invitrogen). After 2
weeks of selection in culture medium containing 400 mg/mL Zeocin
(Invitrogen), sixty drug-resistant stable clones were isolated and
analyzed for ZFP expression as well as CCK2R induction upon
addition of doxycycline to the culture medium. The cell line with
the most appropriate CCK2R ZFP construct was used in all further
assays and was termed the HEKZFP cell line.
Cell Culture
[0573] HEKZFP cells were grown in DMEM supplemented with
L-glutamine (2 mM), penicillin (50 units/mL) and streptomycin (50
pg/mL) and 10% FBS (v/v). HEKZFP cells were treated with 2 mM
doxycycline (Sigma-Aldrich, Mo.; USA) for 2 days to de-repress the
tet-regulated expression of the CCK2 receptor selective zinc finger
proteins and were harvested using a rubber cell scraper.
Membrane Preparation
[0574] Membranes were prepared from the HEKZFP cells after
induction. Frozen cell pellets (-40.degree. C.) were thawed in 14
mL of buffer A (10 mM HEPES, 130 mM NaCl, 4.7 mM KCl, 5 mM MgCl, 1
mM EGTA and 15.4 mg/100 mL bacitracin at pH 7.2), adapted from E.
A. Harper et al. (Br. J. Pharmacol. (1996) 118(7):1717-1726). The
thawed pellets were homogenized using a Polytron PT-10 (7.times.1
s). The homogenates were centrifuged for 5 min at 1500 rpm
(600.times.g), and the resulting pellets were discarded. The
supernatants were re-centrifuged in order to collect the
receptor-membrane pellets (25 min 15,000 rpm; 39,800.times.g),
which were re-suspended in buffer A.
Incubation Conditions
[0575] All assays were conducted in 96-well plates (GF/B millipore
filter plates) using buffer A. For the optimal cell number
determination experiments, cells in concentrations ranging from
2.5.times.10.sup.5 to 12.5.times.10.sup.5 cells/well were incubated
with 20 pM [.sup.125I]-BH-CCK-8S (50 .mu.L 60 .mu.M solution) in a
total volume of 150 .mu.L. Total binding of [.sup.125I]-BH-CCK-8S
was determined in the presence of 15 .mu.L of buffer A.
Non-specific binding of [.sup.125I]-BH-CCK-8S was determined in the
presence of 15 .mu.L of 10 .mu.M YF476, a CCK-2 receptor selective
antagonist that is structurally unrelated to the radioligand
[.sup.125I]-BH-CCK-8S. The assay preparation was incubated for 1 h
at 21.+-.3.degree. C., and then the assay was terminated by rapid
filtration of the preparation under reduced pressure. The loaded
filters were washed three times using undiluted PBS (100 EL), and
then 100 .mu.L of scintillation fluid was added to the filter
plate. Bound radioactivity was determined using a Topcount (Packard
BioScience, Meriden, Conn.) with a count time of 1 min. From these
experiments a cell concentration of 1 pellet in 15 mL of buffer was
chosen for use in other assays. To validate the radioligand
concentration and incubation time for the assay, saturation and
kinetic binding studies were also conducted (see M. F. Morton, The
Pharmacological Characterization of Cholecystokinin Receptors in
the Human Gastrointestinal Tract. PhD Thesis, University of London,
2000). The affinity of novel compounds was estimated by incubating
membrane preparations with 15 .mu.L of competing ligand (0.1 pM-1
mM) for 60 min at 21.+-.3.degree. C. The assay was then terminated
according to the procedure outlined above.
3. Data Analysis for CCK1 and CCK2 Binding Assays
[0576] The pKi values were determined using the equation of Y.-C.
Cheng and W. H. Prusoff (Biochem. Pharmacol., 1973,
22(23):3099-3108):
K i = IC 50 1 + [ L ] K D ##EQU00001##
[0577] To circumvent problems associated with computer-assisted
data analysis of compounds with low affinity, the data obtained in
the current study were weighted according to a method described by
Morton. In brief, 100% and 0% specific binding were defined
independently using total binding and binding obtained in the
presence of a high concentration of the reference antagonist,
2-NAP. Data for compounds tested are presented in Table 1.
TABLE-US-00003 TABLE 1 EX CCK1 pK.sub.i CCK2 pK.sub.i 1 6.9 6.4 2
6.7 7.5 3 6.0 7.4 4 6.2 8.3 5 7.8 6.5 6 7.5 5.0 7 7.3 5.1 8 5.5 6.3
9 6.8 6.4 10 7.7 5.1 11 6.4 6.5 12 5.9 7.2 13 5.9 6.2 14 7.9 6.5 15
7.4 6.7 16 7.2 6.2 17 7.1 5.6 18 6.5 5.8 19 6.7 6.6 20 5.7 7.0 21
6.9 6.0 22 6.3 6.2 23 6.0 6.2 24 7.0 5.9 25 5.0 7.4 26 5.6 7.4 27
5.0 7.5 28 5.0 7.1 29 5.2 7.1 30 7.2 5.6 31 7.1 6.2 32 6.4 7.0 33
6.8 7.4 34 6.4 7.0 35 7.2 6.3 36 7.1 5.8 37 6.4 5.4 38 6.5 5.7 39
7.6 6.6 40 6.9 6.5 41 6.2 7.3 42 7.5 5.5 43 6.9 6.6 44 7.0 5.4 45
6.6 5.8 46 5.8 7.2 47 7.0 5.3 48 7.3 5.7 49 6.7 5.7 50 6.2 5.2 51
5.0 6.1 52 6.3 7.0 53 6.9 5.6 54 6.1 6.5 55 7.4 6.0 56 6.3 6.8 57
7.9 6.3 58 7.5 6.3 59 7.1 6.1 60 7.1 6.4 61 6.9 6.4 62 6.5 5.5 63
5.0 7.5 64 5.8 7.0 65 6.5 6.1 66 5.7 6.3 67 6.7 6.6 68 6.5 7.5 69
7.2 5.1 70 6.7 5.2 71 6.9 5.6 72 7.1 6.3 73 6.8 5.0 74 6.5 5.1 75
6.0 5.4 76 5.5 7.4 77 5.0 7.5 78 5.4 7.5 79 7.2 5.9 80 7.0 5.8 81
6.1 5.7 82 6.1 5.1 83 5.8 6.6 84 5.0 7.5 85 5.0 7.2 86 5.0 7.5 87
5.0 6.8 88 5.2 6.2 89 5.1 7.2 90 5.9 7.5 91 7.1 7.8 92 7.2 7.5 93
6.8 8.3 94 5.2 6.0 95 5.5 6.1 99 7.1 6.1 101 7.4 6.1 106 5.0 5.9
107 5.4 6.1 108 7.6 5.9 115 6.4 7.1 116 6.9 5.7 117 6.6 7.8 118 7.1
6.3 119 6.3 6.7 120 7.1 6.0 121 6.9 6.3 122 6.8 6.4 123 7.0 6.8 124
6.5 7.3 125 6.5 6.2 126 6.6 8.3 127 6.7 7.1 128 7.0 6.2 129 7.0 6.2
130 6.4 6.5 131 6.8 7.8 132 6.6 7.8 133 6.4 7.5 134 6.3 7.7 135 6.3
8.1 136 7.4 6.5 137 7.1 6.7 138 7.0 7.3 139 7.1 6.2 140 6.9 6.5 141
7.0 7.2 142 6.8 6.2 143 6.8 6.7 144 6.3 7.3 145 6.7 7.4 146 6.6 7.6
147 6.8 7.4 148 6.6 7.2 149 6.7 6.7 150 7.1 6.6 151 6.1 6.9 152 6
6.8 153 6.7 6.6 154 6.8 6.6 155 7.0 8.0 156 6.6 8.0 157 6.8 8.0 158
6.5 8.3 159 6.4 8.0 160 6.8 8.2 161 6.9 7.9 162 6.6 8.2 163 6.9
6.4
B. Guinea-pig Gastric Corpeal Muscle Assay
[0578] CCK2 receptor-mediated muscle contraction was measured in an
isolated muscle-strip assay of guinea-pig gastric corpeal muscle
according to the methods described by Roberts et al. (S. P.
Roberts, E. A. Harper, G. F. Watt, V. P. Gerskowitch, R. A. Hull,
N. P. Shankley, and J. W. Black, Br. J. Pharmacol., 1996,
118(7):1779-1789). In brief, strips of muscle were dissected and
suspended in isolated tissue organ baths for isotonic muscle
contraction recording. The baths, containing Krebs-Henseleit
solution, were maintained at 24.degree. C. and gassed continuously
with 95% O.sub.2 and 5% CO.sub.2. CCK1 receptors known to be
present in this assay were blocked using a selective concentration
of a suitable CCK1 receptor antagonist (e.g. 2-NAP). The
effectiveness of the test compounds was assessed by measuring their
effect on contractile concentration-response curves obtained using
a well-characterized surrogate for the hormone gastrin
(pentagastrin). The title compound of Example 2 behaved as a
competitive antagonist in this assay with a pK.sub.B value of
8.8.
* * * * *